
<html lang="en"     class="pb-page"  data-request-id="cf5d27aa-b079-47cc-8812-442bdc9650f0"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.6b00237;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2016.59.issue-12;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design, Synthesis, and Preclinical Evaluation of 4-Substituted-5-methyl-furo[2,3-d]pyrimidines as Microtubule Targeting Agents That Are Effective against Multidrug Resistant Cancer Cells" /></meta><meta name="dc.Creator" content="Ravi Kumar Vyas  Devambatla" /></meta><meta name="dc.Creator" content="Ojas A.  Namjoshi" /></meta><meta name="dc.Creator" content="Shruti  Choudhary" /></meta><meta name="dc.Creator" content="Ernest  Hamel" /></meta><meta name="dc.Creator" content="Corena V.  Shaffer" /></meta><meta name="dc.Creator" content="Cristina C.  Rohena" /></meta><meta name="dc.Creator" content="Susan L.  Mooberry" /></meta><meta name="dc.Creator" content="Aleem  Gangjee" /></meta><meta name="dc.Description" content="The design, synthesis, and biological evaluations of eight 4-substituted 5-methyl-furo[2,3-d]pyrimidines are reported. Synthesis involved N4-alkylation of N-aryl-5-methylfuro[2,3-d]pyrimidin-4-amin..." /></meta><meta name="Description" content="The design, synthesis, and biological evaluations of eight 4-substituted 5-methyl-furo[2,3-d]pyrimidines are reported. Synthesis involved N4-alkylation of N-aryl-5-methylfuro[2,3-d]pyrimidin-4-amin..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 7, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00237" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00237" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00237" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00237" /></link>
        
    
    

<title>Design, Synthesis, and Preclinical Evaluation of 4-Substituted-5-methyl-furo[2,3-d]pyrimidines as Microtubule Targeting Agents That Are Effective against Multidrug Resistant Cancer Cells | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00237" /></meta><meta property="og:title" content="Design, Synthesis, and Preclinical Evaluation of 4-Substituted-5-methyl-furo[2,3-d]pyrimidines as Microtubule Targeting Agents That Are Effective against Multidrug Resistant Cancer Cells" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0017.jpeg" /></meta><meta property="og:description" content="The design, synthesis, and biological evaluations of eight 4-substituted 5-methyl-furo[2,3-d]pyrimidines are reported. Synthesis involved N4-alkylation of N-aryl-5-methylfuro[2,3-d]pyrimidin-4-amines, obtained from Ullmann coupling of 4-amino-5-methylfuro[2,3-d]pyrimidine and appropriate aryl iodides. Compounds 3, 4, and 9 showed potent microtubule depolymerizing activities, while compounds 6–8 had slightly lower potency. Compounds 4, 6, 7, and 9 inhibited tubulin assembly with IC50 values comparable to that of combretastatin A-4 (CA-4). Compounds 3, 4, and 6–9 circumvented Pgp and βIII-tubulin mediated drug resistance, mechanisms that can limit the efficacy of paclitaxel, docetaxel, and the vinca alkaloids. In the NCI 60-cell line panel, compound 3 exhibited GI50 values less than 10 nM in 47 of the cell lines. In an MDA-MB-435 xenograft model, compound 3 had statistically significant antitumor effects. The biological effects of 3 identify it as a novel, potent microtubule depolymerizing agent with antitumor activity." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00237"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00237">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00237&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00237&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00237&amp;href=/doi/10.1021/acs.jmedchem.6b00237" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 5752-5765</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00190" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00324" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Preclinical Evaluation of 4-Substituted-5-methyl-furo[2,3-<i>d</i>]pyrimidines as Microtubule Targeting Agents That Are Effective against Multidrug Resistant Cancer Cells</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ravi+Kumar+Vyas++Devambatla">Ravi Kumar Vyas Devambatla</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ojas+A.++Namjoshi">Ojas A. Namjoshi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shruti++Choudhary">Shruti Choudhary</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ernest++Hamel">Ernest Hamel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Corena+V.++Shaffer">Corena V. Shaffer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cristina+C.++Rohena">Cristina C. Rohena</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan+L.++Mooberry">Susan L. Mooberry</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aleem++Gangjee">Aleem Gangjee</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">§</span> <span class="aff-text">Department of Pharmacology, Cancer Therapy & Research Center, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">‡</span> <span class="aff-text">Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick National Laboratory for Cancer Research, National Institutes of Health, Frederick, Maryland 21702, United States</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#197e78777e737c7c597d6c68377c7d6c"><span class="__cf_email__" data-cfemail="96f1f7f8f1fcf3f3d6f2e3e7b8f3f2e3">[email protected]</span></a>. Tel: 412-396-6070. Fax: 412-396-5593.</div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#5a373535383f2828231a2f2e322939293b743f3e2f"><span class="__cf_email__" data-cfemail="0c6163636e697e7e754c7978647f6f7f6d22696879">[email protected]</span></a>. Tel: 210-567-4788. Fax: 210-567-4300.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00237&amp;href=/doi/10.1021%2Facs.jmedchem.6b00237" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 5752–5765</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 23, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 February 2016</li><li><span class="item_label"><b>Published</b> online</span>7 June 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 June 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00237" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00237</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5752%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRavi%2BKumar%2BVyas%2BDevambatla%252C%2BOjas%2BA.%2BNamjoshi%252C%2BShruti%2BChoudhary%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D12%26contentID%3Dacs.jmedchem.6b00237%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BPreclinical%2BEvaluation%2Bof%2B4-Substituted-5-methyl-furo%255B2%252C3-d%255Dpyrimidines%2Bas%2BMicrotubule%2BTargeting%2BAgents%2BThat%2BAre%2BEffective%2Bagainst%2BMultidrug%2BResistant%2BCancer%2BCells%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5765%26publicationDate%3DJune%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00237"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1841</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">20</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00237" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Preclinical Evaluation of 4-Substituted-5-methyl-furo[2,3-d]pyrimidines as Microtubule Targeting Agents That Are Effective against Multidrug Resistant Cancer Cells&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ravi&quot;,&quot;last_name&quot;:&quot;Kumar Vyas Devambatla&quot;},{&quot;first_name&quot;:&quot;Ojas&quot;,&quot;last_name&quot;:&quot;A. Namjoshi&quot;},{&quot;first_name&quot;:&quot;Shruti&quot;,&quot;last_name&quot;:&quot;Choudhary&quot;},{&quot;first_name&quot;:&quot;Ernest&quot;,&quot;last_name&quot;:&quot;Hamel&quot;},{&quot;first_name&quot;:&quot;Corena&quot;,&quot;last_name&quot;:&quot;V. Shaffer&quot;},{&quot;first_name&quot;:&quot;Cristina&quot;,&quot;last_name&quot;:&quot;C. Rohena&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;L. Mooberry&quot;},{&quot;first_name&quot;:&quot;Aleem&quot;,&quot;last_name&quot;:&quot;Gangjee&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;5752-5765&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00237&quot;},&quot;abstract&quot;:&quot;The design, synthesis, and biological evaluations of eight 4-substituted 5-methyl-furo[2,3-d]pyrimidines are reported. Synthesis involved N4-alkylation of N-aryl-5-methylfuro[2,3-d]pyrimidin-4-amines, obtained from Ullmann coupling of 4-amino-5-methylfuro[2,3-d]pyrimidine and appropriate aryl iodides. Compounds 3, 4, and 9 showed potent microtubule depolymerizing activities, while compounds 6–8 had slightly lower potency. Compounds 4, 6, 7, and 9 inhibited tubulin assembly with IC50 values comparable to that of combretastatin A-4 (CA-4). Compounds 3, 4, and 6–9 circumvented Pgp and βIII-tubulin mediated drug resistance, mechanisms that can limit the efficacy of paclitaxel, docetaxel, and the vinca alkaloids. In the NCI 60-cell line panel, compound 3 exhibited GI50 values less than 10 nM in 47 of the cell lines. In an MDA-MB-435 xenograft model, compound 3 had statistically significant antitumor effects. The biological effects of 3 identify it as a novel, potent microtubule depolymerizing agent with antitumor &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00237&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00237" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00237&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00237" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00237&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00237" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00237&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00237&amp;href=/doi/10.1021/acs.jmedchem.6b00237" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00237" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00237" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00237%26sid%3Dliteratum%253Aachs%26pmid%3D27213719%26genre%3Darticle%26aulast%3DDevambatla%26date%3D2016%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BPreclinical%2BEvaluation%2Bof%2B4-Substituted-5-methyl-furo%255B2%252C3-d%255Dpyrimidines%2Bas%2BMicrotubule%2BTargeting%2BAgents%2BThat%2BAre%2BEffective%2Bagainst%2BMultidrug%2BResistant%2BCancer%2BCells%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D12%26spage%3D5752%26epage%3D5765%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (10)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=290768" title="Antineoplastic agents">Antineoplastic agents</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/jmcmar.2016.59.issue-12/20160623/jmcmar.2016.59.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The design, synthesis, and biological evaluations of eight 4-substituted 5-methyl-furo[2,3-<i>d</i>]pyrimidines are reported. Synthesis involved <i>N</i><sup>4</sup>-alkylation of <i>N</i>-aryl-5-methylfuro[2,3-<i>d</i>]pyrimidin-4-amines, obtained from Ullmann coupling of 4-amino-5-methylfuro[2,3-<i>d</i>]pyrimidine and appropriate aryl iodides. Compounds <b>3</b>, <b>4</b>, and <b>9</b> showed potent microtubule depolymerizing activities, while compounds <b>6</b>–<b>8</b> had slightly lower potency. Compounds <b>4</b>, <b>6</b>, <b>7</b>, and <b>9</b> inhibited tubulin assembly with IC<sub>50</sub> values comparable to that of combretastatin A-4 (CA-4). Compounds <b>3</b>, <b>4</b>, and <b>6</b>–<b>9</b> circumvented Pgp and βIII-tubulin mediated drug resistance, mechanisms that can limit the efficacy of paclitaxel, docetaxel, and the vinca alkaloids. In the NCI 60-cell line panel, compound <b>3</b> exhibited GI<sub>50</sub> values less than 10 nM in 47 of the cell lines. In an MDA-MB-435 xenograft model, compound <b>3</b> had statistically significant antitumor effects. The biological effects of <b>3</b> identify it as a novel, potent microtubule depolymerizing agent with antitumor activity.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03116" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03116" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Microtubules are filamentous cytoskeleton protein polymers composed of αβ-tubulin heterodimers. Microtubules play an important role in many aspects of cellular function, including cellular transport, protein trafficking, and mitosis. Microtubule targeting agents (MTAs) are some of the most effective drugs used to treat cancer.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> MTAs are the only class of cytotoxic agents effective against p53 mutant cell lines, which constitute 39 of the 58 cell lines in the NCI 60-cell line panel.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> MTAs are widely used for the treatment of both solid tumors and hematological malignancies.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> These drugs are structurally diverse and are classified into two main groups: microtubule stabilizers and microtubule destabilizers. Microtubule stabilizers promote microtubule polymerization and include the taxanes, paclitaxel, docetaxel, and cabazitaxel, and the epothilone, ixabepilone. Microtubule destabilizers induce microtubule depolymerization and include the vinca alkaloids and colchicine-site agents. However, at low antiproliferative concentrations, both types of agents suppress microtubule dynamics leading to mitotic arrest and subsequent cell death in cells in culture.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> New evidence suggests that the ability of these drugs to inhibit interphase signaling events likely contributes to their anticancer actions.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">MTAs are divided into five classes based on their interactions within the taxane, vinca, colchicine, laulimalide/peloruside, or the maytansine site on tubulin (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Paclitaxel, docetaxel, cabazitaxel, and ixabepilone bind to β-tubulin in the interior of the microtubule, a site referred to as the taxane site.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> The taxanes are widely used in the treatment of adult solid tumors.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> The vinca alkaloids, including vincristine, vinblastine, vindesine, and vinorelbine, as shown in a crystal structure with vinblastine, require two distinct tubulin αβ-heterodimers to form a binding site. The site is formed by amino acid residues from both α- and β-tubulin, and the vinblastine molecule was located between the two heterodimers. The vinca alkaloids are important in the treatment of hematological malignancies, lymphoma, and childhood cancers.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Laulimalide and peloruside A bind to a distinct site on β-tubulin, referred to as the laulimalide/peloruside site, and both compounds cause microtubule stabilization. This site is located on the exterior of the microtubule.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Recently, Prota et al.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> demonstrated that maytansine binds to a different site on β-tubulin, and they named this the maytansine site. Maytansine, rhizoxin F, and a polyketide PM060184, initially isolated from the marine sponge <i>Lithoplocamia lithistoides</i>, bind within this newly characterized site, occupancy of which prevents the addition of new subunits to the plus ends of microtubules, resulting in microtubule depolymerization.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Maytansine is the cytotoxic component in the antibody–drug conjugate trastuzumab emtansine recently approved by the FDA for the treatment of HER2-positive advanced breast cancer.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The fifth class of MTAs comprises a variety of small molecules that includes colchicine and combretastatins A-1 (CA-1) and A-4 (CA-4), which bind in the colchicine site located on β-tubulin at its interface with α-tubulin.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> Combretastatin A-4 phosphate (CA-4P, fosbretabulin) and A-1 diphosphate (CA-1P, OXi4503), 2-methoxyestradiol, and verubulin<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> are a few of the colchicine site binding agents that have been evaluated in phase 1 and 2 clinical trials as anticancer agents alone and in combination with other drugs. Thus far, no colchicine site agent has been approved as an anticancer agent.<a onclick="showRef(event, 'ref18 ref19 ref20 ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21 ref22 ref23 ref24">(18-24)</a> Hence, this site provides new opportunities for drug discovery.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative microtubule targeting agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i2" class="anchor-spacer"></div><h3 class="article-section__title" id="_i2"> Rationale and Molecular Modeling</h3><div class="NLM_p">We previously reported<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> that cyclopenta[2,3-<i>d</i>]pyrimidine (±)-<b>1</b>·HCl (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) has potent microtubule depolymerization activity (EC<sub>50</sub> in A-10 cells = 47 nM) and in vitro cytotoxic effects against MDA-MB-435 cancer cells (IC<sub>50</sub> ± SD = 18.8 ± 0.4 nM).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Parent 5-methyl-cyclopenta[2,3-<i>d</i>]pyrimidine (±)-<b>1</b> and target 5-methyl-furo[2,3-<i>d</i>]pyrimidines <b>2</b> and <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Replacement of the cyclopentyl and the 2-methyl groups of the potent MTA (±)-<b>1</b> with a furan and a 2-H moiety, respectively, afforded the 5-methyl-furo[2,3-<i>d</i>]pyrimidine scaffold of <b>2</b> and <b>3</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). It was of interest to explore the antitumor activity of compounds with the 5-methyl-furo[2,3-<i>d</i>]pyrimidine scaffold without the 2-position substitution as MTAs to determine the contribution of the 2-position substitution and the furo ring to both inhibition of cancer cell proliferation and microtubule depolymerization. Additionally, these lead compounds are similar in structure to verubulin (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), which is a <i>N</i><sup>4</sup>,2-dimethylquinazoline-4-amine analogue with <i>p</i>-methoxyphenyl substitution at <i>N</i><sup>4</sup>-position.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Similar <i>N</i><sup>4</sup>-<i>p</i>-methoxyphenyl substitution pattern has not been explored before in 5-methyl-furo[2,3-<i>d</i>]pyrimidine series of compounds.</div><div class="NLM_p">Compounds <b>2</b> and <b>3</b> were docked in the X-ray crystal structure of colchicine in tubulin at the colchicine site (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B">4O2B</a>,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> 2.30 Å) using Molecular Operating Environment MOE 2013.0801.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Multiple low energy conformations were obtained on docking. <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a> shows the docked conformation of <b>3</b> (green) as a representative example in the colchicine site of tubulin. The furo[2,3-<i>d</i>]pyrimidine scaffold of <b>3</b> overlaps the C-ring of colchicine (orange) and forms hydrophobic interactions at the αβ tubulin interface with Alaα180, Asnβ258, and Lysβ352. The 5-Me group of <b>3</b> interacts with Leuβ255, Asnβ258, and Metβ259 of tubulin. The <i>N</i>-Me moiety of <b>3</b> mimics the bridged C5- and C6-positions of the B-ring of colchicine and forms hydrophobic interactions with Leuβ248, Alaβ250, and Lysβ254. The 4′-OMe-Ph of <b>3</b> is oriented toward the hydrophobic pocket formed by Thrβ240, Cysβ241, Alaβ316, Ileβ318, and Ileβ378 and binds in the region occupied by the A-ring of colchicine. The phenyl ring of <b>3</b> makes hydrophobic interactions with Leuβ248, Leuβ255, Alaβ316, and Alaβ354. <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a> also shows that the docked pose of <b>3</b> at the colchicine site is similar to that of the lead compound (<i>S</i>)-<b>1</b>. The best docked pose of <b>3</b> had a score of −5.07 kcal/mol comparable to that of colchicine (−5.54 kcal/mol) and the lead compound (<i>S</i>)-<b>1</b> (−5.19 kcal/mol).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Superimposition of the docked pose of <b>3</b> (green) in the colchicine site (colchicine in orange) of tubulin (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B">4O2B</a><a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Design of Target Compounds <b>4</b>–<b>9</b></h3><div class="NLM_p">The <i>N</i>-Me moiety of <b>3</b> forms hydrophobic interactions with Leuβ248, Alaβ250, Lysβ254, and Asnβ258 in the colchicine site (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). To optimize these hydrophobic interactions, compounds <b>4</b>–<b>7</b> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>) with larger alkyl groups at the <i>N</i><sup>4</sup>-position were synthesized. In addition, these compounds were also designed to determine the bulk tolerance at the colchicine site for substituents at the <i>N</i><sup>4</sup>-position for the furo[2,3-<i>d</i>]pyrimidine scaffold. The key binding interactions indicated by the docking study of the lead compound <b>3</b> in the colchicine-binding site of tubulin (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) are retained by target compounds <b>4</b>–<b>7</b> with docking scores (−5.60, −5.11, −4.35, and −5.12 kcal/mol, respectively) similar to that of <b>3</b> (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Target compounds <b>4</b>–<b>9</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compounds <b>8</b> and <b>9</b> were designed to improve hydrophobic interactions of the 4′-OMe of <b>3</b> within the hydrophobic pocket formed by residues Thrβ240, Cysβ241, Alaβ316, Ileβ318, and Ileβ378 at the colchicine site as suggested by the docking scores of <b>8</b> and <b>9</b> (−5.16 and −5.16 kcal/mol, respectively), both of which were similar to that of <b>3</b>. Thus, compounds <b>8</b> and <b>9</b> were designed to evaluate the role of the 4′-OMe group on tubulin depolymerization and inhibition of cancer cell growth by substituting the oxygen of the 4′-OMe with a methylene and sulfur, respectively, thus decreasing the electronegative nature of the 4′-OMe substituent and increasing the hydrophobic interactions at the colchicine site.</div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41340" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41340" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div class="NLM_p">Target compounds <b>2</b> and <b>3</b> were synthesized as described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Compound <b>11</b> was obtained by reacting hydroxyacetone <b>10</b> with malononitrile in the presence of triethylamine and was used without purification for the subsequent step.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Treatment of <b>11</b> with formamidine hydrochloride under basic conditions provided 5-methyl-furo[2,3-<i>d</i>]pyrimidine <b>12</b> in 47% yield (two steps). Ullmann coupling of <b>12</b> and 4-iodo anisole <b>13</b> using CuI and <span class="smallcaps smallerCapital">l</span>-proline afforded target compound <b>2</b>. <i>N</i><sup>4</sup>-Methylation of <b>2</b> with dimethyl sulfate furnished target compound <b>3</b> in 70% yield.</div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0014.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Target Compounds <b>2</b> and <b>3</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds <b>4</b>–<b>7</b> were synthesized from <b>2</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) by <i>N</i><sup>4</sup>-alkylation with the appropriate alkyl iodides <b>14</b>–<b>17</b>, respectively (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0015.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Target Compounds <b>4</b>–<b>7</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ullmann coupling of <b>12</b> and appropriate aryl iodides <b>18</b> and <b>19</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>) using CuI and <span class="smallcaps smallerCapital">l</span>-proline afforded <b>20</b> and <b>21</b>, respectively, which upon <i>N</i><sup>4</sup>-methylation furnished target compounds <b>8</b> and <b>9</b>, respectively.</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0016.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Target Compounds <b>8</b> and <b>9</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Biological Results</h3><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> Effects on Microtubule Depolymerization and Cell Proliferation</h4><div class="NLM_p">Compounds <b>2</b>–<b>9</b> were first evaluated for their ability to depolymerize microtubules (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> and <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). Compounds that caused at least 50% microtubule depolymerization at a concentration of 10 μM were further evaluated to determine the EC<sub>50</sub>, the concentration that causes loss of 50% of cellular microtubules in A-10 cells and for antiproliferative effects against MDA-MB-435 cancer cells. The embryonic rat smooth muscle A-10 cells are useful to evaluate the effects of microtubule targeting agents on interphase microtubules. Unlike cancer cells, A-10 cells do not accumulate in mitosis in response to compounds that disrupt microtubules and allow effects on interphase microtubules to be easily visualized and quantified. The <i>N</i>-H analogue <b>2</b> was inactive in the microtubule depolymerization assay and was not evaluated further. The <i>N</i>-Me analogue <b>3</b> showed potent microtubule depolymerization effects and also inhibited the proliferation of MDA-MB-435 cells with potency comparable to those of CA-4 and paclitaxel. This indicates that for the furo[2,3-<i>d</i>]pyrimidine scaffold the <i>N</i>-Me moiety is important for biological activity. Compound <b>3</b> was 2.3-fold more potent for microtubule depolymerizing effects and about 4-fold more potent for antiproliferative activity (MDA-MB-435) than the lead compound (±)-<b>1</b>·HCl. Compounds <b>4</b> and <b>9</b> were equipotent with (±)-<b>1</b>·HCl as microtubule depolymerizers and were 1.4–2.1-fold more active against MDA-MB-435 cells than (±)-<b>1</b>·HCl. These data indicate that the 2-desmethyl furo[2,3-<i>d</i>]pyrimidine scaffold is conducive to both microtubule depolymerization and antiproliferative effects.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> Values for Inhibition of Proliferation of MDA-MB-435 Cells and EC<sub>50</sub> Values for Microtubule Depolymerization</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> for microtubule depolymerization in A-10 cells (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub>  ± SD MDA-MB-435 (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(±)<b>-1</b>·HCl<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> (Lead)</td><td class="colsep0 rowsep0" align="left">56</td><td class="colsep0 rowsep0" align="left">17.0 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">>10 μM</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">4.3 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">53</td><td class="colsep0 rowsep0" align="left">8.1 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">>10 μM</td><td class="colsep0 rowsep0" align="left">504 ± 28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">306</td><td class="colsep0 rowsep0" align="left">27.3 ± 4.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">340</td><td class="colsep0 rowsep0" align="left">100 ± 6.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">750</td><td class="colsep0 rowsep0" align="left">183 ± 13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="left">12.3 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">>10 μM</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">4.5 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CA-4</td><td class="colsep0 rowsep0" align="left">9.8</td><td class="colsep0 rowsep0" align="left">4.4 ± 0.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Results previously published.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">ND: Not determined.</p></div></div></div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of compounds <b>3</b>, <b>4</b>, and <b>6</b>–<b>9</b> on cellular microtubules. A-10 cells were treated for 18 h with 2× the EC<sub>50</sub>, and cellular microtubules were visualized by indirect immunofluorescence with a β-tubulin antibody.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds <b>4</b>–<b>7</b> with larger alkyl groups at the <i>N</i><sup>4</sup>-position had lower microtubule depolymerizing potency and higher antiproliferative IC<sub>50</sub> values than that of the <i>N</i>-Me compound <b>3</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). The potency decreased with increased homologation and the <i>N</i>-Et analogue <b>4</b> was 2-fold less potent than <b>3</b> and was equipotent with <b>1</b>. The <i>N</i>-<i>i</i>Pr analogue <b>5</b> was ineffective at depolymerizing microtubules even at concentrations as high as 10 μM. However, compound <b>5</b> exhibited some antiproliferative activity, but it was 60-fold less potent (IC<sub>50</sub>) than the <i>N</i>-Et analogue <b>4</b>. The <i>N</i>-Me analogues <b>8</b> and <b>9</b> with variations at the 4′-position had quite different microtubule depolymerization activities in that <b>8</b> had an EC<sub>50</sub> of 750 nM while <b>9</b> was quite potent, with an EC<sub>50</sub> of 45 nM (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), and both were less potent than <b>3</b>. The 4′-Et analogue <b>8</b> had a 30-fold lower potency for microtubule depolymerization than the 4′-OMe analogue <b>3</b>. In the X-ray crystal structure (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B">4O2B</a><a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a>), there is a water mediated hydrogen bond between Cysβ241 of tubulin and the 3-OMe group on the A-ring of colchicine. The 4′-OMe group of <b>3</b> mimics the 3-OMe group on the A-ring of colchicine (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>), suggesting its importance for the biological activity of <b>3</b>. The 4′-SMe analogue <b>9</b> had a 2-fold lower microtubule depolymerizing potency than the 4′-OMe analogue <b>3</b>. In addition, in the MDA-MB-435 cell antiproliferative assay, compounds <b>8</b> and <b>9</b> had 43- and 3-fold lower antiproliferative potencies, respectively, than <b>3</b>. These data indicate that bioisosteric replacement of the electronegative oxygen of the 4′-OMe group with sulfur in the 2-<i>H</i>,5-methylfuro[2,3-<i>d</i>]pyrimidine scaffold is detrimental to cellular microtubule depolymerization and to antiproliferative activity. The <i>N</i><sup>4</sup>-desmethyl synthetic precursor, <b>21</b>, like <b>2</b>, was inactive as a MTA with EC<sub>50</sub> > 10 μM, substantiating the importance of the <i>N</i><sup>4</sup>-alkyl substitution.</div><div class="NLM_p last">The effects of compounds <b>3</b>, <b>4</b>, and <b>6</b>–<b>9</b> on cellular microtubules in A-10 cells are shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>. A concentration of two-times their respective EC<sub>50</sub> values caused almost complete loss of the microtubule cytoskeleton, with only a few remnant microtubules remaining.</div></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> Effects on Mitotic Spindles and Cell Cycle Distribution</h4><div class="NLM_p">A common propensity of MTAs is their ability to interrupt the structure and function of mitotic spindles. The disruption of microtubule dynamics leads to the formation of aberrant mitotic spindles that are unable to align the chromosomes into the metaphase plate leading to the accumulation of cells arrested in mitosis.</div><div class="NLM_p">The effects of the microtubule active compounds on mitotic spindles and cell cycle distribution were evaluated in HeLa cells. The results showed that cells treated with these compounds were devoid of the normal bipolar spindles that were seen in vehicle-treated cells (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). No mitotic spindles were seen in cells treated with any of the test compounds, but multiple spindle poles were apparent, and these effects are consistent with effects seen with other colchicine site agents.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> These aberrant mitotic spindles suggested that these compounds could initiate mitotic arrest, and thus, the cell cycle distribution of the HeLa cells was evaluated by flow cytometry (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of compounds <b>3</b>, <b>4</b>, and <b>6</b>–<b>9</b> on mitotic spindles. HeLa cells were treated for 18 h with a concentration five-times the respective IC<sub>50</sub>, and cellular microtubules and mitotic spindles were visualized by indirect immunofluorescence techniques with a β-tubulin antibody.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cell cycle analysis of HeLa cells treated with <b>3</b>, <b>4</b>, and <b>6</b>–<b>9</b>. (A) Cell cycle distribution profiles of cells treated for 18 h with five-times the IC<sub>50</sub> of each compound. (B) Table showing the percent of cells in G<sub>2</sub>/M in each treatment group. Values are reported as the mean ± SD from two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In the flow cytometry study (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>), typical results were obtained for cells treated with the MTAs <b>3</b>, <b>4</b>, and <b>6</b>–<b>9</b>. These compounds cause the accumulation of cells in the G<sub>2</sub>/M phase of the cell cycle, as was observed following treatment with CA-4, while a normal cell cycle distribution was observed in the vehicle-treated control cells (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A). HeLa cells treated with five-times the IC<sub>50</sub> of <b>3</b>, <b>4</b>, or <b>6</b>–<b>9</b> exhibited a significant accumulation of cells in G<sub>2</sub>/M, as with CA-4 (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A). The percentage of cells in G<sub>2</sub>/M in each treatment group was quantified (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>B).</div></div><div id="sec2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Inhibition of Tubulin Assembly and Colchicine Binding</h4><div class="NLM_p">On the basis of their microtubule depolymerizing activities, compounds <b>3</b>–<b>7</b> and <b>9</b> were evaluated for their direct effects on tubulin assembly and inhibition of colchicine binding (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Except for <b>5</b>, all the compounds at 5 μM inhibited [<sup>3</sup>H]colchicine binding to the protein, and the extent of inhibition was similar to that obtained with CA-4. Straight chain <i>N</i><sup>4</sup>-alkyl analogues <b>4</b> (<i>N</i>-Et), <b>6</b> (<i>N</i>-Pr), and <b>7</b> (<i>N</i>-Bu) inhibited tubulin assembly about as well as CA-4 and were about 2-fold more potent than the lead compound (±)-<b>1</b>·HCl. In the colchicine inhibition assay, compounds <b>4</b> (<i>N</i>-Et), <b>6</b> (<i>N</i>-Pr) and <b>7</b> (<i>N</i>-Bu), at 5 μM, inhibited the binding of [<sup>3</sup>H]colchicine by 87–95%, whereas the branched alkyl <i>N</i>-<i>i</i>Pr <b>5</b> showed only a 47% inhibition of [<sup>3</sup>H]colchicine binding. The lower activity of the sterically bulky isopropyl moiety could be attributed to limited steric tolerance in the colchicine site. The data indicate that <i>N</i><sup>4</sup>-alkylation is tolerated to an extent as predicted by molecular modeling (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Compound <b>9</b> (4′-SMe) inhibited tubulin assembly with an IC<sub>50</sub> value comparable to that of CA-4, and it is 3-fold better than the 4′-OMe analogue <b>3</b>. However, it is interesting to note that <b>3</b>, despite its somewhat lower activity as an inhibitor of tubulin assembly, compared to CA-4, was a strong inhibitor of [<sup>3</sup>H]colchicine binding to tubulin.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibition of Tubulin Assembly and Colchicine Binding</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="±"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">inhibition of colchicine binding (% inhibition ± SD)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">inhibition of tubulin assembly (IC<sub>50</sub>  ± SD (μM))</th><th class="colsep0 rowsep0" align="center" char="±">1 μM</th><th class="colsep0 rowsep0" align="center" char="±">5 μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(±)<b>-1</b>·HCl<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (lead)</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">60 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">84 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">71 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">96 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char="±">0.97 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">84 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">95 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="char" char="±">3.0 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">ND</td><td class="colsep0 rowsep0" align="char" char="±">47 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">75 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">92 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">61 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">87 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 0.007</td><td class="colsep0 rowsep0" align="char" char="±">79 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">94 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CA-4</td><td class="colsep0 rowsep0" align="char" char="±">0.96 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">90 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">99 ± 0.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Results previously published.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div></div></div></div><div id="sec2_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Ability to Overcome Multidrug Resistance Mechanisms</h4><div class="NLM_p">The clinical activity of the taxanes and the vinca alkaloids is limited by two mechanisms of drug resistance: the expression of the drug efflux pump Pgp and the βIII-isotype of tubulin.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Pgp expression is observed clinically, particularly in patients who have received prior chemotherapy.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The expression of Pgp was associated with poor response to paclitaxel-based chemotherapy in patients with nonsmall cell lung and breast cancer.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> While the use of Pgp inhibitors to overcome this resistance has been explored, it has been unsuccessful due to the side effects, which occur when using the high doses required.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Tubulin binding agents that are not substrates for Pgp represent a viable alternate strategy for circumventing Pgp-mediated resistance. Such agents would be extremely useful for patients that develop tumor resistance due to Pgp expression.<a onclick="showRef(event, 'ref30 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref30 ref34 ref35">(30, 34, 35)</a></div><div class="NLM_p last">The expression of βIII-tubulin is involved in clinical resistance to taxanes and vinca alkaloids in nonsmall cell lung,<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36-38)</a> breast,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> ovarian,<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40, 41)</a> and gastric<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> cancers. Colchicine site agents are generally not susceptible to βIII-tubulin mediated resistance,<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> illustrating the importance of developing anticancer agents that bind to the colchicine site. Development of tubulin binding agents that are less sensitive to Pgp and/or βIII-tubulin mediated resistance could result in broader antitumor activity and improved rates of survival with significant advantages over other MTAs.</div></div><div id="sec2_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Effect on Pgp and βIII-Tubulin Mediated Cancer Cell Resistance</h4><div class="NLM_p">The potent MTAs <b>3</b>, <b>4</b>, and <b>6</b>–<b>9</b> were evaluated for their activity in the SK-OV-3 ovarian carcinoma cell line and the Pgp expressing subline SK-OV-3 MDR1-M6/6 (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> In these cell lines, compound <b>3</b> was the most potent compound in the series, and it had 5-fold higher potency than the lead compound (±)-<b>1</b>·HCl. In addition, compound <b>3</b> had potency similar to paclitaxel and CA-4 in the SK-OV-3 cell line. Comparison of the IC<sub>50</sub> values in the parental SK-OV-3 and genetically manipulated SK-OV-3 MDR1-M6/6 cell line allows for the calculation of a relative resistance value, designated Rr. This value is calculated by dividing the IC<sub>50</sub> value obtained in the Pgp-expressing MDR1-M6/6 cells by the IC<sub>50</sub> obtained in the parental SK-OV-3 cells. Paclitaxel, a known Pgp substrate has an Rr value of 240, while CA-4, a poor substrate, has an Rr value of 1.3 (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Compound <b>3</b> had IC<sub>50</sub> values in SK-OV-3 and SK-OV-3 MDR1-M6/6 cells comparable to that of CA-4 and an Rr of 1.1, indicating that it is able to overcome drug resistance mediated by Pgp. Compounds <b>4</b> and <b>6</b>–<b>9</b> also had Rr values less than 2, suggesting that they are all poor substrates for Pgp-mediated transport and have advantages over the taxanes and vinca alkaloids.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Target Compounds <b>3</b>, <b>4</b>, and <b>6</b>–<b>9</b> Circumvent Pgp and βIII-Tubulin Mediated Resistance</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">IC<sub>50</sub>  ± SD (nM)</th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">IC<sub>50</sub>  ± SD (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">SK-OV-3</th><th class="colsep0 rowsep0" align="center" char="±">SK-OV-3 MDR1-M6/6</th><th class="colsep0 rowsep0" align="center" char=".">Rr</th><th class="colsep0 rowsep0" align="center" char="±">HeLa</th><th class="colsep0 rowsep0" align="center" char="±">HeLa WTβIII</th><th class="colsep0 rowsep0" align="center" char=".">Rr</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(±)<b>-1</b>·HCl<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> (Lead)</td><td class="colsep0 rowsep0" align="char" char="±">38.6 ± 3.1</td><td class="colsep0 rowsep0" align="char" char="±">44.4 ± 3.2</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char="±">37.3 ± 4.1</td><td class="colsep0 rowsep0" align="char" char="±">23.9 ± 1.7</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char="±">7.7 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">8.4 ± 0.4</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char="±">9.5 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">8.1 ± 0.9</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char="±">14.5 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">18.3 ± 1.0</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char="±">15.8 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">14.6 ± 1.8</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="char" char="±">40.3 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">71.0 ± 19</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char="±">33.8 ± 7.4</td><td class="colsep0 rowsep0" align="char" char="±">35.3 ± 9.9</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="char" char="±">147.8 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">200.0 ± 17.1</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char="±">111.1 ± 19.0</td><td class="colsep0 rowsep0" align="char" char="±">115.9 ± 9.8</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="char" char="±">155.8 ± 15.0</td><td class="colsep0 rowsep0" align="char" char="±">161.9 ± 21.5</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char="±">120.5 ± 4.2</td><td class="colsep0 rowsep0" align="char" char="±">159.0 ± 17.6</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char="±">18.6 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">32.1 ± 1.5</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char="±">15.7 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">14.9 ± 1.9</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">paclitaxel</td><td class="colsep0 rowsep0" align="char" char="±">5.0 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">1,200 ± 58</td><td class="colsep0 rowsep0" align="char" char=".">240</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 0.36</td><td class="colsep0 rowsep0" align="char" char="±">24.0 ± 3.0</td><td class="colsep0 rowsep0" align="char" char=".">8.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CA-4</td><td class="colsep0 rowsep0" align="char" char="±">5.5 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 1.1</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 0.3</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Results previously published.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div></div></div><div class="NLM_p last">Compounds <b>3</b>, <b>4</b> and <b>6</b>–<b>9</b> were also evaluated for the ability to overcome βIII-tubulin mediated resistance in an isogenic HeLa cell line pair (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Compound <b>3</b> was the most potent compound in the series in HeLa and HeLa WT βIII cell lines with 4-fold better activity than the lead compound (±)-<b>1</b>·HCl. Similar to the Rr value in the SK-OV-3 isogenic cell line pair, the Rr value was calculated by dividing the IC<sub>50</sub> of the βIII-tubulin expressing line by the IC<sub>50</sub> obtained in the parental HeLa cells. The expression of βIII-tubulin is known to lead to paclitaxel resistance, and paclitaxel has an Rr value of 8.6 in this cell line pair (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). The target compounds <b>3</b>, <b>4</b>, and <b>6</b>–<b>9</b> have Rr values ∼1.0 (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>), suggesting that they circumvent βIII-tubulin mediated drug resistance.</div></div><div id="sec2_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Activity of Compound <b>3</b> in the NCI Cancer Cell Line Panel</h4><div class="NLM_p">The most potent compound (<b>3</b>) of the series was evaluated in the NCI cancer cell line panel,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> and it had GI<sub>50</sub> values <10 nM against 47 of the 57 cancer cell lines (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Compound <b>3</b> had better potency than the lead compound (±)-<b>1</b>·HCl<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> in 29 cancer cell lines and comparable potency to (±)-<b>1</b>·HCl<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> in 19 cancer cell lines (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Comparison of Cancer Cell Growth Inhibitory Activity (NCI) GI<sub>50</sub> (nM) of <b>3</b> with (±)-<b>1</b>·HCl<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">GI<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">GI<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">GI<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">GI<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">panel/cell line</th><th class="colsep0 rowsep0" align="center" char="."><b>3</b></th><th class="colsep0 rowsep0" align="center" char=".">(±)-<b>1</b>· HCl</th><th class="colsep0 rowsep0" align="center">panel/cell line</th><th class="colsep0 rowsep0" align="center" char="."><b>3</b></th><th class="colsep0 rowsep0" align="center" char=".">(±)-<b>1</b>· HCl</th><th class="colsep0 rowsep0" align="center">panel/cell line</th><th class="colsep0 rowsep0" align="center" char="."><b>3</b></th><th class="colsep0 rowsep0" align="center" char=".">(±)-<b>1</b>·HCl</th><th class="colsep0 rowsep0" align="center">panel/cell line</th><th class="colsep0 rowsep0" align="center" char="."><b>3</b></th><th class="colsep0 rowsep0" align="center" char=".">(±)-<b>1</b>·HCl</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>leukemia</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"><b>colon cancer</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"><b>melanoma</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"><b>renal cancer</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCRF-CEM</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">16.3</td><td class="colsep0 rowsep0" align="left">COLO 205</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">18.3</td><td class="colsep0 rowsep0" align="left">LOX IMVI</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">22.7</td><td class="colsep0 rowsep0" align="left">786–0</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">34.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HL-60(TB)</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="left">HCC-2998</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">24.0</td><td class="colsep0 rowsep0" align="left">MALME-3M</td><td class="colsep0 rowsep0" align="char" char=".">38.7<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">A498</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="left">HCT-116</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">15.1</td><td class="colsep0 rowsep0" align="left">M14</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">10.2</td><td class="colsep0 rowsep0" align="left">ACHN</td><td class="colsep0 rowsep0" align="char" char=".">22.5</td><td class="colsep0 rowsep0" align="char" char=".">14.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MOLT-4</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">31.8</td><td class="colsep0 rowsep0" align="left">HCT-15</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="left">MDA-MB-435</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="left">CAKI-1</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RPMI-8226</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">15.7</td><td class="colsep0 rowsep0" align="left">HT29</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">11.8</td><td class="colsep0 rowsep0" align="left">SK-MEL-28</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="left">RXF 393</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SR</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="left">KM12</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="left">SK-MEL-5</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="left">SN12C</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">31.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>NSCLC</b></td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">SW-620</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="left">UACC-62</td><td class="colsep0 rowsep0" align="char" char=".">29.6<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="left">TK10</td><td class="colsep0 rowsep0" align="char" char=".">75.3<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">292</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549/ATCC</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">24.4</td><td class="colsep0 rowsep0" align="left"><b>CNS cancer</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"><b>ovarian cancer</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">UO-31</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">13.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EKVX</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">19.6</td><td class="colsep0 rowsep0" align="left">SF-268</td><td class="colsep0 rowsep0" align="char" char=".">10.1</td><td class="colsep0 rowsep0" align="char" char=".">15.2</td><td class="colsep0 rowsep0" align="left">IGROVI</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">11.0</td><td class="colsep0 rowsep0" align="left"><b>prostate cancer</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HOP-62</td><td class="colsep0 rowsep0" align="char" char=".">18.4<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">19.4</td><td class="colsep0 rowsep0" align="left">SF-295</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="left">OVCAR-3</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="left">PC-3</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">14.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HOP-92</td><td class="colsep0 rowsep0" align="char" char=".">62.5</td><td class="colsep0 rowsep0" align="char" char=".">55.4</td><td class="colsep0 rowsep0" align="left">SF-539</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">11.4</td><td class="colsep0 rowsep0" align="left">OVCAR-4</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">26.8</td><td class="colsep0 rowsep0" align="left">DU-145</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">21.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCI-H226</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">31.5</td><td class="colsep0 rowsep0" align="left">SNB-19</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">36.9</td><td class="colsep0 rowsep0" align="left">OVCAR-5</td><td class="colsep0 rowsep0" align="char" char=".">12.8</td><td class="colsep0 rowsep0" align="char" char=".">38.5</td><td class="colsep0 rowsep0" align="left"><b>breast cancer</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCI-H23</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">16.4</td><td class="colsep0 rowsep0" align="left">SNB-75</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="left">OVCAR-8</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">32.8</td><td class="colsep0 rowsep0" align="left">MCF7</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCI-H322M</td><td class="colsep0 rowsep0" align="char" char=".">>100<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">59.0</td><td class="colsep0 rowsep0" align="left">U251</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">12.5</td><td class="colsep0 rowsep0" align="left">NCI/ADR-RES</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="left">MDA-MB-231/ATCC</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">24.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCI-H460</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">23.4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">SK-OV-3</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">27.5</td><td class="colsep0 rowsep0" align="left">HS 578T</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCI-H522</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">BT-549</td><td class="colsep0 rowsep0" align="char" char=".">59.6</td><td class="colsep0 rowsep0" align="char" char=".">21.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">MDA-MB-468</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char="."><10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Results previously published.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">GI<sub>50</sub> values in μM.</p></div></div></div></div><div id="sec2_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <sup>1</sup>H NMR Evidence for Conformational Restriction in Compound <b>3</b></h4><div class="NLM_p">The <sup>1</sup>H NMR spectra of the <i>N</i>-H analogue <b>2</b> and <i>N</i>-Me analogue <b>3</b> in DMSO-<i>d</i><sub>6</sub> afforded additional information related to the conformational restriction in <b>3</b> (<a class="ref internalNav" href="#fig8" aria-label="Figures 8">Figures 8</a> and <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). For <b>2</b>, the “5-Me” protons appeared at δ 2.40, whereas for <b>3</b> they were significantly shielded at δ 1.05. This shielding of the “5-Me” protons in <b>3</b> was attributed to a diamagnetic anisotropic effect in <b>3</b> arising from the proximity of the phenyl ring as shown in <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a> (more favored <i>anti</i>-conformation for <b>3</b> on the basis of the <i>N</i>-Me and the 5-Me groups). The steric bulk of the <i>N</i>-Me and/or steric clash of the <i>N</i>-Me and the 5-Me groups in <b>3</b> restricts the conformation and positions the phenyl group on top of the 5-Me moiety (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>B), resulting in the observed shielding effect, in the <sup>1</sup>H NMR, on the 5-Me group in <b>3</b> as compared to that in <b>2</b>.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Conformational restriction of C4–N and N–C1′ bonds in the presence of the <i>N</i>-Me moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0010.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Conformations and <sup>1</sup>H NMR analyses of <b>2</b> (A) and <b>3</b> (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This shielding effect of the phenyl group on the 5-Me group (δ ≈ 1.10) was also observed for the <i>N</i><sup>4</sup>-alkyl analogues <b>4</b>–<b>7</b> and <i>N</i><sup>4</sup>-Me analogues <b>8</b> and <b>9</b> (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>).</div><figure id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0011.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. δ values (<sup>1</sup>H NMR) for compounds <b>2</b>–<b>9</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The prediction of the possible putative bound conformation of <b>3</b> gleaned from the <sup>1</sup>H NMR was further supported by the docked pose of <b>3</b> in the colchicine site (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>A, MOE 2013.0801<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>). The phenyl ring of <b>3</b> sits on top of the 5-Me group of the furo[2,3-<i>d</i>]pyrimidine scaffold and exerts its anisotropic effect on the 5-Me protons. In the docked pose of <b>3</b>, the distance of the 5-Me with the most proximal carbons on the phenyl ring were found to be 3.62 and 4.08 Å. Similar mode of binding was observed for compounds <b>4</b>–<b>9</b> when docked in the colchicine site of tubulin (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>B).</div><figure id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0012.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Docked pose of <b>3</b> without the protein showing the distance (in Å) between 5-Me and the closest carbons on the phenyl ring. (B) Stereoview. Superimposition of docked poses of <b>3</b> (green), <b>4</b> (magenta), <b>5</b> (yellow), <b>6</b> (blue), <b>7</b> (brown), <b>8</b> (orange), and <b>9</b> (cyan) in the colchicine site of tubulin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Antitumor Activity of Compound <b>3</b> in MDA-MB-435 Xenografts</h4><div class="NLM_p">Compound <b>3</b> was selected for an in vivo xenograft mouse study in light of its nanomolar potency in vitro in the NCI cancer cell line panel and its potent microtubule depolymerization activity. Compound <b>3</b> was tested for in vivo antitumor effects in the MDA-MB-435 xenograft model (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>). MDA-MB-435 tumor fragments were injected sc into the flank of nude mice. Once tumors reached ∼200 mm<sup>3</sup>, mice were injected three times ip with <b>3</b> (cumulative dose 170 mg/kg) or six times with paclitaxel (120 mg/kg cumulative dose). The results show that <b>3</b> caused statistically significant inhibition of tumor growth as compared to the untreated control, and the mean tumor volume was slightly lower than that achieved with paclitaxel.</div><figure id="fig12" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0013.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Effect of <b>3</b> and paclitaxel (PTX) on MDA-MB-435 tumor growth. Nude mice bilaterally implanted with MDA-MB-435 tumor fragments were dosed with 60 mg/kg of <b>3</b> on days 0 and 2; and 50 mg/kg of <b>3</b> on day 8 or PTX at 20 mg/kg on days 0, 2, 4, 6, 8, and 11 as a positive control. (A) The average tumor volume is graphed with error bars representing the standard deviation. (B) The final tumor volumes are plotted with lines representing the mean and 95% confidence intervals. *<i>p</i> = 0.0425 and **<i>p</i> = 0.0014.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76108" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76108" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A series of eight 5-methyl-furo[2,3-<i>d</i>]pyrimidines were designed and synthesized as microtubule depolymerizing agents. Synthesis of target compounds involved an Ullmann coupling reaction as the key step. Compounds <b>3</b>, <b>4</b>, and <b>9</b> showed microtubule depolymerizing activity at concentrations less than 100 nM. Compounds <b>3</b>, <b>4</b>, and <b>6</b>–<b>9</b> demonstrated the ability to cause G<sub>2</sub>/M cell cycle accumulation and induce the formation of abnormal mitotic spindles. Replacing the <i>N</i>-Me group with higher alkyl groups led to a 2–10-fold decrease in microtubule depolymerizing activity. <i>N</i><sup>4</sup>-Alkyl-4′-OMe analogues <b>4</b>, <b>6</b>, and <b>7</b> and the <i>N</i><sup>4</sup>-Me-4′-SMe analogue <b>9</b> inhibited tubulin assembly with activity comparable to that of CA-4. Compounds <b>3</b>, <b>4</b>, <b>6</b>, and <b>9</b>, at 5 μM, inhibited [<sup>3</sup>H]colchicine binding to tubulin about as well as did CA-4. Compounds <b>3</b>, <b>4</b>, and <b>6</b>–<b>9</b> circumvented Pgp and βIII-tubulin mediated drug resistance. Proton NMR and molecular modeling were utilized to determine the role of the <i>N</i><sup>4</sup>-methyl group in tubulin inhibitory activity. The <i>N</i><sup>4</sup>-alkyl group, in addition to the 5-Me group, on the furo[2,3-<i>d</i>]pyrimidine scaffold restricts the conformation about the C4–N and N–C1′ bonds and contributes, in part, to the biological activity of these analogues. The <i>N</i><sup>4</sup>-H analogue <b>2</b>, where such a conformational restriction is not attainable, is essentially devoid of activity as an MTA. Compound <b>3</b> displayed nanomolar antiproliferative activity in the NCI cancer cell line panel and thus was selected for xenograft study. In MDA-MB-435 xenografts in mice, compound <b>3</b> significantly inhibited tumor growth. Compound <b>3</b> is an important preclinical candidate as a MTA and is currently undergoing extensive preclinical evaluations.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25400" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25400" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Chemistry</h3><div class="NLM_p">All evaporations were carried out in vacuum with a rotary evaporator. Analytical samples were dried in vacuo (0.2 mmHg) in a CHEM-DRY drying apparatus over P<sub>2</sub>O<sub>5</sub> at 50 °C. Thin–layer chromatography (TLC) was performed on Whatman Sil G/UV254 silica gel plates, and the spots were visualized by irradiation with ultraviolet light (254 and 366 nm). Proportions of solvents used for TLC are by volume. All analytical samples were homogeneous on TLC in at least two different solvent systems. Column chromatography was performed on a 70-230 mesh silica gel (Fisher Scientific) column. The amount (weight) of silica gel for column chromatography was in the range of 50–100 times the amount (weight) of the crude compounds being separated. Columns were wet-packed with appropriate solvent unless specified otherwise. Melting points were determined using a digital MEL-TEMP II melting point apparatus with FLUKE 51 K/J electronic thermometer or using an MPA100 OptiMelt automated melting point system and are uncorrected. Nuclear magnetic resonance spectra for proton (<sup>1</sup>H NMR) were recorded on Bruker Avance II 400 (400 MHz) and 500 (500 MHz) systems and were analyzed using MestReC NMR data processing software. The chemical shift (δ) values are expressed in ppm (parts per million) relative to tetramethylsilane as an internal standard: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad singlet; exch, protons exchangeable by addition of D<sub>2</sub>O.</div><div class="NLM_p last">Elemental analyses or high-performance liquid chromatography (HPLC)/mass analysis were used to determine the purities of the target compounds. Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, GA, USA. Elemental compositions are within ±0.4% of the calculated values and indicate >95% purity. Fractional moles of water or organic solvents frequently found in some analytical samples could not be prevented despite 24–48 h of drying in vacuo and were confirmed where possible by their presence in the <sup>1</sup>H NMR spectra. Mass spectral data were acquired on an Agilent G6220AA TOF LC/MS system using the nano ESI (Agilent chip tube system with infusion chip). HPLC analysis was performed on a Waters HPLC system using XSelect CSH C18 column. Peak area of the major peak versus other peaks was used to determine purity. All solvents and chemicals were purchased from Sigma-Aldrich Co. or Fisher Scientific Inc. and were used as received.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>N</i>-(4-Methoxyphenyl)-5-methylfuro[2,3-<i>d</i>]pyrimidin-4-amine (<b>2</b>)</h3><div class="NLM_p last">A 50 mL round-bottom flask was charged with CuI (66.5 mg, 0.35 mmol), anhydrous potassium carbonate (480 mg, 3.5 mmol), <span class="smallcaps smallerCapital">l</span>-proline (80 mg, 0.7 mmol), compound <b>12</b> (150 mg, 1 mmol), and 4-iodoanisole <b>13</b> (350 mg, 3.5 mmol). The flask was connected to a vacuum for 3 min followed by addition of anhydrous DMF (15 mL) using syringe. The flask was purged with argon for 5 min and then stirred at 110 °C. Upon heating, the color of the suspension turned blueish gray, and this color persisted for about 2 h. The reaction was stirred for another 22 h at 110 °C, at the end of which the mixture was allowed to cool to room temperature. Ethyl acetate (25 mL) was added, and the mixture was poured into water (100 mL). The product was extracted with ethyl acetate (100 mL × 2). The combined organic extracts were washed with brine (100 mL), dried (anhydrous Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure. Silica gel (500 mg) was added and the solvent evaporated to obtain a plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to 2:1) afforded 87.5 mg (33%) of <b>2</b> as a light brown solid. TLC <i>R</i><sub>f</sub> = 0.77 (CHCl<sub>3</sub>/MeOH, 10:1); mp 99.5–101.6 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ = 2.383–2.386 (d, 3H, 5-CH<sub>3</sub>, <i>J</i> = 1.2 Hz), 3.75 (s, 3H, OCH<sub>3</sub>), 6.92–6.94 (d, 2H, Ar, <i>J</i> = 8.8 Hz), 7.47–7.49 (d, 2H, Ar, <i>J</i> = 8.8 Hz), 7.650–7.653 (d, 1H, C6-CH, <i>J</i> = 1.2 Hz), 8.23 (s, 1H, C2-CH), 8.38 (s, 1H, 4-NH, exch). Anal. (C<sub>14</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>-(4-Methoxyphenyl)-<i>N</i>,5-dimethylfuro[2,3-<i>d</i>]pyrimidin-4-amine (<b>3</b>)</h3><div class="NLM_p last">In a 25 mL round-bottom flask, compound <b>2</b> (510 mg, 2 mmol) was dissolved in DMF (10 mL). The flask was purged with argon for 5 min and cooled to 0 °C using an ice bath. NaH (144 mg, 6 mmol) was added to the solution at 0 °C, and the reaction mixture was stirred for 30 min at 0 °C under an argon atmosphere. Dimethyl sulfate (757 mg, 6 mmol) was injected into the reaction mixture, and the flask was warmed to room temperature. The mixture was stirred for 3 h, and 1 N HCl (5 mL) was added carefully to quench the reaction. Water (20 mL) was added, resulting in formation of a precipitate. The product was extracted with ethyl acetate (50 mL × 3). The combined organic extracts were washed with brine (10 mL), dried (anhydrous Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure. Silica gel (2 g) was added, and the solvent was evaporated to yield a plug. Column chromatography by elution with hexanes and ethyl acetate (5:1) afforded <b>3</b> (416 mg, 70%) as an off-white solid. TLC <i>R</i><sub>f</sub> = 0.87 (CHCl<sub>3</sub>/MeOH, 10:1); mp 87–88 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ = 1.05 (s, 3H, 5-CH<sub>3</sub>), 3.44 (s, 3H, OCH<sub>3</sub>), 3.77 (s, 3H, NCH<sub>3</sub>), 6.96–6.98 (d, 2H, Ar, <i>J</i> = 9.0 Hz), 7.19–7.22 (d, 2H, Ar, <i>J</i> = 9.0 Hz), 7.52 (s, 1H, C6-CH), 8.45 (s, 1H, C2-CH). Anal. (C<sub>15</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure for the Synthesis of Substituted Furo[2,3-<i>d</i>]pyrimidines <b>4</b>–<b>7</b></h3><div class="NLM_p">In a 25 mL round-bottom flask, compound <b>2</b> (1 equiv) was dissolved in DMF (2 mL). The flask was purged with argon for 5 min and cooled to 0 °C using an ice bath. NaH (3 equiv) was added to the solution at 0 °C, and the reaction mixture was stirred for 20 min under argon atmosphere. The appropriate alkyl iodide (3–4 equiv) was injected into the reaction mixture, and the flask was warmed to room temperature. The mixture was stirred at room temperature until TLC showed disappearance of the reactant <b>2</b>. Aqueous 1 N HCl was added dropwise to quench the reaction. Water (4 mL) was added, resulting in formation of a precipitate. The product was extracted with ethyl acetate (10 mL × 3). The combined organic extracts were washed with brine (10 mL), dried (anhydrous Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure. Silica gel (200 mg) was added, and the solvent was evaporated under reduced pressure. The resulting plug was loaded onto a silica gel column in hexanes (the silica was 20 times the weight of the plug), and the column was eluted with hexanes and ethyl acetate (5:1) to obtain <b>4</b>–<b>7</b> in yields of 57–85%.</div><div id="sec4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-Ethyl-<i>N</i>-(4-methoxyphenyl)-5-methylfuro[2,3-<i>d</i>]pyrimidin-4-amine (<b>4</b>)</h4><div class="NLM_p last">Using the general procedure described above, ethyl iodide <b>14</b> (61.70 mg or 0.1 mL, 1.2 mmol) was added to an ice-cold solution of <b>2</b> (100 mg, 0.4 mmol) and NaH (28.8 mg, 1.2 mmol) in 2 mL of DMF, and the reaction was run at room temperature for 2 h to provide 94 mg (85%) of <b>4</b> as an off-white solid. TLC <i>R</i><sub>f</sub> = 0.88 (CHCl<sub>3</sub>/MeOH, 15:1); mp 77.8–78.3 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ = 1.064–1.067 (d, 3H, 5-CH<sub>3</sub>, <i>J</i> = 1.2 Hz), 1.22 (t, 3H, CH<sub>3</sub>, <i>J</i> = 7 Hz), 3.82 (s, 3H, OCH<sub>3</sub>), 4.06–4.11 (q, 2H, N–CH<sub>2</sub>, <i>J</i> = 7 Hz), 6.88–6.91 (d, 2H, Ar, <i>J</i> = 8.9 Hz), 7.074–7.077 (d, 1H, C6-CH, <i>J</i> = 1.2 Hz), 7.09–7.11 (d, 2H, Ar, <i>J</i> = 8.9 Hz), 8.48 (s, 1H, C2-CH). Anal. (C<sub>16</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-Isopropyl-<i>N</i>-(4-methoxyphenyl)-5-methylfuro[2,3-<i>d</i>]pyrimidin-4-amine (<b>5</b>)</h4><div class="NLM_p last">Using the general procedure described above, isopropyl iodide <b>15</b> (266.36 mg, 1.6 mmol) was added to an ice-cold solution of <b>2</b> (100 mg, 0.4 mmol) and NaH (38.4 mg, 1.6 mmol) in 2 mL of DMF, and the reaction was run at room temperature for 6 h to provide 75 mg (63%) of <b>5</b> as an off-white solid. TLC <i>R</i><sub>f</sub> = 0.88 (CHCl<sub>3</sub>/MeOH, 15:1); mp 95.8–96.6 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ = 1.02 (d, 3H, 5-CH<sub>3</sub>, <i>J</i> = 1.3 Hz), 1.14–1.16 (d, 6H, two CH<sub>3</sub>, <i>J</i> = 6.8 Hz), 3.79 (s, 3H, OCH<sub>3</sub>), 5.30–5.37 (m, 1H, N–CH), 6.85–6.87 (d, 2H, Ar, <i>J</i> = 8.9 Hz), 7.000–7.004 (d, 1H, C6-CH, <i>J</i> = 1.3 Hz), 7.02–7.04 (d, 2H, Ar, <i>J</i> = 8.9 Hz), 8.42 (s, 1H, C2-CH). Anal. (C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-(4-Methoxyphenyl)-5-methyl-<i>N</i>-propylfuro[2,3-<i>d</i>]pyrimidin-4-amine (<b>6</b>)</h4><div class="NLM_p last">Using the general procedure described above, propyl iodide <b>16</b> (199 mg or 0.12 mL, 1.2 mmol) was added to an ice-cold solution of <b>2</b> (100 mg, 0.4 mmol) and NaH (28.8 mg, 1.2 mmol) in 2 mL of DMF, and the reaction was run at room temperature for 2 h to provide 80 mg (69%) of <b>6</b> as an off-white solid. TLC <i>R</i><sub>f</sub> = 0.88 (CHCl<sub>3</sub>/MeOH, 15:1); mp 113.5–114.2 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ = 0.94–0.97 (t, 3H, CH<sub>3</sub>), 1.095–1.098 (d, 3H, 5-CH<sub>3</sub>, <i>J</i> = 1.2 Hz), 1.70–1.74 (m, 2H, CH<sub>2</sub>), 3.84 (s, 3H, OCH<sub>3</sub>), 3.96–3.99 (m, 2H, N–CH<sub>2</sub>), 6.89–6.91 (d, 2H, Ar, <i>J</i> = 8.95 Hz), 7.092–7.095 (d, 1H, C6-CH, <i>J</i> = 1.2 Hz), 7.10–7.12 (d, 2H, Ar, <i>J</i> = 9.0 Hz), 8.49 (s, 1H, C2-CH). Anal. (C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N</i>-Butyl-<i>N</i>-(4-methoxyphenyl)-5-methylfuro[2,3-<i>d</i>]pyrimidin-4-amine (<b>7</b>)</h4><div class="NLM_p last">Using the general procedure described above, butyl iodide <b>17</b> (216.26 mg or 0.13 mL, 1.2 mmol) was added to an ice-cold solution of <b>2</b> (100 mg, 0.4 mmol) and NaH (28.8 mg, 1.2 mmol) in 2 mL of DMF, and the reaction was run at room temperature for 2.5 h to provide 70 mg (57%) of <b>7</b> as a semisolid. TLC <i>R</i><sub>f</sub> = 0.88 (CHCl<sub>3</sub>/MeOH, 15:1); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ = 0.88–0.92 (t, 3H, CH<sub>3</sub>), 1.06 (s, 3H, 5-CH<sub>3</sub>), 1.30–1.39 (m, 2H, CH<sub>2</sub>), 1.59–1.67 (m, 2H, CH<sub>2</sub>), 3.81 (s, 3H, OCH<sub>3</sub>), 3.96–4.00 (m, 2H, N–CH<sub>2</sub>), 6.86–6.88 (d, 2H, Ar, <i>J</i> = 8.9 Hz), 7.06–7.09 (m, 3H, Ar and C6-CH), 8.45 (s, 1H, C2-CH). HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>18</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 312.1712. Found: 312.1709. HPLC analysis: retention time = 38.76 min; peak area, 97.33%; eluent A, H<sub>2</sub>O; eluent B, ACN; gradient elution (100% H<sub>2</sub>O to 10% H<sub>2</sub>O) over 60 min with a flow rate of 0.5 mL/min and detection at 254 nm; column temperature, rt.</div></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Procedure for the Synthesis of Substituted Furo[2,3-<i>d</i>]pyrimidines <b>8</b> and <b>9</b></h3><div class="NLM_p">In a 25 mL round-bottom flask, the appropriate furo[2,3-<i>d</i>]pyrimidine (1 equiv of <b>20</b> or <b>21</b>) was dissolved in DMF. The flask was purged with argon for 5 min and cooled to 0 °C using an ice bath. To the solution at 0 °C was added NaH (3 equiv), and the reaction mixture was stirred for 20 min at 0 °C under argon atmosphere. Dimethyl sulfate (3 equiv) was injected into the reaction mixture, and the flask was warmed to room temperature. The mixture was stirred at room temperature until TLC showed disappearance of the reactant <b>20</b> or <b>21</b>. Aqueous 1 N HCl was added dropwise to quench the reaction, followed by water (20 mL) to yield a precipitate. The product was extracted with ethyl acetate (10 mL × 3). The combined organic extracts were washed with brine (10 mL), dried (anhydrous sodium sulfate), and concentrated under reduced pressure. Silica gel (200 mg) was added, and the solvent was evaporated to obtain a plug. The plug was loaded onto a silica gel column in hexanes (the silica was 20 times the weight of the plug), and the column was eluted with hexanes and ethyl acetate (5:1) to obtain <b>8</b> or <b>9</b>.</div><div id="sec4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-Methyl-<i>N</i>-(4-ethylphenyl)-5-methylfuro[2,3-<i>d</i>]pyrimidin-4-amine (<b>8</b>)</h4><div class="NLM_p last">Using the general procedure described above, the reaction between <b>20</b> (40 mg, 0.16 mmol) and dimethyl sulfate (0.04 mL, 0.48 mmol) in DMF (2 mL) in the presence of NaH (11.5 mg, 0.48 mmol) provided 23 mg (53%) of <b>8</b> as a white solid. TLC <i>R</i><sub>f</sub> = 0.77 (CHCl<sub>3</sub>/MeOH, 10:1); mp 116.3–116.8 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ = 1.09 (s, 3H, 5-CH<sub>3</sub>), 1.24–1.28 (t, 3H, CH<sub>3</sub>), 2.64–2.70 (q, 2H, CH<sub>2</sub>), 3.57 (s, 3H, NCH<sub>3</sub>), 7.10–7.12 (d, 2H, Ar), 7.19–7.21 (m, 3H, Ar and C6-CH), 8.56 (s, 1H, C2-CH). Anal. (C<sub>16</sub>H<sub>17</sub>N<sub>3</sub>O·0.07CH<sub>3</sub>CO<sub>2</sub>C<sub>2</sub>H<sub>5</sub>) C, H, N.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>,5-Dimethyl-<i>N</i>-(4-(methylthio)phenyl)furo[2,3-<i>d</i>]pyrimidin-4-amine (<b>9</b>)</h4><div class="NLM_p last">Using the general procedure described above, the reaction between <b>21</b> (105 mg, 0.4 mmol) and dimethyl sulfate (0.08 mL, 1.2 mmol) in DMF (8 mL) in the presence of NaH (28.8 mg, 1.2 mmol) provided 56 mg (51%) of <b>9</b> as a brown solid. TLC <i>R</i><sub>f</sub> = 0.88 (CHCl<sub>3</sub>/MeOH, 10:1); mp 95.8–96.2 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ = 1.109–1.112 (d, 3H, 5-CH<sub>3</sub>, <i>J</i> = 1.1 Hz), 2.48 (s, 3H, SCH<sub>3</sub>), 3.47 (s, 3H, NCH<sub>3</sub>), 7.20–7.22 (d, 2H, Ar, <i>J</i> = 8.65 Hz), 7.28–7.30 (d, 2H, Ar, <i>J</i> = 8.66 Hz), 7.567–7.570 (d, 1H, C6-CH, <i>J</i> = 1.2 Hz), 8.50 (s, 1H, C2-CH). Anal. (C<sub>15</sub>H<sub>15</sub>N<sub>3</sub>OS) C, H, N, S.</div></div></div><div id="sec100" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 2-Amino-4-methylfuran-3-carbonitrile (<b>11</b>)</h3><div class="NLM_p last">To a solution of malononitrile (1.46 g, 22.1 mmol) in anhydrous MeOH (20 mL) was added triethylamine (2.23 g, 22.1 mmol) under argon atmosphere. To this solution at 0 °C was added a solution of hydroxyacetone <b>10</b> (1.64 g, 1.08 g/mL, 22.1 mmol) in 10 mL of anhydrous methanol. The solution was warmed to room temperature and stirred for 14 h. The solvents were removed in vacuo to give <b>11</b> as a brown-colored crude solid. TLC <i>R</i><sub>f</sub> = 0.60 (hexane/EtOAc, 10:1); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ = 2.01 (s, 3H, 4-CH<sub>3</sub>), 4.75 (br, 2H, 2-NH<sub>2</sub>), 6.61 (s, 1H, C5-CH). <sup>1</sup>H NMR agreed well with the literature<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> values. This material was used directly for the next step without purification.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 5-Methylfuro[2,3-<i>d</i>]pyrimidin-4-amine (<b>12</b>)</h3><div class="NLM_p last">In a 500 mL round-bottom flask, sodium metal (2.3 g, 0.1 mol) was added cautiously to stirred anhydrous EtOH (5.8 mL, 0.1 mol) over 10 min at room temperature. After stirring for another 5 min, formamidine hydrochloride (8.05 g, 0.1 mol) was added. The resulting slurry was stirred at room temperature for 30 min, after which a solution of <b>11</b> (13 g crude, ∼0.1 mol) in anhydrous EtOH (200 mL) was added. The mixture was heated to reflux for 8 h. After cooling the reaction mixture to room temperature, silica gel (25 g) was added, and the solvent was evaporated under reduced pressure to obtain a plug. Purification was performed by flash chromatography using 1% MeOH in CHCl<sub>3</sub>. Fractions containing the product (TLC) were pooled and evaporated to provide 7.1 g (47%, two steps) of <b>12</b> as lustrous pink crystals. TLC <i>R</i><sub>f</sub> = 0.29 (CHCl<sub>3</sub>/MeOH, 10:1); mp 240.2–242.5 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ = 2.288–2.292 (d, 3H, CH<sub>3</sub>, <i>J</i> = 1.4 Hz), 7.02 (br, 2H, NH<sub>2</sub>, exch), 7.533–5.536 (d, 1H, C6-CH, <i>J</i> = 1.4 Hz), 8.13 (s, 1H, C2-CH). Anal. (C<sub>7</sub>H<sub>7</sub>N<sub>3</sub>O) C, H, N.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> General Procedure for the Synthesis of <i>N</i>-(4-Substitutedphenyl)-5-methylfuro[2,3-<i>d</i>]pyrimidin-4-amines <b>20</b> and <b>21</b></h3><div class="NLM_p">A 50 mL round-bottom flask was charged with CuI (66.5 mg, 0.35 mmol), anhydrous potassium carbonate (480 mg, 3.5 mmol), <span class="smallcaps smallerCapital">l</span>-proline (80 mg, 0.7 mmol), compound <b>12</b> (150 mg, 1 mmol), and the appropriate iodobenzene (3.5 mmol). The flask was connected to a vacuum for 3 min, followed by addition of anhydrous DMF (15 mL) using a syringe. The flask was purged with argon for 5 min and then stirred at 110 °C. On heating, the color of the suspension turned blueish gray, and this color change lasted for about 2 h. The reaction was stirred for an additional 22 h at 110 °C, at the end of which the mixture was allowed to cool to room temperature. Ethyl acetate (25 mL) was added, and the mixture was poured into water (100 mL). The product was extracted with ethyl acetate (100 mL × 2). The combined organic extracts were washed with brine (100 mL), dried (anhydrous Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure. Silica gel (500 mg) was added, and the solvent evaporated to yield a plug, which was purified by column chromatography using hexanes and ethyl acetate (10:1 to 2:1). Fractions containing the product (TLC) were pooled and evaporated to afford <b>20</b> or <b>21</b>.</div><div id="sec4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-(4-Ethylphenyl)-5-methylfuro[2,3-<i>d</i>]pyrimidin-4-amine (<b>20</b>)</h4><div class="NLM_p last">Using the general procedure described above, reaction between <b>12</b> (150 mg, 1 mmol) and 1-ethyl-4-iodobenzene <b>18</b> (350 mg, 3.5 mmol) provided 74 mg (29%) of <b>20</b> as a brown semisolid. TLC <i>R</i><sub>f</sub> = 0.78 (CHCl<sub>3</sub>/MeOH, 10:1); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ = 1.23–1.27 (t, 3H, CH<sub>3</sub>), 2.421–2.423 (d, 3H, 5-CH<sub>3,</sub><i>J</i> = 0.9 Hz), 2.65–2.69 (q, 2H, CH<sub>2</sub>), 6.85 (s, 1H, 4-NH, exch), 7.21–7.23 (d, 2H, Ar, <i>J</i> = 8.3 Hz), 7.296–7.298 (d, 1H, C6-CH, <i>J</i> = 0.9 Hz), 7.51–7.53 (d, 2H, Ar, <i>J</i> = 8.3 Hz), 8.45 (s, 1H, C2-CH). Anal. (C<sub>15</sub>H<sub>15</sub>N<sub>3</sub>O·0.1CH<sub>3</sub>CO<sub>2</sub>C<sub>2</sub>H<sub>5</sub>) C, H, N.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 5-Methyl-<i>N</i>-(4-(methylthio)phenyl)furo[2,3-<i>d</i>]pyrimidin-4-amine (<b>21</b>)</h4><div class="NLM_p last">Using the general procedure described above, reaction between <b>12</b> (150 mg, 1 mmol) and 4-iodo-thioanisole <b>19</b> (350 mg, 3.5 mmol) afforded 40 mg (15%) of <b>21</b> as a brown semisolid. TLC <i>R</i><sub>f</sub> = 0.83 (CHCl<sub>3</sub>/MeOH, 10:1); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ = 2.41 (s, 3H, SCH<sub>3</sub>), 2.51 (s, 3H, 5-CH<sub>3</sub>), 7.02 (s, 1H, 4-NH, exch), 7.28–7.34 (m, 3H, Ar and C6-CH), 7.57–7.59 (d, 2H, Ar), 8.47 (s, 1H, C2-CH). Anal. (C<sub>14</sub>H<sub>13</sub>N<sub>3</sub>OS·0.07CH<sub>3</sub>(CH<sub>2</sub>)<sub>4</sub>CH<sub>3</sub>) C, H, N, S.</div></div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Molecular Modeling</h3><div class="NLM_p">Docking of target compounds <b>2</b>–<b>9</b> was carried out in the colchicine site of tubulin (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B">4O2B</a>, 2.30 Å)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> using Molecular Operating Environment (MOE 2013.0801).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The crystal structures were obtained from the protein database and imported into MOE 2013.0801. The proteins were then prepared using the LigX function and the Amber99 forcefield for energy minimization under default settings. Ligands were prepared using the builder function in MOE and minimized using MMF94x forcefield. The ligands were then docked in the binding site using the Alpha triangle placement method. Refinement was carried out using Forcefield and scored using the Affinity dG scoring system.</div><div class="NLM_p last">After the preparation of the protein using the LigX function, chains C, D, E, and F were deleted along with Ca<sup>2+</sup>, Mg<sup>2+</sup>, GDP, GTP, and all the other bound ligands except colchicine. To validate the docking study at the colchicine site, the native ligand colchicine was redocked into the binding site using the same set of parameters as described above. The rmsd of the best docked pose was 0.5347 Å, thus validating the docking using MOE.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Biological Studies</h3><div id="sec4_17_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Effects of Compounds on Cellular Microtubules</h4><div class="NLM_p last">A-10 cells were used to evaluate the effects of the compounds on cellular microtubules using indirect immunofluorescence techniques. Cells were treated for 18 h with compounds, and microtubules were visualized with a β-tubulin antibody (Sigma-Aldrich, St. Louis, MO). EC<sub>50</sub> values were calculated as previously described<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and represent an average of at least three independent experiments.</div></div><div id="sec4_17_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Sulforhodamine B (SRB) Assay</h4><div class="NLM_p last">The SRB assay was used to evaluate the antiproliferative and cytotoxic effects of the compounds against cancer cells as previously described.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> MDA-MB-435, SK-OV-3, and HeLa cells were purchased from the American Type Culture Collection (Manassas, VA). Details about the generation of the SK-OV-3 MDR1-M6/6 and HeLa WTβIII cells were previously described.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The IC<sub>50</sub> values represent an average of three independent experiments using triplicate points in each experiment.</div></div><div id="sec4_17_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Quantitative Tubulin Studies</h4><div class="NLM_p last">Bovine brain tubulin was purified as described previously.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The tubulin assembly assay has been described in detail.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Briefly, 1.0 mg/mL of tubulin (10 μM) was preincubated for 15 min at 30 °C in 0.8 M monosodium glutamate (pH of 2 M stock solution adjusted to 6.6 with HCl), varying compound concentrations and 4% (v/v) DMSO as compound solvent. After preincubation, the reaction mixtures were placed on ice, and 0.4 mM GTP was added. The reaction mixtures were transferred to cuvettes at 0 °C in a recording spectrophotometer equipped with an electronic temperature controller. After baselines were established, the temperature was elevated over about 30 s to 30 °C, and changes in turbidity were monitored for 20 min. The compound concentration that caused a 50% reduction in increase in turbidity, interpolated from the values obtained with defined compound concentrations, was defined as the IC<sub>50</sub> value. The assay to measure inhibition of [<sup>3</sup>H]colchicine binding was described in detail previously.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Briefly, 0.1 mg/mL (1.0 μM) tubulin was incubated at 37 °C with 5.0 μM [<sup>3</sup>H]colchicine and potential inhibitors at 1.0 or 5.0 μM, as indicated. Incubation was for 10 min, at which point the reaction has reached 40–60% of the maximum colchicine that can be bound in reaction mixtures without inhibitor. The [<sup>3</sup>H]colchicine was a product of PerkinElmer. CA4 was a generous gift of Dr. G. R. Pettit, Arizona State University.</div></div><div id="sec4_17_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Cell Culture</h4><div class="NLM_p last">HeLa, A-10, SK-OV-3, and SK-OV-3 MDR1-M6/6 cells were grown at 37 °C with 5% CO<sub>2</sub> and maintained in Basal Medium Eagle (Sigma-Aldrich, St. Louis, MO) supplemented with 10% FBS (Hyclone, GE Life Sciences, Logan, UT), 1% GlutaMAX (Gibco, Life Technologies, Waltham, MA), and 50 μg/mL gentamycin (Life Technologies). HeLa WTβIII cells were grown at 37 °C with 5% CO<sub>2</sub> and maintained in Dulbecco’s Modified Eagle Medium (Life Technologies) supplemented with 10% FBS (Hyclone, GE Life Sciences) and 50 μg/mL gentamycin (Life Technologies). MDA-MB-435 cells were grown at 37 °C with 5% CO<sub>2</sub> and maintained in Improved Minimum Essential Medium (Life Technologies) supplemented with 10% FBS (Hyclone, GE Life Sciences) and 25 μg/mL gentamycin (Life Technologies).</div></div><div id="sec4_17_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Flow Cytometry</h4><div class="NLM_p last">Cell cycle distribution was evaluated by flow cytometry. HeLa cells in log phase growth were treated with 5-times the IC<sub>50</sub> value (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>) of each test compound: 16.5 nM CA-4, 47.5 nM <b>3</b>, 79 nM <b>4</b>, 169 nM <b>6</b>, 605 nM <b>8</b>, 555 nM <b>7</b>, 78.5 nM <b>9</b>, or vehicle (0.2% DMSO). Cells were treated for 18 h, harvested on ice and stained with Krishan’s reagent.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> DNA content was analyzed using a BD LSRII flow cytometer (BD Biosciences, San Jose, CA). ModFitLT 3.3 (Verity Software House, Topsham, ME) was used to determine the percentage of cells in each phase of the cell cycle.</div></div><div id="sec4_17_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> MDA-MB-435 Flank Xenograft Model</h4><div class="NLM_p last">MDA-MB-435 tumor fragments were implanted sc into the flanks of nude mice. Once tumors reached ∼200 mm<sup>3</sup>, mice were injected ip with compound <b>3</b> (60 mg/kg on days 0 and 2 and 50 mg/kg on day 8) or paclitaxel (20 mg/kg on days 0, 2, 4, 6, 8, and 11). Compound <b>3</b> was dissolved in a 50:50 Cremophor/DMSO mixture and further dissolved in PBS for a final concentration of less than 5% (v/v) Cremophor/DMSO in PBS. Paclitaxel was dissolved in a 50:50 Cremophor/EtOH mixture and further dissolved in PBS for a final solvent concentration of less than 5% (v/v) Cremophor/EtOH in PBS. Tumor volumes and mouse weights were measured 2–3 times a week. One-way ANOVA with Dunnett’s post hoc test was used to determine significance of final tumor volumes of drug-treated groups as compared to untreated control. Other experimental agents were evaluated during this trial and the untreated and paclitaxel controls published previously.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> These animal studies were performed in compliance with a protocol approved by the Institutional Animal Care and Use Committee at the University of Texas Health Science Center at San Antonio.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00237">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00626" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00626" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00237" class="ext-link">10.1021/acs.jmedchem.6b00237</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Elemental analysis, high-resolution mass spectra (HRMS) (EI), and docked poses of target compounds <b>4</b>–<b>9</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Figure 3 (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Figure 11b (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Figure S1 (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Figure S2 (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_006.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Figure S3 (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_007.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Figure S4 (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_008.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Figure S5 (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_009.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Figure S6 (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_010.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_001.pdf">jm6b00237_si_001.pdf (682.93 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_002.csv">jm6b00237_si_002.csv (0.47 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_003.pdb">jm6b00237_si_003.pdb (556.12 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_004.pdb">jm6b00237_si_004.pdb (3.75 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_005.pdb">jm6b00237_si_005.pdb (553.16 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_006.pdb">jm6b00237_si_006.pdb (1.06 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_007.pdb">jm6b00237_si_007.pdb (1.06 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_008.pdb">jm6b00237_si_008.pdb (553.36 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_009.pdb">jm6b00237_si_009.pdb (553.05 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_010.pdb">jm6b00237_si_010.pdb (553.05 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00237" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00105" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00105" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan L. Mooberry</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, Cancer Therapy & Research Center, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a3ceccccc1c6d1d1dae3d6d7cbd0c0d0c28dc6c7d6"><span class="__cf_email__" data-cfemail="b4d9dbdbd6d1c6c6cdf4c1c0dcc7d7c7d59ad1d0c1">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aleem Gangjee</span> - <span class="hlFld-Affiliation affiliation">Division
of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#badddbd4ddd0dfdffadecfcb94dfdecf"><span class="__cf_email__" data-cfemail="3b5c5a555c515e5e7b5f4e4a155e5f4e">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ravi Kumar Vyas Devambatla</span> - <span class="hlFld-Affiliation affiliation">Division
of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ojas A. Namjoshi</span> - <span class="hlFld-Affiliation affiliation">Division
of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shruti Choudhary</span> - <span class="hlFld-Affiliation affiliation">Division
of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ernest Hamel</span> - <span class="hlFld-Affiliation affiliation">Screening
Technologies Branch, Developmental Therapeutics Program, Division
of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick
National Laboratory for Cancer Research, National Institutes of Health, Frederick, Maryland 21702, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Corena V. Shaffer</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, Cancer Therapy & Research Center, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cristina C. Rohena</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, Cancer Therapy & Research Center, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>R.K.V.D. and O.A.N. contributed equally to this work and are cofirst authors. A.G. and S.L.M. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The content of this paper is solely the responsibility of the authors and does not necessarily reflect the official views of the National Institutes of Health.<br /></br>The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d128e4713-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83243" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83243" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge the National Cancer Institute Developmental Therapeutics Program for performing the in vitro evaluation in the NCI 60-cell line panel. This work was supported, in part, by a grant from the National Institutes of Health, National Cancer Institute (CA142868 (to A.G., S.L.M.)); by the President’s Council Research Excellence Award (to S.L.M.), Duquesne University Adrian Van Kaam Chair in Scholarly Excellence (to A.G.); the CTRC Cancer Center Support Grant P30 CA054174 and the Flow Cytometry Shared Resource; and by an NSF equipment grant for NMR instrumentation (NMR: CHE 0614785). We thank Mr. Arpit Doshi, Duquesne University, for the NMR analysis of compound <b>2</b>.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i52" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i52"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i53" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i53"> Abbreviations Used</h2><tr><td class="NLM_term">National Cancer Institute</td><td class="NLM_def"><p class="first last">NCI</p></td></tr><tr><td class="NLM_term">microtubule targeting agents</td><td class="NLM_def"><p class="first last">MTAs</p></td></tr><tr><td class="NLM_term">combretastatin A-1</td><td class="NLM_def"><p class="first last">CA-1</p></td></tr><tr><td class="NLM_term">combretastatin A-4</td><td class="NLM_def"><p class="first last">CA-4</p></td></tr><tr><td class="NLM_term">dimethyl sulfoxide</td><td class="NLM_def"><p class="first last">DMSO</p></td></tr><tr><td class="NLM_term">dimethylformamide</td><td class="NLM_def"><p class="first last">DMF</p></td></tr><tr><td class="NLM_term">Protein Data Bank</td><td class="NLM_def"><p class="first last">PDB</p></td></tr><tr><td class="NLM_term">sulforhodamine B</td><td class="NLM_def"><p class="first last">SRB</p></td></tr><tr><td class="NLM_term">P-glycoprotein</td><td class="NLM_def"><p class="first last">Pgp</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34514" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34514" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 52 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Dumontet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, M. A.</span><span> </span><span class="NLM_article-title">Microtubule-binding agents: A dynamic field of cancer therapeutics</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">790</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span><span class="refDoi"> DOI: 10.1038/nrd3253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1038%2Fnrd3253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=20885410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=790-803&author=C.+Dumontetauthor=M.+A.+Jordan&title=Microtubule-binding+agents%3A+A+dynamic+field+of+cancer+therapeutics&doi=10.1038%2Fnrd3253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-binding agents: a dynamic field of cancer therapeutics</span></div><div class="casAuthors">Dumontet, Charles; Jordan, Mary Ann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">790-803</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an important therapeutic target in tumor cells.  Agents that bind to microtubules have been part of the pharmacopoeia of anticancer therapy for decades and until the advent of targeted therapy, microtubules were the only alternative to DNA as a therapeutic target in cancer.  The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties.  In the current search for novel microtubule-binding agents, enhanced tumor specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms are the three main objectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ43DyXjdN7rVg90H21EOLACvtfcHk0lgZUIfP4jC1BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI&md5=9fc6fd966859785605936ecbe6dca44e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd3253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3253%26sid%3Dliteratum%253Aachs%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DM.%2BA.%26atitle%3DMicrotubule-binding%2520agents%253A%2520A%2520dynamic%2520field%2520of%2520cancer%2520therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D790%26epage%3D803%26doi%3D10.1038%2Fnrd3253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Risinger, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Microtubule dynamics as a target in oncology</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2008.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1016%2Fj.ctrv.2008.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=19117686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVantrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=255-261&author=A.+L.+Risingerauthor=F.+J.+Gilesauthor=S.+L.+Mooberry&title=Microtubule+dynamics+as+a+target+in+oncology&doi=10.1016%2Fj.ctrv.2008.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule dynamics as a target in oncology</span></div><div class="casAuthors">Risinger, April L.; Giles, Francis J.; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-261</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Drugs that affect microtubule dynamics, including the taxanes and vinca alkaloids, have been a mainstay in the treatment of leukemias and solid tumors for decades.  New, more effective microtubule-targeting agents continue to enter into clin. trials and some, including the epothilone ixapebilone, have been approved for use.  In contrast, several other drugs of this class with promising preclin. data were later shown to be ineffective or intolerable in animal models or clin. trials.  In this review, we discuss the mol. mechanisms as well as preclin. and clin. results for a variety of microtubule-targeting agents in various stages of development.  We also offer a frank discussion of which microtubule-targeting agents are amenable to further development based on their availability, efficacy and toxic profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh2wR_5ls3DLVg90H21EOLACvtfcHk0lgZUIfP4jC1BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVantrg%253D&md5=2d18cb599b5c35f1e0bc0292c183826f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2008.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2008.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DRisinger%26aufirst%3DA.%2BL.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DMicrotubule%2520dynamics%2520as%2520a%2520target%2520in%2520oncology%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2009%26volume%3D35%26spage%3D255%26epage%3D261%26doi%3D10.1016%2Fj.ctrv.2008.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Stanton, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gernert, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aneja, R.</span><span> </span><span class="NLM_article-title">Drugs that target dynamic microtubules: A new molecular perspective</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">481</span><span class="refDoi"> DOI: 10.1002/med.20242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1002%2Fmed.20242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=21381049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksVKlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=443-481&author=R.+A.+Stantonauthor=K.+M.+Gernertauthor=J.+H.+Nettlesauthor=R.+Aneja&title=Drugs+that+target+dynamic+microtubules%3A+A+new+molecular+perspective&doi=10.1002%2Fmed.20242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs that target dynamic microtubules: A new molecular perspective</span></div><div class="casAuthors">Stanton, Richard A.; Gernert, Kim M.; Nettles, James H.; Aneja, Ritu</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">443-481</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Microtubules have long been considered an ideal target for anticancer drugs because of the essential role they play in mitosis, forming the dynamic spindle app.  As such, there is a wide variety of compds. currently in clin. use and in development that act as antimitotic agents by altering microtubule dynamics.  Although these diverse mols. are known to affect microtubule dynamics upon binding to one of the three established drug domains (taxane, vinca alkaloid, or colchicine site), the exact mechanism by which each drug works is still an area of intense speculation and research.  In this study, we review the effects of microtubule-binding chemotherapeutic agents from a new perspective, considering how their mode of binding induces conformational changes and alters biol. function relative to the mol. vectors of microtubule assembly or disassembly.  These "biol. vectors" can thus be used as a spatiotemporal context to describe mol. mechanisms by which microtubule-targeting drugs work. © 2011 Wiley Periodicals, Inc.  Med Res Rev, 31, No. 3, 443-481, 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB6_lcUQbXYrVg90H21EOLACvtfcHk0lgZUIfP4jC1BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksVKlsLs%253D&md5=acce5b9cc89581a7dab0236072b68c72</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fmed.20242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20242%26sid%3Dliteratum%253Aachs%26aulast%3DStanton%26aufirst%3DR.%2BA.%26aulast%3DGernert%26aufirst%3DK.%2BM.%26aulast%3DNettles%26aufirst%3DJ.%2BH.%26aulast%3DAneja%26aufirst%3DR.%26atitle%3DDrugs%2520that%2520target%2520dynamic%2520microtubules%253A%2520A%2520new%2520molecular%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2011%26volume%3D31%26spage%3D443%26epage%3D481%26doi%3D10.1002%2Fmed.20242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span> </span><span class="NLM_article-title">Targeting p53 for novel anticancer therapy</span> <span class="citation_source-journal">Transl. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1593/tlo.09250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1593%2Ftlo.09250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=20165689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A280%3ADC%252BC3c7hsFOgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=1-12&author=Z.+Wangauthor=Y.+Sun&title=Targeting+p53+for+novel+anticancer+therapy&doi=10.1593%2Ftlo.09250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting p53 for Novel Anticancer Therapy</span></div><div class="casAuthors">Wang Zhen; Sun Yi</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Carcinogenesis is a multistage process, involving oncogene activation and tumor suppressor gene inactivation as well as complex interactions between tumor and host tissues, leading ultimately to an aggressive metastatic phenotype.  Among many genetic lesions, mutational inactivation of p53 tumor suppressor, the "guardian of the genome," is the most frequent event found in 50% of human cancers. p53 plays a critical role in tumor suppression mainly by inducing growth arrest, apoptosis, and senescence, as well as by blocking angiogenesis.  In addition, p53 generally confers the cancer cell sensitivity to chemoradiation.  Thus, p53 becomes the most appealing target for mechanism-driven anticancer drug discovery.  This review will focus on the approaches currently undertaken to target p53 and its regulators with an overall goal either to activate p53 in cancer cells for killing or to inactivate p53 temporarily in normal cells for chemoradiation protection.  The compounds that activate wild type (wt) p53 would have an application for the treatment of wt p53-containing human cancer.  Likewise, the compounds that change p53 conformation from mutant to wt p53 (p53 reactivation) or that kill the cancer cells with mutant p53 using a synthetic lethal mechanism can be used to selectively treat human cancer harboring a mutant p53.  The inhibitors of wt p53 can be used on a temporary basis to reduce the normal cell toxicity derived from p53 activation.  Thus, successful development of these three classes of p53 modulators, to be used alone or in combination with chemoradiation, will revolutionize current anticancer therapies and benefit cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTeSdXZp7lZxNNTrvPZP1IpfW6udTcc2eZ03-xbyVjDArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7hsFOgtw%253D%253D&md5=4f0975ff3e93a1dd766084db4eb06158</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1593%2Ftlo.09250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Ftlo.09250%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DTargeting%2520p53%2520for%2520novel%2520anticancer%2520therapy%26jtitle%3DTransl.%2520Oncol.%26date%3D2010%26volume%3D3%26spage%3D1%26epage%3D12%26doi%3D10.1593%2Ftlo.09250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">O’Connor, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bae, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutoh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scudiero, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friend, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fornace, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohn, K. W.</span><span> </span><span class="NLM_article-title">Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4285</span><span class="NLM_x">–</span> <span class="NLM_lpage">4300</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=4285-4300&author=P.+M.+O%E2%80%99Connorauthor=J.+Jackmanauthor=I.+Baeauthor=T.+G.+Myersauthor=S.+Fanauthor=M.+Mutohauthor=D.+A.+Scudieroauthor=A.+Monksauthor=E.+A.+Sausvilleauthor=J.+N.+Weinsteinauthor=S.+Friendauthor=A.+J.+Fornaceauthor=K.+W.+Kohn&title=Characterization+of+the+p53+tumor+suppressor+pathway+in+cell+lines+of+the+National+Cancer+Institute+anticancer+drug+screen+and+correlations+with+the+growth-inhibitory+potency+of+123+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DP.%2BM.%26aulast%3DJackman%26aufirst%3DJ.%26aulast%3DBae%26aufirst%3DI.%26aulast%3DMyers%26aufirst%3DT.%2BG.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DMutoh%26aufirst%3DM.%26aulast%3DScudiero%26aufirst%3DD.%2BA.%26aulast%3DMonks%26aufirst%3DA.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26aulast%3DFriend%26aufirst%3DS.%26aulast%3DFornace%26aufirst%3DA.%2BJ.%26aulast%3DKohn%26aufirst%3DK.%2BW.%26atitle%3DCharacterization%2520of%2520the%2520p53%2520tumor%2520suppressor%2520pathway%2520in%2520cell%2520lines%2520of%2520the%2520National%2520Cancer%2520Institute%2520anticancer%2520drug%2520screen%2520and%2520correlations%2520with%2520the%2520growth-inhibitory%2520potency%2520of%2520123%2520anticancer%2520agents%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D4285%26epage%3D4300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Komlodi-Pasztor, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sackett, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkerson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fojo, T.</span><span> </span><span class="NLM_article-title">Mitosis is not a key target of microtubule agents in patient tumors</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">244</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2010.228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1038%2Fnrclinonc.2010.228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=21283127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFKlsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=244-250&author=E.+Komlodi-Pasztorauthor=D.+Sackettauthor=J.+Wilkersonauthor=T.+Fojo&title=Mitosis+is+not+a+key+target+of+microtubule+agents+in+patient+tumors&doi=10.1038%2Fnrclinonc.2010.228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Mitosis is not a key target of microtubule agents in patient tumors</span></div><div class="casAuthors">Komlodi-Pasztor, Edina; Sackett, Dan; Wilkerson, Julia; Fojo, Tito</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">244-250</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In this Perspective, the clin. disappointment of mitosis-specific agents is explained in the context of the mechanism of action of microtubule-targeting agents.  The authors propose a new paradigm for the anticancer activity of microtubule-targeting agents and suggest that mitosis-specific inhibitors will not result in significant clin. impact.  Mitosis-specific agents have, to date, not been clin. successful.  By contrast, microtubule-targeting agents (MTAs) have a long record of success, usually attributed to the induction of mitotic arrest.  Indeed, it was this success that led to the search for mitosis-specific inhibitors.  We believe the clin. disappointment of mitosis-specific inhibitors stands as evidence that MTAs have been successful not only by interfering with mitosis but, more importantly, by disrupting essential interphase cellular mechanisms.  In this Perspective we will review literature that supports a paradigm shift in how we think about one of our most widely used classes of chemotherapeutics-MTAs.  We believe that the steady presence and const. physiol. role of microtubules are responsible for the overall success of MTAs.  While mitosis-specific inhibitors are effective on only a small fraction of the tumor mass (dividing cells), MTAs target tubulin, a protein that has crucial roles in both mitotic and non-mitotic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYOmCILGEs2LVg90H21EOLACvtfcHk0liZ0POMo5W8yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFKlsLY%253D&md5=2a72541e9b990534b74e88c18265e4c8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2010.228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2010.228%26sid%3Dliteratum%253Aachs%26aulast%3DKomlodi-Pasztor%26aufirst%3DE.%26aulast%3DSackett%26aufirst%3DD.%26aulast%3DWilkerson%26aufirst%3DJ.%26aulast%3DFojo%26aufirst%3DT.%26atitle%3DMitosis%2520is%2520not%2520a%2520key%2520target%2520of%2520microtubule%2520agents%2520in%2520patient%2520tumors%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D8%26spage%3D244%26epage%3D250%26doi%3D10.1038%2Fnrclinonc.2010.228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Löwe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nogales, E.</span><span> </span><span class="NLM_article-title">Refined structure of αβ-tubulin at 3.5 Å resolution</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">1045</span><span class="NLM_x">–</span> <span class="NLM_lpage">1057</span><span class="refDoi"> DOI: 10.1006/jmbi.2001.5077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1006%2Fjmbi.2001.5077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=11700061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A280%3ADC%252BD3Mnksl2muw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2001&pages=1045-1057&author=J.+L%C3%B6weauthor=H.+Liauthor=K.+H.+Downingauthor=E.+Nogales&title=Refined+structure+of+%CE%B1%CE%B2-tubulin+at+3.5+%C3%85+resolution&doi=10.1006%2Fjmbi.2001.5077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Refined structure of alpha beta-tubulin at 3.5 A resolution</span></div><div class="casAuthors">Lowe J; Li H; Downing K H; Nogales E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of molecular biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1045-57</span>
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    </div><div class="casAbstract">We present a refined model of the alpha beta-tubulin dimer to 3.5 A resolution.  An improved experimental density for the zinc-induced tubulin sheets was obtained by adding 114 electron diffraction patterns at 40-60 degrees tilt and increasing the completeness of structure factor amplitudes to 84.7 %.  The refined structure was obtained using maximum-likelihood including phase information from experimental images, and simulated annealing Cartesian refinement to an R-factor of 23.2 and free R-factor of 29.7.  The current model includes residues alpha:2-34, alpha:61-439, beta:2-437, one molecule of GTP, one of GDP, and one of taxol, as well as one magnesium ion at the non-exchangeable nucleotide site, and one putative zinc ion near the M-loop in the alpha-tubulin subunit.  The acidic C-terminal tails could not be traced accurately, neither could the N-terminal loop including residues 35-60 in the alpha-subunit.  There are no major changes in the overall fold of tubulin with respect to the previous structure, testifying to the quality of the initial experimental phases.  The overall geometry of the model is, however, greatly improved, and the position of side-chains, especially those of exposed polar/charged groups, is much better defined.  Three short protein sequence frame shifts were detected with respect to the non-refined structure.  In light of the new model we discuss details of the tubulin structure such as nucleotide and taxol binding sites, lateral contacts in zinc-sheets, and the significance of the location of highly conserved residues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDXIwG-_BEjn6HPRus0rAafW6udTcc2eZ03-xbyVjDArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3Mnksl2muw%253D%253D&md5=f791000e3cfbfdc2eff7a032ec58b60b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.2001.5077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.2001.5077%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6we%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DDowning%26aufirst%3DK.%2BH.%26aulast%3DNogales%26aufirst%3DE.%26atitle%3DRefined%2520structure%2520of%2520%25CE%25B1%25CE%25B2-tubulin%2520at%25203.5%2520%25C3%2585%2520resolution%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2001%26volume%3D313%26spage%3D1045%26epage%3D1057%26doi%3D10.1006%2Fjmbi.2001.5077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Rao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ojima, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horwitz, S. B.</span><span> </span><span class="NLM_article-title">Characterization of the taxol binding site on the microtubule. Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of taxol</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">37990</span><span class="NLM_x">–</span> <span class="NLM_lpage">37994</span><span class="refDoi"> DOI: 10.1074/jbc.274.53.37990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1074%2Fjbc.274.53.37990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10608867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkt1Gltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=37990-37994&author=S.+Raoauthor=L.+Heauthor=S.+Chakravartyauthor=I.+Ojimaauthor=G.+A.+Orrauthor=S.+B.+Horwitz&title=Characterization+of+the+taxol+binding+site+on+the+microtubule.+Identification+of+Arg%28282%29+in+beta-tubulin+as+the+site+of+photoincorporation+of+a+7-benzophenone+analogue+of+taxol&doi=10.1074%2Fjbc.274.53.37990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Taxol binding site on the microtubule: Identification of Arg282 in β-tubulin as the site of photoincorporation of a 7-benzophenone analogue of taxol</span></div><div class="casAuthors">Rao, Srinivasa; He, Lifeng; Chakravarty, Subrata; Ojima, Iwao; Orr, George A.; Horwitz, Susan Band</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">53</span>),
    <span class="NLM_cas:pages">37990-37994</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Photoaffinity labeling methods have allowed a definition of the sites of interaction between Taxol and its cellular target, the microtubule, specifically β-tubulin.  Our previous studies have indicated that [3H]3'-(p-azidobenzamido)Taxol photolabels the N-terminal 31 amino acids of β-tubulin and [3H]2-(m-azidobenzoyl)Taxol photolabels a peptide contg. amino acid residues 217-233 of β-tubulin.  The site of photoincorporation of a third photoaffinity analog of Taxol, [3H]7-(benzoyldihydrocinnamoyl) Taxol, has been detd.  This analog stabilizes microtubules polymd. in the presence of GTP, but in contrast to Taxol, does not by itself enhance the polymn. of tubulin to its polymer form.  CNBr digestion of [3H]7-(benzoyldihydrocinnamoyl)Taxol-labeled tubulin, with further arginine-specific cleavage by clostripain resulted in the isolation of a peptide contg. amino acid residues 277-293.  Amino acid sequence anal. indicated that the photoaffinity analog crosslinks to Arg282 in β-tubulin.  Advances made by electron crystallog. in understanding the structure of the tubulin dimer have allowed us to visualize the three sites of photoincorporation by mol. modeling.  There is good agreement between the binding site of Taxol in β-tubulin as detd. by photoaffinity labeling and electron crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKSE1QG2SG7LVg90H21EOLACvtfcHk0li6JSp2LFhByw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkt1Gltw%253D%253D&md5=81a886bb1b567132079be101f5900149</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.53.37990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.53.37990%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DChakravarty%26aufirst%3DS.%26aulast%3DOjima%26aufirst%3DI.%26aulast%3DOrr%26aufirst%3DG.%2BA.%26aulast%3DHorwitz%26aufirst%3DS.%2BB.%26atitle%3DCharacterization%2520of%2520the%2520taxol%2520binding%2520site%2520on%2520the%2520microtubule.%2520Identification%2520of%2520Arg%2528282%2529%2520in%2520beta-tubulin%2520as%2520the%2520site%2520of%2520photoincorporation%2520of%2520a%25207-benzophenone%2520analogue%2520of%2520taxol%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D37990%26epage%3D37994%26doi%3D10.1074%2Fjbc.274.53.37990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Lee, J. F.; Harris, L. N.</span><span> </span><span class="NLM_article-title">Antimicrotubule Agents</span>. In  <span class="citation_source-book">Cancer: Principles & Practice of Oncology</span>, <span class="NLM_edition">8</span>th ed.; <span class="NLM_contrib-group">DeVita, V. T.,  Jr.; Lawrence, T. S.; Rosenberg, S. A.</span> Eds.; <span class="NLM_publisher-name">Lippincott Williams & Wilkins</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">447</span><span class="NLM_x">–</span> <span class="NLM_lpage">456</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=447-456&author=J.+F.+Lee&author=L.+N.+Harrisauthor=V.+T.+DeVita&author=T.+S.+Lawrence&author=S.+A.+Rosenberg&title=Cancer%3A+Principles+%26+Practice+of+Oncology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BF.%26atitle%3DAntimicrotubule%2520Agents%26btitle%3DCancer%253A%2520Principles%2520%2526%2520Practice%2520of%2520Oncology%26aulast%3DDeVita%26aufirst%3DV.%2BT.%26pub%3DLippincott%2520Williams%2520%2526%2520Wilkins%26date%3D2008%26spage%3D447%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Altmann, K.-H.</span><span> </span><span class="NLM_article-title">Microtubule-stabilizing agents: A growing class of important anticancer drugs</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">424</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1016/S1367-5931(00)00225-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1016%2FS1367-5931%2800%2900225-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=11470606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltlyqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2001&pages=424-431&author=K.-H.+Altmann&title=Microtubule-stabilizing+agents%3A+A+growing+class+of+important+anticancer+drugs&doi=10.1016%2FS1367-5931%2800%2900225-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-stabilizing agents: a growing class of important anticancer drugs</span></div><div class="casAuthors">Altmann, K.-H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">424-431</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  Microtubule-stabilizing agents continue to play an important role in anticancer drug discovery and development.  New agents were again discovered in the past year, including small synthetic mols.  At least three new taxanes and two compds. of the epothilone class of natural products underwent clin. trials in 2000.  Unexpected new findings about synergistic effects between different microtubule-stabilizing agents in vitro raise new prospects for combination chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEbKmPFiPGKbVg90H21EOLACvtfcHk0li6JSp2LFhByw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltlyqsLg%253D&md5=dcdbd861319db7538654e2e9244d522e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS1367-5931%2800%2900225-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1367-5931%252800%252900225-8%26sid%3Dliteratum%253Aachs%26aulast%3DAltmann%26aufirst%3DK.-H.%26atitle%3DMicrotubule-stabilizing%2520agents%253A%2520A%2520growing%2520class%2520of%2520important%2520anticancer%2520drugs%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2001%26volume%3D5%26spage%3D424%26epage%3D431%26doi%3D10.1016%2FS1367-5931%2800%2900225-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Prota, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargsten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northcote, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altmann, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díaz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span> </span><span class="NLM_article-title">Structural basis of microtubule stabilization by laulimalide and peloruside A</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1621</span><span class="NLM_x">–</span> <span class="NLM_lpage">1625</span><span class="refDoi"> DOI: 10.1002/anie.201307749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1002%2Fanie.201307749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlegt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1621-1625&author=A.+E.+Protaauthor=K.+Bargstenauthor=P.+T.+Northcoteauthor=M.+Marshauthor=K.-H.+Altmannauthor=J.+H.+Millerauthor=J.+F.+D%C3%ADazauthor=M.+O.+Steinmetz&title=Structural+basis+of+microtubule+stabilization+by+laulimalide+and+peloruside+A&doi=10.1002%2Fanie.201307749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Microtubule Stabilization by Laulimalide and Peloruside A</span></div><div class="casAuthors">Prota, Andrea E.; Bargsten, Katja; Northcote, Peter T.; Marsh, May; Altmann, Karl-Heinz; Miller, John H.; Diaz, Jose Fernando; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1621-1625</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Laulimalide and peloruside A are microtubule-stabilizing agents (MSAs), the mechanism of action on microtubules of which is poorly defined.  Here, using X-ray crystallog. it is shown that laulimalide and peloruside A bind to a unique non-taxane site on β-tubulin and use their resp. macrolide core structures to interact with a second tubulin dimer across protofilaments.  At the same time, they allosterically stabilize the taxane-site M-loop that establishes lateral tubulin contacts in microtubules.  Structures of ternary complexes of tubulin with laulimalide/peloruside A and epothilone A are also solved, and a crosstalk between the laulimalide/peloruside and taxane sites via the M-loop of β-tubulin is found.  Together, the data define the mechanism of action of laulimalide and peloruside A on tubulin and microtubules.  The data further provide a structural framework for understanding the synergy obsd. between two classes of MSAs in tubulin assembly and the inhibition of cancer cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0Dd_nMEpmVrVg90H21EOLACvtfcHk0li6JSp2LFhByw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlegt74%253D&md5=add9ce5e97ae55ad70d04ebc58245728</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fanie.201307749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201307749%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DNorthcote%26aufirst%3DP.%2BT.%26aulast%3DMarsh%26aufirst%3DM.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DMiller%26aufirst%3DJ.%2BH.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DStructural%2520basis%2520of%2520microtubule%2520stabilization%2520by%2520laulimalide%2520and%2520peloruside%2520A%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D1621%26epage%3D1625%26doi%3D10.1002%2Fanie.201307749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Prota, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargsten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuevas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liniger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuhaus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altmann, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span> </span><span class="NLM_article-title">A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">13817</span><span class="NLM_x">–</span> <span class="NLM_lpage">13821</span><span class="refDoi"> DOI: 10.1073/pnas.1408124111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1073%2Fpnas.1408124111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=25114240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCju7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=13817-13821&author=A.+E.+Protaauthor=K.+Bargstenauthor=J.+F.+Diazauthor=M.+Marshauthor=C.+Cuevasauthor=M.+Linigerauthor=C.+Neuhausauthor=J.+M.+Andreuauthor=K.-H.+Altmannauthor=M.+O.+Steinmetz&title=A+new+tubulin-binding+site+and+pharmacophore+for+microtubule-destabilizing+anticancer+drugs&doi=10.1073%2Fpnas.1408124111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</span></div><div class="casAuthors">Prota, Andrea E.; Bargsten, Katja; Diaz, J. Fernando; Marsh, May; Cuevas, Carmen; Liniger, Marc; Neuhaus, Christian; Andreu, Jose M.; Altmann, Karl-Heinz; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">13817-13821</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The recent success of antibody-drug conjugates (ADCs) in the treatment of cancer has led to a revived interest in microtubule-destabilizing agents.  Here, we detd. the high-resoln. crystal structure of the complex between tubulin and maytansine, which is part of an ADC that is approved by the US Food and Drug Administration (FDA) for the treatment of advanced breast cancer.  We found that the drug binds to a site on β-tubulin that is distinct from the vinca domain and that blocks the formation of longitudinal tubulin interactions in microtubules.  We also solved crystal structures of tubulin in complex with both a variant of rhizoxin and the phase 1 drug PM060184.  Consistent with biochem. and mutagenesis data, we found that the two compds. bound to the same site as maytansine and that the structures revealed a common pharmacophore for the three ligands.  Our results delineate a distinct mol. mechanism of action for the inhibition of microtubule assembly by clin. relevant agents.  They further provide a structural basis for the rational design of potent microtubule-destabilizing agents, thus opening opportunities for the development of next-generation ADCs for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX4icqk698gLVg90H21EOLACvtfcHk0lgZrO-Wo1pR5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCju7vM&md5=798cae320e427ff76c2099387d9e6ba4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1408124111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1408124111%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DDiaz%26aufirst%3DJ.%2BF.%26aulast%3DMarsh%26aufirst%3DM.%26aulast%3DCuevas%26aufirst%3DC.%26aulast%3DLiniger%26aufirst%3DM.%26aulast%3DNeuhaus%26aufirst%3DC.%26aulast%3DAndreu%26aufirst%3DJ.%2BM.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DA%2520new%2520tubulin-binding%2520site%2520and%2520pharmacophore%2520for%2520microtubule-destabilizing%2520anticancer%2520drugs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D13817%26epage%3D13821%26doi%3D10.1073%2Fpnas.1408124111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Verma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welslau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diéras, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guardino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwell, K.</span><span> </span><span class="NLM_article-title">Trastuzumab emtansine for HER2-positive advanced breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">1783</span><span class="NLM_x">–</span> <span class="NLM_lpage">1791</span><span class="refDoi"> DOI: 10.1056/NEJMoa1209124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1056%2FNEJMoa1209124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=23020162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1783-1791&author=S.+Vermaauthor=D.+Milesauthor=L.+Gianniauthor=I.+E.+Kropauthor=M.+Welslauauthor=J.+Baselgaauthor=M.+Pegramauthor=D.-Y.+Ohauthor=V.+Di%C3%A9rasauthor=E.+Guardinoauthor=L.+Fangauthor=M.+W.+Luauthor=S.+Olsenauthor=K.+Blackwell&title=Trastuzumab+emtansine+for+HER2-positive+advanced+breast+cancer&doi=10.1056%2FNEJMoa1209124"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab emtansine for HER2-positive advanced breast cancer</span></div><div class="casAuthors">Verma, Sunil; Miles, David; Gianni, Luca; Krop, Ian E.; Welslau, Manfred; Baselga, Jose; Pegram, Mark; Oh, Do-Youn; Dieras, Veronique; Guardino, Ellie; Fang, Liang; Lu, Michael W.; Olsen, Steven; Blackwell, Kim</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1783-1791</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.  The antibody and the cytotoxic agent are conjugated by means of a stable linker.  METHODS: We randomly assigned patients with HER2-pos. advanced breast cancer, who had previously been treated with trastuzumab and a taxane, to T-DM1 or lapatinib plus capecitabine.  The primary end points were progression-free survival (as assessed by independent review), overall survival, and safety.  Secondary end points included progression-free survival (investigator-assessed), the objective response rate, and the time to symptom progression.  Two interim analyses of overall survival were conducted.  RESULTS: Among 991 randomly assigned patients, median progression-free survival as assessed by independent review was 9.6 mo with T-DM1 vs. 6.4 mo with lapatinib plus capecitabine (hazard ratio for progression or death from any cause, 0.65; 95% confidence interval [CI], 0.55 to 0.77; P<0.001), and median overall survival at the second interim anal. crossed the stopping boundary for efficacy (30.9 mo vs. 25.1 mo; hazard ratio for death from any cause, 0.68; 95% CI, 0.55 to 0.85; P<0.001).  The objective response rate was higher with T-DM1 (43.6%, vs. 30.8% with lapatinib plus capecitabine; P<0.001); results for all addnl. secondary end points favored T-DM1.  Rates of grade 3 or above were higher with lapatinib plus capecitabine than with T-DM1 (57% vs. 41%).  The incidences of thrombocytopenia and increased serum aminotransferase levels were higher with T-DM1, whereas the incidences of diarrhea, nausea, vomiting, and palmar-plantar erythrodysesthesia were higher with lapatinib plus capecitabine.  CONCLUSIONS: T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-pos. advanced breast cancer previously treated with trastuzumab and a taxane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGRhxRQ7JSJrVg90H21EOLACvtfcHk0lgZrO-Wo1pR5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73M&md5=3be5bac27a81b530442dc8a6b4a1f82e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1209124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1209124%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DS.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DGianni%26aufirst%3DL.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DWelslau%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DPegram%26aufirst%3DM.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26aulast%3DGuardino%26aufirst%3DE.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DS.%26aulast%3DBlackwell%26aufirst%3DK.%26atitle%3DTrastuzumab%2520emtansine%2520for%2520HER2-positive%2520advanced%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1783%26epage%3D1791%26doi%3D10.1056%2FNEJMoa1209124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D.</span><span> </span><span class="NLM_article-title">An overview of tubulin inhibitors that interact with the colchicine binding site</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2943</span><span class="NLM_x">–</span> <span class="NLM_lpage">2971</span><span class="refDoi"> DOI: 10.1007/s11095-012-0828-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1007%2Fs11095-012-0828-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=22814904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOis7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=2943-2971&author=Y.+Luauthor=J.+Chenauthor=M.+Xiaoauthor=W.+Liauthor=D.+Miller&title=An+overview+of+tubulin+inhibitors+that+interact+with+the+colchicine+binding+site&doi=10.1007%2Fs11095-012-0828-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site</span></div><div class="casAuthors">Lu, Yan; Chen, Jianjun; Xiao, Min; Li, Wei; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2943-2971</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Tubulin dynamics is a promising target for new chemotherapeutic agents.  The colchicine binding site is one of the most important pockets for potential tubulin polymn. destabilizers.  Colchicine binding site inhibitors (CBSI) exert their biol. effects by inhibiting tubulin assembly and suppressing microtubule formation.  A large no. of mols. interacting with the colchicine binding site have been designed and synthesized with significant structural diversity.  CBSIs have been modified as to chem. structure as well as pharmacokinetic properties, and tested in order to find a highly potent, low toxicity agent for treatment of cancers.  CBSIs are believed to act by a common mechanism via binding to the colchicine site on tubulin.  The present review is a synopsis of compds. that have been reported in the past decade that have provided an increase in our understanding of the actions of CBSIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFrFQVgeCbBbVg90H21EOLACvtfcHk0lgZrO-Wo1pR5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOis7vN&md5=dfe42e8eb1f0ff22b256641aaa8c17ab</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs11095-012-0828-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-012-0828-z%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%26atitle%3DAn%2520overview%2520of%2520tubulin%2520inhibitors%2520that%2520interact%2520with%2520the%2520colchicine%2520binding%2520site%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26spage%3D2943%26epage%3D2971%26doi%3D10.1007%2Fs11095-012-0828-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Massarotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coluccia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvestri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorba, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brancale, A.</span><span> </span><span class="NLM_article-title">The tubulin colchicine domain: A molecular modeling perspective</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span><span class="refDoi"> DOI: 10.1002/cmdc.201100361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1002%2Fcmdc.201100361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=21990124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12qt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=33-42&author=A.+Massarottiauthor=A.+Colucciaauthor=R.+Silvestriauthor=G.+Sorbaauthor=A.+Brancale&title=The+tubulin+colchicine+domain%3A+A+molecular+modeling+perspective&doi=10.1002%2Fcmdc.201100361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The Tubulin Colchicine Domain: a Molecular Modeling Perspective</span></div><div class="casAuthors">Massarotti, Alberto; Coluccia, Antonio; Silvestri, Romano; Sorba, Giovanni; Brancale, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-42</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Computational approaches have been increasingly applied to drug design over the past three decades and have already provided some useful results in the discovery of anticancer drugs.  Given the increased availability of crystal structures in recent years, a growing no. of mol. modeling studies on tubulin have been reported.  Herein we present a brief overview of the role played by computational methods in anti-tubulin research, specifically in the context of colchicine binding agent research.  An overview of current structures is reported, along with a brief discussion on the issues assocd. with the various tubulin isotypes.  Finally, a summary of the most recent and relevant results is presented, highlighting the challenges and opportunities faced by researchers in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpomkM8Gy2eS7Vg90H21EOLACvtfcHk0lh4fHxCFGPZng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12qt7zO&md5=84b4f8c78b635c2b7df31bbd1e4a89de</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100361%26sid%3Dliteratum%253Aachs%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DSilvestri%26aufirst%3DR.%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DBrancale%26aufirst%3DA.%26atitle%3DThe%2520tubulin%2520colchicine%2520domain%253A%2520A%2520molecular%2520modeling%2520perspective%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D33%26epage%3D42%26doi%3D10.1002%2Fcmdc.201100361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baichwal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skvortsova, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skvortsov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">English, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisoma, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pervin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pleiman, C. M.</span><span> </span><span class="NLM_article-title">MPC-6827: A small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">5865</span><span class="NLM_x">–</span> <span class="NLM_lpage">5871</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-0127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1158%2F0008-5472.CAN-07-0127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=17575155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFCqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=5865-5871&author=S.+Kasibhatlaauthor=V.+Baichwalauthor=S.+X.+Caiauthor=B.+Rothauthor=I.+Skvortsovaauthor=S.+Skvortsovauthor=P.+Lukasauthor=N.+M.+Englishauthor=N.+Sirisomaauthor=J.+Dreweauthor=A.+Pervinauthor=B.+Tsengauthor=R.+O.+Carlsonauthor=C.+M.+Pleiman&title=MPC-6827%3A+A+small-molecule+inhibitor+of+microtubule+formation+that+is+not+a+substrate+for+multidrug+resistance+pumps&doi=10.1158%2F0008-5472.CAN-07-0127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">MPC-6827: A small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps</span></div><div class="casAuthors">Kasibhatla, Shailaja; Baichwal, Vijay; Cai, Sui Xiong; Roth, Bruce; Skvortsova, Ira; Skvortsov, Sergej; Lukas, Peter; English, Nicole M.; Sirisoma, Nilantha; Drewe, John; Pervin, Azra; Tseng, Ben; Carlson, Robert O.; Pleiman, Christopher M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5865-5871</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A novel series of 4-arylaminoquinazolines were identified from a cell-based screening assay as potent apoptosis inducers.  Through structure-activity relationship studies, MPC-6827 and its close structural analog, MPI-0441138, were discovered as proapoptotic mols. and mitotic inhibitors with potencies at low nanomolar concns. in multiple tumor cell lines.  Photoaffinity and radiolabeled analogs of MPC-6827 were found to bind a 55-kDa protein, and this binding was competed by MPC-6827, paclitaxel, and colchicine, but not vinblastine.  MPC-6827 effectively inhibited the polymn. of tubulin in vitro, competed with colchicine binding, and disrupted the formation of microtubules in a variety of tumor cell lines, which together showed the mol. target as tubulin.  Treatment of MCF-7 breast carcinoma or Jurkat leukemia cells with MPC-6827 led to pronounced G2-M cell cycle arrest followed by apoptosis.  Apoptosis, as detd. by terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay, was preceded by loss of mitochondrial membrane potential, cytochrome c translocation from mitochondria to nuclei, activation of caspase-3, and cleavage of poly(ADP-ribose) polymerase.  MPC-6827 was equipotent in an in vitro growth inhibition assay in several cancer cell lines regardless of the expression levels of the multidrug resistance ABC transporters MDR-1 (Pgp-1), MRP-1, and BCRP-1.  In B16-F1 allografts and in OVCAR-3, MIAPaCa-2, MCF-7, HT-29, MDA-MB-435, and MX-1 xenografts, statistically significant tumor growth inhibition was obsd. with MPC-6827.  These studies show that MPC-6827 is a microtubule-disrupting agent with potent and broad-spectrum in vitro and in vivo cytotoxic activities and, therefore, MPC-6827 is a promising candidate for development as a novel therapeutic for multiple cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo-qab7pG6E7Vg90H21EOLACvtfcHk0lh4fHxCFGPZng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFCqtrg%253D&md5=3ce57c281fdc663115a794ac7e91f177</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-0127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-0127%26sid%3Dliteratum%253Aachs%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DBaichwal%26aufirst%3DV.%26aulast%3DCai%26aufirst%3DS.%2BX.%26aulast%3DRoth%26aufirst%3DB.%26aulast%3DSkvortsova%26aufirst%3DI.%26aulast%3DSkvortsov%26aufirst%3DS.%26aulast%3DLukas%26aufirst%3DP.%26aulast%3DEnglish%26aufirst%3DN.%2BM.%26aulast%3DSirisoma%26aufirst%3DN.%26aulast%3DDrewe%26aufirst%3DJ.%26aulast%3DPervin%26aufirst%3DA.%26aulast%3DTseng%26aufirst%3DB.%26aulast%3DCarlson%26aufirst%3DR.%2BO.%26aulast%3DPleiman%26aufirst%3DC.%2BM.%26atitle%3DMPC-6827%253A%2520A%2520small-molecule%2520inhibitor%2520of%2520microtubule%2520formation%2520that%2520is%2520not%2520a%2520substrate%2520for%2520multidrug%2520resistance%2520pumps%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D5865%26epage%3D5871%26doi%3D10.1158%2F0008-5472.CAN-07-0127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Tsimberidou, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akerley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schabel, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehara, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chhabra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mather, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodland, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swabb, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span> </span><span class="NLM_article-title">Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">3410</span><span class="NLM_x">–</span> <span class="NLM_lpage">3419</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1158%2F1535-7163.MCT-10-0516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=21159616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGrsLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=3410-3419&author=A.-M.+Tsimberidouauthor=W.+Akerleyauthor=M.+C.+Schabelauthor=D.+S.+Hongauthor=C.+Ueharaauthor=A.+Chhabraauthor=T.+Warrenauthor=G.+G.+Matherauthor=B.+A.+Evansauthor=D.+P.+Woodlandauthor=E.+A.+Swabbauthor=R.+Kurzrock&title=Phase+I+clinical+trial+of+MPC-6827+%28Azixa%29%2C+a+microtubule+destabilizing+agent%2C+in+patients+with+advanced+cancer&doi=10.1158%2F1535-7163.MCT-10-0516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer</span></div><div class="casAuthors">Tsimberidou, Apostolia-Maria; Akerley, Wallace; Schabel, Matthias C.; Hong, David S.; Uehara, Cynthia; Chhabra, Anil; Warren, Terri; Mather, Gary G.; Evans, Brent A.; Woodland, Deane P.; Swabb, Edward A.; Kurzrock, Razelle</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3410-3419</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">MPC-6827 (Azixa) is a small-mol. microtubule-destabilizing agent that binds to the same (or nearby) sites on β-tubulin as colchicine.  This phase I study was designed to det. the dose-limiting toxicities (DLT), max. tolerated dose (MTD), and pharmacokinetics (PK) of MPC-6827 in patients with solid tumors.  Patients with advanced/metastatic cancer were treated with once-weekly, 1- to 2-h i.v. administration of MPC-6827 for 3 consecutive weeks every 28 days (1 cycle).  Dose escalation began with 0.3, 0.6, 1, and 1.5 mg/m2, with subsequent increments of 0.6 mg/m2 until the MTD was detd.  A 3 + 3 design was used.  Pharmacokinetics of MPC-6827 and its metabolite MPI-0440627 were evaluated.  Forty-eight patients received therapy; 79 cycles were completed (median, 1; range, 1-10).  The most common adverse events were nausea, fatigue, flushing, and hyperglycemia.  The DLT was nonfatal grade 3 myocardial infarction at 3.9 mg/m2 (1/6 patients) and at 4.5 mg/m2 (1/7 patients).  The MTD was detd. to be 3.3 mg/m2 (0/13 patients had a DLT).  Five (10.4%) of the 48 patients achieved stable disease (Response Evaluation Criteria in Solid Tumors) for 4 mo or greater.  MPC-6827 has a high vol. of distribution and clearance.  Half-life ranged from 3.8 to 7.5 h.  In conclusion, MPC-6827 administered i.v. over 2 h at a dose of 3.3 mg/m2 once weekly for 3 wk every 28 days was safe in patients with heavily pretreated cancer.  Clin. trials with MPC-6827 and chemotherapy are ongoing.  Mol Cancer Ther; 9(12); 3410-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQxB3bYYYZ1rVg90H21EOLACvtfcHk0lh4fHxCFGPZng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGrsLjN&md5=97b0a255d67eec98f8bd7c3709cdcf6c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0516%26sid%3Dliteratum%253Aachs%26aulast%3DTsimberidou%26aufirst%3DA.-M.%26aulast%3DAkerley%26aufirst%3DW.%26aulast%3DSchabel%26aufirst%3DM.%2BC.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DUehara%26aufirst%3DC.%26aulast%3DChhabra%26aufirst%3DA.%26aulast%3DWarren%26aufirst%3DT.%26aulast%3DMather%26aufirst%3DG.%2BG.%26aulast%3DEvans%26aufirst%3DB.%2BA.%26aulast%3DWoodland%26aufirst%3DD.%2BP.%26aulast%3DSwabb%26aufirst%3DE.%2BA.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DPhase%2520I%2520clinical%2520trial%2520of%2520MPC-6827%2520%2528Azixa%2529%252C%2520a%2520microtubule%2520destabilizing%2520agent%252C%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D3410%26epage%3D3419%26doi%3D10.1158%2F1535-7163.MCT-10-0516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Harrison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pili, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnott, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidor, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span> </span><span class="NLM_article-title">A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1465</span><span class="NLM_x">–</span> <span class="NLM_lpage">1474</span><span class="refDoi"> DOI: 10.1007/s10637-010-9455-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1007%2Fs10637-010-9455-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1465-1474&author=M.+Harrisonauthor=N.+Hahnauthor=R.+Piliauthor=W.+Ohauthor=H.+Hammersauthor=C.+Sweeneyauthor=K.+Kimauthor=S.+Perlmanauthor=J.+Arnottauthor=C.+Sidorauthor=G.+Wildingauthor=G.+Liu&title=A+phase+II+study+of+2-methoxyestradiol+%282ME2%29+NanoCrystal%C2%AE+dispersion+%28NCD%29+in+patients+with+taxane-refractory%2C+metastatic+castrate-resistant+prostate+cancer+%28CRPC%29&doi=10.1007%2Fs10637-010-9455-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs10637-010-9455-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-010-9455-x%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DM.%26aulast%3DHahn%26aufirst%3DN.%26aulast%3DPili%26aufirst%3DR.%26aulast%3DOh%26aufirst%3DW.%26aulast%3DHammers%26aufirst%3DH.%26aulast%3DSweeney%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DPerlman%26aufirst%3DS.%26aulast%3DArnott%26aufirst%3DJ.%26aulast%3DSidor%26aufirst%3DC.%26aulast%3DWilding%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DG.%26atitle%3DA%2520phase%2520II%2520study%2520of%25202-methoxyestradiol%2520%25282ME2%2529%2520NanoCrystal%25C2%25AE%2520dispersion%2520%2528NCD%2529%2520in%2520patients%2520with%2520taxane-refractory%252C%2520metastatic%2520castrate-resistant%2520prostate%2520cancer%2520%2528CRPC%2529%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2011%26volume%3D29%26spage%3D1465%26epage%3D1474%26doi%3D10.1007%2Fs10637-010-9455-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Bruce, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eickhoff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pili, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carducci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnott, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span> </span><span class="NLM_article-title">A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">794</span><span class="NLM_x">–</span> <span class="NLM_lpage">802</span><span class="refDoi"> DOI: 10.1007/s10637-010-9618-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1007%2Fs10637-010-9618-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=794-802&author=J.+Bruceauthor=J.+Eickhoffauthor=R.+Piliauthor=T.+Loganauthor=M.+Carducciauthor=J.+Arnottauthor=A.+Trestonauthor=G.+Wildingauthor=G.+Liu&title=A+phase+II+study+of+2-methoxyestradiol+nanocrystal+colloidal+dispersion+alone+and+in+combination+with+sunitinib+malate+in+patients+with+metastatic+renal+cell+carcinoma+progressing+on+sunitinib+malate&doi=10.1007%2Fs10637-010-9618-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs10637-010-9618-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-010-9618-9%26sid%3Dliteratum%253Aachs%26aulast%3DBruce%26aufirst%3DJ.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DPili%26aufirst%3DR.%26aulast%3DLogan%26aufirst%3DT.%26aulast%3DCarducci%26aufirst%3DM.%26aulast%3DArnott%26aufirst%3DJ.%26aulast%3DTreston%26aufirst%3DA.%26aulast%3DWilding%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DG.%26atitle%3DA%2520phase%2520II%2520study%2520of%25202-methoxyestradiol%2520nanocrystal%2520colloidal%2520dispersion%2520alone%2520and%2520in%2520combination%2520with%2520sunitinib%2520malate%2520in%2520patients%2520with%2520metastatic%2520renal%2520cell%2520carcinoma%2520progressing%2520on%2520sunitinib%2520malate%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D794%26epage%3D802%26doi%3D10.1007%2Fs10637-010-9618-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span> </span><span class="NLM_article-title">A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">462</span><span class="NLM_x">–</span> <span class="NLM_lpage">471</span><span class="refDoi"> DOI: 10.1097/CAD.0000000000000070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1097%2FCAD.0000000000000070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=24500030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1SksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=462-471&author=P.+Liuauthor=Y.+Qinauthor=L.+Wuauthor=S.+Yangauthor=N.+Liauthor=H.+Wangauthor=H.+Xuauthor=K.+Sunauthor=S.+Zhangauthor=X.+Hanauthor=Y.+Sunauthor=Y.+Shi&title=A+phase+I+clinical+trial+assessing+the+safety+and+tolerability+of+combretastatin+A4+phosphate+injections&doi=10.1097%2FCAD.0000000000000070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections</span></div><div class="casAuthors">Liu, Peng; Qin, Yan; Wu, Lingying; Yang, Sheng; Li, Nan; Wang, Haijun; Xu, Haiyan; Sun, Kelin; Zhang, Shuxiang; Han, Xiaohong; Sun, Yan; Shi, Yuankai</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">462-471</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Combretastatin A4 phosphate (CA4P) is a prodrug that selectively destroys tumor blood vessels, and has shown efficacy as a targeted anticancer drug in both animal models and clin. trials.  The aims of this single-center, open label, phase I clin. trial were to investigate the safety and tolerability of CA4P administered i.v. to patients aged 18-65 years with advanced solid tumors.  Using a dose-escalation protocol, patients were assigned to five groups that received injections with 20 (n=3), 33 (n=3), 50 (n=11), 65 (n=6), or 85 (n=2) mg/m CA4P.  Patients in the 20 and 85 mg/m groups received a single dose and the other groups received multiple doses.  Adverse events (AE), cardiovascular parameters, and biochem. investigations were studied, and the max. tolerated dose was detd.  Of twenty-five patients enrolled, eight were withdrawn/excluded (not because of AE).  There were no deaths.  A total of 394 AE occurred in the 25 patients, with 89.3% considered related/possibly related to the drug.  AE included headache and dizziness (19.8%), tumor-induced pain (14.2%), vascular vagal excitation (10.7%), and vomiting (9.4%).  Ninety-five percent of AE were mild (grades 0-II), with only 5% being grade III-IV.  Drug administration was assocd. with biphasic changes in heart rate and blood pressure, and only limited abnormalities in the lab. investigations performed.  The max. tolerated dose was 65 mg/m.  We conclude that CA4P is generally well tolerated, with the vast majority of AE that occurred being of mild severity.  Further studies will establish the role of CA4P in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobvmdFO81FLLVg90H21EOLACvtfcHk0ljR4-25elYdRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1SksLg%253D&md5=1573e6f13d625ddc78fdac4ffff13181</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000070%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DA%2520phase%2520I%2520clinical%2520trial%2520assessing%2520the%2520safety%2520and%2520tolerability%2520of%2520combretastatin%2520A4%2520phosphate%2520injections%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2014%26volume%3D25%26spage%3D462%26epage%3D471%26doi%3D10.1097%2FCAD.0000000000000070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Ng, Q.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandeville, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padhani, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saunders, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoskin, P. J.</span><span> </span><span class="NLM_article-title">Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">237</span><span class="refDoi"> DOI: 10.1093/annonc/mdr332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1093%2Fannonc%2Fmdr332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=21765046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FptVClsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=231-237&author=Q.-S.+Ngauthor=H.+Mandevilleauthor=V.+Gohauthor=R.+Alonziauthor=J.+Milnerauthor=D.+Carnellauthor=K.+Meerauthor=A.+R.+Padhaniauthor=M.+I.+Saundersauthor=P.+J.+Hoskin&title=Phase+Ib+trial+of+radiotherapy+in+combination+with+combretastatin-A4-phosphate+in+patients+with+non-small-cell+lung+cancer%2C+prostate+adenocarcinoma%2C+and+squamous+cell+carcinoma+of+the+head+and+neck&doi=10.1093%2Fannonc%2Fmdr332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck</span></div><div class="casAuthors">Ng Q-S; Mandeville H; Goh V; Alonzi R; Milner J; Carnell D; Meer K; Padhani A R; Saunders M I; Hoskin P J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">231-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The vascular disrupting agent combretastatin-A4-phosphate (CA4P) demonstrated antitumour activity in preclinical studies when combined with radiation.  METHODS:  Patients with non-small-cell lung cancer (NSCLC), prostate adenocarcinoma, and squamous cell carcinoma of the head and neck (SCCHN) received 27 Gy in 6 fractions treating twice weekly over 3 weeks, 55 Gy in 20 fractions over 4 weeks, and 66 Gy in 33 fractions over 6 weeks respectively.  CA4P was escalated from 50 mg/m2 to 63 mg/m2.  CA4P exposure was further increased from one to three to six doses.  Patients with SCCHN received cetuximab in addition.  RESULTS:  Thirty-nine patients received 121 doses of CA4P.  Dose-limiting toxic effects (DLTs) of reversible ataxia and oculomotor nerve palsy occurred in two patients with prostate cancer receiving weekly CA4P at 63 mg/m2.  DLT of cardiac ischaemia occurred in two patients with SCCHN at a weekly dose of 50 mg/m2 in combination with cetuximab.  Three patients developed grade 3 hypertension.  Responses were seen in 7 of 18 patients with NSCLC.  At 3 years, 3 of 18 patients with prostate cancer had prostate-specific antigen relapse.  CONCLUSIONS:  Radiotherapy with CA4P appears well tolerated in most patients.  The combination of CA4P, cetuximab, and radiotherapy needs further scrutiny before it can be recommended for clinical studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUpqvW00Wv3kkUaC_kzhvyfW6udTcc2eY_2mEZxiJUjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FptVClsA%253D%253D&md5=81485b098f126d9a1f6355dd440b28f9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdr332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdr332%26sid%3Dliteratum%253Aachs%26aulast%3DNg%26aufirst%3DQ.-S.%26aulast%3DMandeville%26aufirst%3DH.%26aulast%3DGoh%26aufirst%3DV.%26aulast%3DAlonzi%26aufirst%3DR.%26aulast%3DMilner%26aufirst%3DJ.%26aulast%3DCarnell%26aufirst%3DD.%26aulast%3DMeer%26aufirst%3DK.%26aulast%3DPadhani%26aufirst%3DA.%2BR.%26aulast%3DSaunders%26aufirst%3DM.%2BI.%26aulast%3DHoskin%26aufirst%3DP.%2BJ.%26atitle%3DPhase%2520Ib%2520trial%2520of%2520radiotherapy%2520in%2520combination%2520with%2520combretastatin-A4-phosphate%2520in%2520patients%2520with%2520non-small-cell%2520lung%2520cancer%252C%2520prostate%2520adenocarcinoma%252C%2520and%2520squamous%2520cell%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26spage%3D231%26epage%3D237%26doi%3D10.1093%2Fannonc%2Fmdr332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Zweifel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayson, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeves, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkissoon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span> </span><span class="NLM_article-title">Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2036</span><span class="NLM_x">–</span> <span class="NLM_lpage">2041</span><span class="refDoi"> DOI: 10.1093/annonc/mdq708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1093%2Fannonc%2Fmdq708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=21273348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A280%3ADC%252BC3MjpvVSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=2036-2041&author=M.+Zweifelauthor=G.+C.+Jaysonauthor=N.+S.+Reedauthor=R.+Osborneauthor=B.+Hassanauthor=J.+Ledermannauthor=G.+Shreevesauthor=L.+Poupardauthor=S.-P.+Luauthor=J.+Balkissoonauthor=D.+J.+Chaplinauthor=G.+J.+S.+Rustin&title=Phase+II+trial+of+combretastatin+A4+phosphate%2C+carboplatin%2C+and+paclitaxel+in+patients+with+platinum-resistant+ovarian+cancer&doi=10.1093%2Fannonc%2Fmdq708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer</span></div><div class="casAuthors">Zweifel M; Jayson G C; Reed N S; Osborne R; Hassan B; Ledermann J; Shreeves G; Poupard L; Lu S-P; Balkissoon J; Chaplin D J; Rustin G J S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2036-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer.  PATIENTS AND METHODS:  Patients with ovarian cancer that had relapsed and who could start trial therapy within 6 months of their last platinum chemotherapy were given CA4P 63 mg/m(2) minimum 18 h before paclitaxel 175 mg/m(2) and carboplatin AUC (area under the concentration curve) 5, repeated every 3 weeks.  RESULTS:  Five of the first 18 patients' disease responded, so the study was extended and closed after 44 patients were recruited.  Grade ≥2 toxic effects were neutropenia in 75% and thrombocytopenia in 9% of patients (weekly blood counts), tumour pain, fatigue, and neuropathy, with one patient with rapidly reversible ataxia.  Hypertension (23% of patients) was controlled by glyceryl trinitrate or prophylactic amlodipine.  The response rate by RECIST was 13.5% and by Gynecologic Cancer InterGroup CA 125 criteria 34%.  CONCLUSIONS:  The addition of CA4P to paclitaxel and carboplatin is well tolerated and appears to produce a higher response rate in this patient population than if the chemotherapy was given without CA4P.  A planned randomised trial will test this hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKPQKWSYY7Sqe0F5ixvZgXfW6udTcc2eYgofSELqUvdbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjpvVSrsQ%253D%253D&md5=6b960ad4dcccdbbc67ffa9398e85d2be</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdq708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdq708%26sid%3Dliteratum%253Aachs%26aulast%3DZweifel%26aufirst%3DM.%26aulast%3DJayson%26aufirst%3DG.%2BC.%26aulast%3DReed%26aufirst%3DN.%2BS.%26aulast%3DOsborne%26aufirst%3DR.%26aulast%3DHassan%26aufirst%3DB.%26aulast%3DLedermann%26aufirst%3DJ.%26aulast%3DShreeves%26aufirst%3DG.%26aulast%3DPoupard%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DS.-P.%26aulast%3DBalkissoon%26aufirst%3DJ.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26atitle%3DPhase%2520II%2520trial%2520of%2520combretastatin%2520A4%2520phosphate%252C%2520carboplatin%252C%2520and%2520paclitaxel%2520in%2520patients%2520with%2520platinum-resistant%2520ovarian%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26spage%3D2036%26epage%3D2041%26doi%3D10.1093%2Fannonc%2Fmdq708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Nathan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweifel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padhani, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, D.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smythe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirling, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3428</span><span class="NLM_x">–</span> <span class="NLM_lpage">3439</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-3376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1158%2F1078-0432.CCR-11-3376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=22645052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1Oks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3428-3439&author=P.+Nathanauthor=M.+Zweifelauthor=A.+R.+Padhaniauthor=D.-M.+Kohauthor=M.+Ngauthor=D.+J.+Collinsauthor=A.+Harrisauthor=C.+Cardenauthor=J.+Smytheauthor=N.+Fisherauthor=N.+J.+Taylorauthor=J.+J.+Stirlingauthor=S.-P.+Luauthor=M.+O.+Leachauthor=G.+J.+S.+Rustinauthor=I.+Judson&title=Phase+I+trial+of+combretastatin+A4+phosphate+%28CA4P%29+in+combination+with+bevacizumab+in+patients+with+advanced+cancer&doi=10.1158%2F1078-0432.CCR-11-3376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer</span></div><div class="casAuthors">Nathan, Paul; Zweifel, Martin; Padhani, Anwar R.; Koh, Dow-Mu; Ng, Matthew; Collins, David J.; Harris, Adrian; Carden, Craig; Smythe, Jon; Fisher, Nita; Taylor, N. Jane; Stirling, J. James; Lu, Shiao-Ping; Leach, Martin O.; Rustin, Gordon J. S.; Judson, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3428-3439</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The vascular disrupting agent (VDA) combretastatin A4 phosphate (CA4P) induces significant tumor necrosis as a single agent.  Preclin. models have shown that the addn. of an anti-VEGF antibody to a VDA attenuates the revascularization of the surviving tumor rim and thus significantly increases antitumor activity.  Exptl. Design: Patients with advanced solid malignancies received CA4P at 45, 54, or 63 mg/m2 on day 1, day 8, and then every 14 days.  Bevacizumab 10 mg/kg was given on day 8 and at subsequent cycles four hours after CA4P.  Functional imaging with dynamic contrast enhanced-MRI (DCE-MRI) was conducted at baseline, after CA4P alone, and after cycle 1 CA4P + bevacizumab.  Results: A total of 63 mg/m2 CA4P + 10 mg/kg bevacizumab q14 is the recommended phase II dose.  A total of 15 patients were enrolled.  Dose-limiting toxicities were grade III asymptomatic atrial fibrillation and grade IV liver hemorrhage in a patient with a history of hemorrhage.  Most common toxicities were hypertension, headache, lymphopenia, pruritus, and pyrexia.  Asymptomatic electrocardiog. changes were seen in five patients.  Nine of 14 patients experienced disease stabilization.  A patient with ovarian cancer had a CA125 response lasting for more than a year.  DCE-MRI showed statistically significant redns. in tumor perfusion/vascular permeability, which reversed after CA4P alone but which were sustained following bevacizumab.  Circulating CD34+ and CD133+ bone marrow progenitors increased following CA4P as did VEGF and granulocyte colony-stimulating factor levels.  Conclusions: CA4P in combination with bevacizumab appears safe and well tolerated in this dosing schedule.  CA4P induced profound vascular changes, which were maintained by the presence of bevacizumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDhWR6xfmKNbVg90H21EOLACvtfcHk0lj29OaYfEMGtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1Oks70%253D&md5=b7d93331d8ad4e6d21fff0ddf35fe461</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3376%26sid%3Dliteratum%253Aachs%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DZweifel%26aufirst%3DM.%26aulast%3DPadhani%26aufirst%3DA.%2BR.%26aulast%3DKoh%26aufirst%3DD.-M.%26aulast%3DNg%26aufirst%3DM.%26aulast%3DCollins%26aufirst%3DD.%2BJ.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DCarden%26aufirst%3DC.%26aulast%3DSmythe%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DN.%2BJ.%26aulast%3DStirling%26aufirst%3DJ.%2BJ.%26aulast%3DLu%26aufirst%3DS.-P.%26aulast%3DLeach%26aufirst%3DM.%2BO.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DPhase%2520I%2520trial%2520of%2520combretastatin%2520A4%2520phosphate%2520%2528CA4P%2529%2520in%2520combination%2520with%2520bevacizumab%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3428%26epage%3D3439%26doi%3D10.1158%2F1078-0432.CCR-11-3376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Patterson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweifel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halford, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkissoon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padhani, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span> </span><span class="NLM_article-title">Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1415</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1158%2F1078-0432.CCR-11-2414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=22235096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wlurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1415-1425&author=D.+M.+Pattersonauthor=M.+Zweifelauthor=M.+R.+Middletonauthor=P.+M.+Priceauthor=L.+K.+Folkesauthor=M.+R.+L.+Stratfordauthor=P.+Rossauthor=S.+Halfordauthor=J.+Petersauthor=J.+Balkissoonauthor=D.+J.+Chaplinauthor=A.+R.+Padhaniauthor=G.+J.+S.+Rustin&title=Phase+I+clinical+and+pharmacokinetic+evaluation+of+the+vascular-disrupting+agent+OXi4503+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-11-2414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Patterson, Dan M.; Zweifel, Martin; Middleton, Mark R.; Price, Patricia M.; Folkes, Lisa K.; Stratford, Michael R. L.; Ross, Phil; Halford, Sarah; Peters, Jane; Balkissoon, Jai; Chaplin, Dai J.; Padhani, Anwar R.; Rustin, Gordon J. S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1415-1425</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Preclin. studies show that OXi4503 (combretastatin A1 diphosphate, CA1P) is more potent than other clin. evaluated vascular-disrupting agents.  Exptl. Design: Escalating doses of OXi4503 were given i.v. over 10 min on days 1, 8, and 15 every 28 days to patients with advanced solid tumors.  RESULTS: Doses were escalated in single-patient cohorts from 0.06 to 1.92 mg/m2, then expanded cohorts to 15.4 mg/m2 in 43 patients.  Common adverse drug reactions were hypertension, tumor pain, anemia, lymphopenia, and easily controllable nausea/vomiting and fatigue.  Five patients experienced different drug-related dose-limiting toxicities, atrial fibrillation, increased troponin, blurred vision, diplopia, and tumor lysis.  Prophylactic amlodipine failed to prevent adverse events.  Pharmacokinetics showed dose-dependent linear increases in peak plasma concns. and area under the curve value of OXi4503.  One partial response was seen in a heavily pretreated patient with ovarian cancer.  Dynamic contrast-enhanced MRI confirmed a dose effect and showed significant antivascular effects in 10 of 13 patients treated at doses of 11 mg/m2 or higher.  CONCLUSIONS: The max. tolerated dose was 8.5 mg/m2 but escalation to 14 mg/m2 was possible with only temporary reversible cerebrovascular toxicity by excluding hypertensive patients.  As a tumor response was seen at 14 mg/m2 and max. tumor perfusion redns. were seen at doses of 11 mg/m2 or higher, the recommended phase II dose is from 11 to 14 mg/m2.  Clin Cancer Res; 18(5); 1415-25.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgz59a0dQud7Vg90H21EOLACvtfcHk0lg5Xw3e6u07tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wlurc%253D&md5=9414d480dc5eef26ec066054dc96b124</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2414%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DD.%2BM.%26aulast%3DZweifel%26aufirst%3DM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DPrice%26aufirst%3DP.%2BM.%26aulast%3DFolkes%26aufirst%3DL.%2BK.%26aulast%3DStratford%26aufirst%3DM.%2BR.%2BL.%26aulast%3DRoss%26aufirst%3DP.%26aulast%3DHalford%26aufirst%3DS.%26aulast%3DPeters%26aufirst%3DJ.%26aulast%3DBalkissoon%26aufirst%3DJ.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DPadhani%26aufirst%3DA.%2BR.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26atitle%3DPhase%2520I%2520clinical%2520and%2520pharmacokinetic%2520evaluation%2520of%2520the%2520vascular-disrupting%2520agent%2520OXi4503%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1415%26epage%3D1425%26doi%3D10.1158%2F1078-0432.CCR-11-2414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohena, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">Structure-activity relationship and in vitro and in vivo evaluation of the potent cytotoxic anti-microtubule agent <i>N</i>-(4-methoxyphenyl)-<i>N</i>,2,6-trimethyl-6,7-dihydro-5<i>H</i>-cyclo-penta[<i>d</i>]pyrimidin-4-aminium chloride and its analogues as antitumor agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6829</span><span class="NLM_x">–</span> <span class="NLM_lpage">6844</span><span class="refDoi"> DOI: 10.1021/jm400639z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400639z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6829-6844&author=A.+Gangjeeauthor=Y.+Zhaoauthor=S.+Raghavanauthor=C.+C.+Rohenaauthor=S.+L.+Mooberryauthor=E.+Hamel&title=Structure-activity+relationship+and+in+vitro+and+in+vivo+evaluation+of+the+potent+cytotoxic+anti-microtubule+agent+N-%284-methoxyphenyl%29-N%2C2%2C6-trimethyl-6%2C7-dihydro-5H-cyclo-penta%5Bd%5Dpyrimidin-4-aminium+chloride+and+its+analogues+as+antitumor+agents&doi=10.1021%2Fjm400639z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm400639z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400639z%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DRohena%26aufirst%3DC.%2BC.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DStructure-activity%2520relationship%2520and%2520in%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%2520the%2520potent%2520cytotoxic%2520anti-microtubule%2520agent%2520N-%25284-methoxyphenyl%2529-N%252C2%252C6-trimethyl-6%252C7-dihydro-5H-cyclo-penta%255Bd%255Dpyrimidin-4-aminium%2520chloride%2520and%2520its%2520analogues%2520as%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6829%26epage%3D6844%26doi%3D10.1021%2Fjm400639z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Prota, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargsten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buey, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pohlmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinelt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span> </span><span class="NLM_article-title">The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">426</span><span class="NLM_x">, </span> <span class="NLM_fpage">1848</span><span class="NLM_x">–</span> <span class="NLM_lpage">1860</span><span class="refDoi"> DOI: 10.1016/j.jmb.2014.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1016%2Fj.jmb.2014.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=24530796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2014&pages=1848-1860&author=A.+E.+Protaauthor=F.+Danelauthor=F.+Bachmannauthor=K.+Bargstenauthor=R.+M.+Bueyauthor=J.+Pohlmannauthor=S.+Reineltauthor=H.+Laneauthor=M.+O.+Steinmetz&title=The+novel+microtubule-destabilizing+drug+BAL27862+binds+to+the+colchicine+site+of+tubulin+with+distinct+effects+on+microtubule+organization&doi=10.1016%2Fj.jmb.2014.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization</span></div><div class="casAuthors">Prota, Andrea E.; Danel, Franck; Bachmann, Felix; Bargsten, Katja; Buey, Ruben M.; Pohlmann, Jens; Reinelt, Stefan; Lane, Heidi; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1848-1860</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Microtubule-targeting agents are widely used for the treatment of cancer and as tool compds. to study the microtubule cytoskeleton.  BAL27862 is a novel microtubule-destabilizing drug that is currently undergoing phase I clin. evaluation as the prodrug BAL101553.  The drug is a potent inhibitor of tumor cell growth and shows a promising activity profile in a panel of human cancer models resistant to clin. relevant microtubule-targeting agents.  Here, we evaluated the mol. mechanism of the tubulin-BAL27862 interaction using a combination of cell biol., biochem. and structural biol. methods.  Tubulin-binding assays revealed that BAL27862 potently inhibited tubulin assembly at 37 °C with an IC50 of 1.4 μM and bound to unassembled tubulin with a stoichiometry of 1 mol/mol tubulin and a dissocn. const. of 244 ± 30 nM.  BAL27862 bound to tubulin independently of vinblastine, without the formation of tubulin oligomers.  The kinetics of BAL27862 binding to tubulin were distinct from those of colchicine, with evidence of competition between BAL27862 and colchicine for binding.  Detn. of the tubulin-BAL27862 structure by X-ray crystallog. demonstrated that BAL27862 binds to the same site as colchicine at the intradimer interface.  Comparison of crystal structures of tubulin-BAL27862 and tubulin-colchicine complexes shows that the binding mode of BAL27862 to tubulin is similar to that of colchicine.  However, comparative analyses of the effects of BAL27862 and colchicine on the microtubule mitotic spindle and in tubulin protease-protection expts. suggest different outcomes of tubulin binding.  Taken together, our data define BAL27862 as a potent, colchicine site-binding, microtubule-destabilizing agent with distinct effects on microtubule organization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIsVCA_6rcHLVg90H21EOLACvtfcHk0lg5Xw3e6u07tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlSrtrs%253D&md5=147ddbbfe5b90157cb8b2e04e1791668</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2014.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2014.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DDanel%26aufirst%3DF.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DBuey%26aufirst%3DR.%2BM.%26aulast%3DPohlmann%26aufirst%3DJ.%26aulast%3DReinelt%26aufirst%3DS.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DThe%2520novel%2520microtubule-destabilizing%2520drug%2520BAL27862%2520binds%2520to%2520the%2520colchicine%2520site%2520of%2520tubulin%2520with%2520distinct%2520effects%2520on%2520microtubule%2520organization%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D426%26spage%3D1848%26epage%3D1860%26doi%3D10.1016%2Fj.jmb.2014.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span> <span class="citation_source-book">Molecular Operating Environment</span> (MOE 2013.08); <span class="NLM_publisher-name">Chemical Computing Group, Inc.</span>: <span class="NLM_publisher-loc">Montreal, Quebec, Canada</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span><a href="http://www.chemcomp.com" class="extLink">www.chemcomp.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Molecular+Operating+Environment+%28MOE+2013.08%29%3B+Chemical+Computing+Group%2C+Inc.%3A+Montreal%2C+Quebec%2C+Canada%2C+2013%3B+www.chemcomp.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DMolecular%2520Operating%2520Environment%26pub%3DChemical%2520Computing%2520Group%252C%2520Inc%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Gewald, K.</span><span> </span><span class="NLM_article-title">Heterocycles from CH-acidic nitriles. IX. Reaction of α-hydroxy ketones with malononitrile</span> <span class="citation_source-journal">Chem. Ber.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1966</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">1002</span><span class="NLM_x">–</span> <span class="NLM_lpage">1007</span><span class="refDoi"> DOI: 10.1002/cber.19660990340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1002%2Fcber.19660990340" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1966&pages=1002-1007&author=K.+Gewald&title=Heterocycles+from+CH-acidic+nitriles.+IX.+Reaction+of+%CE%B1-hydroxy+ketones+with+malononitrile&doi=10.1002%2Fcber.19660990340"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcber.19660990340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcber.19660990340%26sid%3Dliteratum%253Aachs%26aulast%3DGewald%26aufirst%3DK.%26atitle%3DHeterocycles%2520from%2520CH-acidic%2520nitriles.%2520IX.%2520Reaction%2520of%2520%25CE%25B1-hydroxy%2520ketones%2520with%2520malononitrile%26jtitle%3DChem.%2520Ber.%26date%3D1966%26volume%3D99%26spage%3D1002%26epage%3D1007%26doi%3D10.1002%2Fcber.19660990340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Tinley, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leal, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randall-Hlubek, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cessac, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkens, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Novel 2-methoxyestradiol analogues with antitumor activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1538</span><span class="NLM_x">–</span> <span class="NLM_lpage">1549</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=1538-1549&author=T.+L.+Tinleyauthor=R.+M.+Lealauthor=D.+A.+Randall-Hlubekauthor=J.+W.+Cessacauthor=L.+R.+Wilkensauthor=P.+N.+Raoauthor=S.+L.+Mooberry&title=Novel+2-methoxyestradiol+analogues+with+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTinley%26aufirst%3DT.%2BL.%26aulast%3DLeal%26aufirst%3DR.%2BM.%26aulast%3DRandall-Hlubek%26aufirst%3DD.%2BA.%26aulast%3DCessac%26aufirst%3DJ.%2BW.%26aulast%3DWilkens%26aufirst%3DL.%2BR.%26aulast%3DRao%26aufirst%3DP.%2BN.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DNovel%25202-methoxyestradiol%2520analogues%2520with%2520antitumor%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D1538%26epage%3D1549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Perez, E. A.</span><span> </span><span class="NLM_article-title">Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2086</span><span class="NLM_x">–</span> <span class="NLM_lpage">2095</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1158%2F1535-7163.MCT-09-0366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=19671735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFCnurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2086-2095&author=E.+A.+Perez&title=Microtubule+inhibitors%3A+Differentiating+tubulin-inhibiting+agents+based+on+mechanisms+of+action%2C+clinical+activity%2C+and+resistance&doi=10.1158%2F1535-7163.MCT-09-0366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance</span></div><div class="casAuthors">Perez, Edith A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2086-2095</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Microtubules are important cellular targets for anticancer therapy because of their key role in mitosis.  Microtubule inhibitors (MTI) such as taxanes, vinca alkaloids, and epothilones stabilize or destabilize microtubules, thereby suppressing microtubule dynamics required for proper mitotic function, effectively blocking cell cycle progression and resulting in apoptosis.  In spite of their antitumor activity, innate or acquired drug resistance to MTIs such as the taxanes is common, limiting their overall clin. efficacy.  Further insight into the mechanisms of action of microtubule-targeting drugs has lead to the discovery of novel agents that may provide higher efficacy with limited toxicity and help overcome resistance to conventional MTIs.  This review will focus on the different mechanisms of action of MTIs, potential factors related to resistance and tolerability, and will discuss the recent approval as well as the development of new antineoplastic agents. [Mol Cancer Ther 2009;8(8):2086-95].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1HM8JP4QG8LVg90H21EOLACvtfcHk0lgM_p3SqP648w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFCnurw%253D&md5=1d8dec9ed6c0f061032cec57c96c833e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0366%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DE.%2BA.%26atitle%3DMicrotubule%2520inhibitors%253A%2520Differentiating%2520tubulin-inhibiting%2520agents%2520based%2520on%2520mechanisms%2520of%2520action%252C%2520clinical%2520activity%252C%2520and%2520resistance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2086%26epage%3D2095%26doi%3D10.1158%2F1535-7163.MCT-09-0366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Chiou, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, A.</span><span> </span><span class="NLM_article-title">Comparing the relationship of taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer</span> <span class="citation_source-journal">Lung</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">181</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1007/s00408-003-1029-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1007%2Fs00408-003-1029-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2003&pages=267-273&author=J.+F.+Chiouauthor=J.+A.+Liangauthor=W.+H.+Hsuauthor=J.+J.+Wangauthor=S.+T.+Hoauthor=A.+Kao&title=Comparing+the+relationship+of+taxol-based+chemotherapy+response+with+P-glycoprotein+and+lung+resistance-related+protein+expression+in+non-small+cell+lung+cancer&doi=10.1007%2Fs00408-003-1029-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2Fs00408-003-1029-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00408-003-1029-7%26sid%3Dliteratum%253Aachs%26aulast%3DChiou%26aufirst%3DJ.%2BF.%26aulast%3DLiang%26aufirst%3DJ.%2BA.%26aulast%3DHsu%26aufirst%3DW.%2BH.%26aulast%3DWang%26aufirst%3DJ.%2BJ.%26aulast%3DHo%26aufirst%3DS.%2BT.%26aulast%3DKao%26aufirst%3DA.%26atitle%3DComparing%2520the%2520relationship%2520of%2520taxol-based%2520chemotherapy%2520response%2520with%2520P-glycoprotein%2520and%2520lung%2520resistance-related%2520protein%2520expression%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DLung%26date%3D2003%26volume%3D181%26spage%3D267%26epage%3D273%26doi%3D10.1007%2Fs00408-003-1029-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Trock, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonessa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, R.</span><span> </span><span class="NLM_article-title">Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">–</span> <span class="NLM_lpage">931</span><span class="refDoi"> DOI: 10.1093/jnci/89.13.917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1093%2Fjnci%2F89.13.917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=9214671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A280%3ADyaK2szlslensA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=917-931&author=B.+J.+Trockauthor=F.+Leonessaauthor=R.+Clarke&title=Multidrug+resistance+in+breast+cancer%3A+A+meta-analysis+of+MDR1%2Fgp170+expression+and+its+possible+functional+significance&doi=10.1093%2Fjnci%2F89.13.917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance</span></div><div class="casAuthors">Trock B J; Leonessa F; Clarke R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">917-31</span>
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">BACKGROUND:  P-glycoprotein (gp170; encoded by the MDR1 gene [also known as PGY1]) is a membrane protein capable of exporting a variety of anticancer drugs from cells.  MDR1/gp170 expression has been studied in breast cancer, but the prevalence of this expression and its role in breast tumor drug resistance are unclear.  PURPOSE:  We conducted a critical review and meta-analysis of studies examining MDR1/gp170 expression in breast cancer to estimate the likely prevalence and clinical relevance of this expression.  We also explored reasons for differences in the findings from individual studies.  METHODS:  Published papers on MDR1/gp170 expression in breast cancer were identified by searching several literature databases and reviewing the bibliographies of identified papers.  Variability across the studies in the proportion of tumors expressing MDR1/gp170 was assessed by use of chi-squared tests of homogeneity, weighted means, and weighted linear regression.  Pooled relative risks (RRs) for the association between the induction of MDR1/gp170 expression and prior chemotherapy and associations between MDR1/gp170 expression and several clinical outcomes were estimated by use of Mantel-Haenszel methods.  Heterogeneity among the pooled RRs was explored by use of chi-squared tests.  Reported P values are two-sided.  RESULTS:  Thirty-one studies were identified and evaluated.  The proportion of breast tumors expressing MDR1/gp170 in all of the studies was 41.2%, but there was substantial heterogeneity in the values across individual studies (P<.0001).  Regression analyses demonstrated that a considerable portion of the observed heterogeneity was a consequence of the change, over time, from RNA hybridization-based assays to immunohistochemistry-based assays of MDR1/gp170 expression.  Measuring MDR1/gp170 expression before versus after chemotherapy and use of cytotoxic drugs that are not substrates for gp170 also contributed to the heterogeneity.  Treatment with chemotherapeutic drugs or hormonal agents was associated with an increase in the proportion of tumors expressing MDR1/gp170 (RR = 1.77; 95% confidence interval [CI] = 1.46-2.15).  Patients with tumors expressing MDR1/gp170 were three times more likely to fail to respond to chemotherapy than patients whose tumors were MDR1/gp170 negative (RR = 3.21; 95% CI = 2.28-4.51); this RR increased to 4.19 (95% CI = 2.71-6.47) when considering only patients whose tumor expression of MDR1/gp170 was measured after chemotherapy.  MDR1/gp170 expression was not associated with lymph node metastases, estrogen receptor status, tumor size, tumor grade, or tumor histology.  CONCLUSIONS AND IMPLICATIONS:  MDR1/gp170 expression in breast tumors is associated with treatment and with a poor response to chemotherapy.  The data are consistent with a contributory role for MDR1/gp170 in the multidrug resistance in some breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQbw1eYY31XbVvAgqb2vdc5fW6udTcc2eZ1CZAj4DqtTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2szlslensA%253D%253D&md5=b575e441d936b05ec924ead0ef4ccd4a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F89.13.917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F89.13.917%26sid%3Dliteratum%253Aachs%26aulast%3DTrock%26aufirst%3DB.%2BJ.%26aulast%3DLeonessa%26aufirst%3DF.%26aulast%3DClarke%26aufirst%3DR.%26atitle%3DMultidrug%2520resistance%2520in%2520breast%2520cancer%253A%2520A%2520meta-analysis%2520of%2520MDR1%252Fgp170%2520expression%2520and%2520its%2520possible%2520functional%2520significance%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1997%26volume%3D89%26spage%3D917%26epage%3D931%26doi%3D10.1093%2Fjnci%2F89.13.917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Binkhathlan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavasanifar, A.</span><span> </span><span class="NLM_article-title">P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: Current status and future perspectives</span> <span class="citation_source-journal">Curr. Cancer Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">326</span><span class="NLM_x">–</span> <span class="NLM_lpage">346</span><span class="refDoi"> DOI: 10.2174/15680096113139990076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.2174%2F15680096113139990076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=23369096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVOjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=326-346&author=Z.+Binkhathlanauthor=A.+Lavasanifar&title=P-glycoprotein+inhibition+as+a+therapeutic+approach+for+overcoming+multidrug+resistance+in+cancer%3A+Current+status+and+future+perspectives&doi=10.2174%2F15680096113139990076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives</span></div><div class="casAuthors">Binkhathlan, Ziyad; Lavasanifar, Afsaneh</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">326-346</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  One of the major causes of failure in cancer chemotherapy is multidrug resistance (MDR), where cancer cells simultaneously become resistant to different anticancer drugs.  Over-expression of membrane efflux pumps like P-glycoprotein (P-gp) that recognizes different chemotherapeutic agents and transports them out of the cell, plays a major role in MDR.  The shortcoming of P-gp inhibitors in clinic was attributed to their non-specific action on P-gp and/or non-selective distribution to non-target organs that leads to intolerable side effects by the P-gp inhibitor at doses required for P-gp inhibition upon systemic administration.  Another major issue is the reduced elimination of P-gp substrates (e.g. anticancer drugs) and intolerable toxicities by anticancer drugs when co-administered with P-gp inhibitors.  To overcome these shortcomings, new generation of P-gp inhibitors with improved specificity for P-gp were developed.  More recently, attention was paid to the use of drug delivery systems primarily to restrict P-gp inhibition to tumor and reduce the non-selective inhibition of P-gp in non-target organs.  This review will provide an overview and update on the status of P-gp inhibition approaches and the role of drug delivery systems in overcoming P-gp mediated MDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6kCA4RDN2s7Vg90H21EOLACvtfcHk0lhPMyUmPnDh1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVOjsbY%253D&md5=9fc1e50504313ae7735049fcaadcb9ff</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2174%2F15680096113139990076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15680096113139990076%26sid%3Dliteratum%253Aachs%26aulast%3DBinkhathlan%26aufirst%3DZ.%26aulast%3DLavasanifar%26aufirst%3DA.%26atitle%3DP-glycoprotein%2520inhibition%2520as%2520a%2520therapeutic%2520approach%2520for%2520overcoming%2520multidrug%2520resistance%2520in%2520cancer%253A%2520Current%2520status%2520and%2520future%2520perspectives%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2013%26volume%3D13%26spage%3D326%26epage%3D346%26doi%3D10.2174%2F15680096113139990076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Leonard, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fojo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, S. E.</span><span> </span><span class="NLM_article-title">The role of ABC transporters in clinical practice</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">411</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span><span class="refDoi"> DOI: 10.1634/theoncologist.8-5-411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1634%2Ftheoncologist.8-5-411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=14530494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslyls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=411-424&author=G.+D.+Leonardauthor=T.+Fojoauthor=S.+E.+Bates&title=The+role+of+ABC+transporters+in+clinical+practice&doi=10.1634%2Ftheoncologist.8-5-411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ABC transporters in clinical practice</span></div><div class="casAuthors">Leonard, Gregory D.; Fojo, Tito; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">411-424</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Drug resistance remains one of the primary causes of suboptimal outcomes in cancer therapy.  ATP-binding cassette (ABC) transporters are a family of transporter proteins that contribute to drug resistance via ATP-dependent drug efflux pumps.  P-glycoprotein (P-gp), encoded by the MDR1 gene, is an ABC transporter normally involved in the excretion of toxins from cells.  It also confers resistance to certain chemotherapeutic agents.  P-gp is overexpressed at baseline in chemotherapy-resistant tumors, such as colon and kidney cancers, and is upregulated after disease progression following chemotherapy in malignancies such as leukemia and breast cancer.  Other transporter proteins mediating drug resistance include those in the multidrug-resistance-assocd. protein (MRP) family, notably MRP1, and ABCG2.  These transporters are also involved in normal physiol. functions.  The expressions of MRP family members and ABCG2 were not well worked out in cancer.  Increased drug accumulation and drug resistance reversal with P-gp inhibitors were well documented in vitro, but only suggested in clin. trials.  Limitations in the design of early resistance reversal trials contributed to disappointing results.  Despite this, 3 randomized trials have shown statistically significant benefits with the use of a P-gp inhibitor in combination with chemotherapy.  Improved diagnostic techniques aimed at the selection of patients with tumors that express P-gp should result in more successful outcomes.  Further optimism is warranted with the advent of potent, nontoxic inhibitors and new treatment strategies, including the combination of new targeted therapies with therapies aimed at the prevention of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr317MZ9jawCbVg90H21EOLACvtfcHk0lhPMyUmPnDh1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslyls74%253D&md5=b474f45fd5c45962acfff61840c04a6b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.8-5-411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.8-5-411%26sid%3Dliteratum%253Aachs%26aulast%3DLeonard%26aufirst%3DG.%2BD.%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DThe%2520role%2520of%2520ABC%2520transporters%2520in%2520clinical%2520practice%26jtitle%3DOncologist%26date%3D2003%26volume%3D8%26spage%3D411%26epage%3D424%26doi%3D10.1634%2Ftheoncologist.8-5-411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Fojo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menefee, M.</span><span> </span><span class="NLM_article-title">Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.1093/annonc/mdm172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1093%2Fannonc%2Fmdm172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=17656560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A280%3ADC%252BD2sngs1SitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&pages=3-8&author=T.+Fojoauthor=M.+Menefee&title=Mechanisms+of+multidrug+resistance%3A+The+potential+role+of+microtubule-stabilizing+agents&doi=10.1093%2Fannonc%2Fmdm172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents</span></div><div class="casAuthors">Fojo T; Menefee M</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">18 Suppl 5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">v3-8</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">Antimitotic agents that target the dynamic equilibrium between the microtubule polymer and tubulin heterodimers are key components of chemotherapeutic regimens for various solid tumors.  These agents can be divided into two major classes based on their effect on microtubule polymerization and the mass of microtubule polymers: those that inhibit polymerization, such as the vinca alkaloids and those that stabilize microtubules, such as the taxanes and epothilones.  The taxanes paclitaxel (Taxol) and docetaxel (Taxotere) were the first antimicrotubule agents approved for use in solid tumors, but their usefulness is often limited by development of drug resistance.  The epothilones are distinguished from the taxanes structurally and functionally and have been shown in vitro and in preclinical models to have superior potency to the taxanes.  The epothilones are not susceptible to P-glycoprotein-mediated efflux and have shown activity against taxane-resistant tumors.  Other natural-product microtubule-stabilizing agents also have promising pharmacologic profiles.  This article discusses mechanisms of drug resistance and summarizes scientific and clinical data supporting the potential of novel microtubule-stabilizing agents for achieving broad antitumor efficacy without the emergence of drug resistance.  The ability to reduce the development of resistance with the epothilones and other microtubule-stabilizing agents may provide additional treatment options at the time of presentation and in the setting of taxane resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTF5uhi21MM5z0O18WR3iAofW6udTcc2eYdNeCTxK9Apbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sngs1SitA%253D%253D&md5=ddbd9ea289b1a1cb1f79d6be860f2bfa</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdm172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdm172%26sid%3Dliteratum%253Aachs%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DMenefee%26aufirst%3DM.%26atitle%3DMechanisms%2520of%2520multidrug%2520resistance%253A%2520The%2520potential%2520role%2520of%2520microtubule-stabilizing%2520agents%26jtitle%3DAnn.%2520Oncol.%26date%3D2007%26volume%3D18%26spage%3D3%26epage%3D8%26doi%3D10.1093%2Fannonc%2Fmdm172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scagliotti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danenberg, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, R. V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bepler, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novello, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooc, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boni, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marinis, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marangolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozzelino, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costanzo, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rinaldi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salonga, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, C.</span><span> </span><span class="NLM_article-title">Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3548</span><span class="NLM_x">–</span> <span class="NLM_lpage">3553</span><span class="refDoi"> DOI: 10.1038/sj.onc.1206419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1038%2Fsj.onc.1206419" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=3548-3553&author=R.+Rosellauthor=G.+Scagliottiauthor=K.+D.+Danenbergauthor=R.+V.+N.+Lordauthor=G.+Beplerauthor=S.+Novelloauthor=J.+Coocauthor=L.+Crinoauthor=J.+J.+Sanchezauthor=M.+Taronauthor=C.+Boniauthor=F.+D.+Marinisauthor=M.+Tonatoauthor=M.+Marangoloauthor=F.+Gozzelinoauthor=F.+D.+Costanzoauthor=M.+Rinaldiauthor=D.+Salongaauthor=C.+Stephens&title=Transcripts+in+pretreatment+biopsies+from+a+three-arm+randomized+trial+in+metastatic+non-small-cell+lung+cancer&doi=10.1038%2Fsj.onc.1206419"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1206419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1206419%26sid%3Dliteratum%253Aachs%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DScagliotti%26aufirst%3DG.%26aulast%3DDanenberg%26aufirst%3DK.%2BD.%26aulast%3DLord%26aufirst%3DR.%2BV.%2BN.%26aulast%3DBepler%26aufirst%3DG.%26aulast%3DNovello%26aufirst%3DS.%26aulast%3DCooc%26aufirst%3DJ.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DJ.%2BJ.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DBoni%26aufirst%3DC.%26aulast%3DMarinis%26aufirst%3DF.%2BD.%26aulast%3DTonato%26aufirst%3DM.%26aulast%3DMarangolo%26aufirst%3DM.%26aulast%3DGozzelino%26aufirst%3DF.%26aulast%3DCostanzo%26aufirst%3DF.%2BD.%26aulast%3DRinaldi%26aufirst%3DM.%26aulast%3DSalonga%26aufirst%3DD.%26aulast%3DStephens%26aufirst%3DC.%26atitle%3DTranscripts%2520in%2520pretreatment%2520biopsies%2520from%2520a%2520three-arm%2520randomized%2520trial%2520in%2520metastatic%2520non-small-cell%2520lung%2520cancer%26jtitle%3DOncogene%26date%3D2003%26volume%3D22%26spage%3D3548%26epage%3D3553%26doi%3D10.1038%2Fsj.onc.1206419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Dumontet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaac, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Souquet, P.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bejui-Thivolet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacheco, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peloux, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankfurter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luduena, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perol, M.</span><span> </span><span class="NLM_article-title">Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy</span> <span class="citation_source-journal">Bull. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=15749640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A280%3ADC%252BD2M7hslyntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2005&pages=25-30&author=C.+Dumontetauthor=S.+Isaacauthor=P.-J.+Souquetauthor=F.+Bejui-Thivoletauthor=Y.+Pachecoauthor=N.+Pelouxauthor=A.+Frankfurterauthor=R.+Luduenaauthor=M.+Perol&title=Expression+of+class+III+beta+tubulin+in+non-small+cell+lung+cancer+is+correlated+with+resistance+to+taxane+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy</span></div><div class="casAuthors">Dumontet Charles; Isaac Sylvie; Souquet Pierre-Jean; Bejui-Thivolet Francoise; Pacheco Yves; Peloux Nadine; Frankfurter Anthony; Luduena Richard; Perol Maurice</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin du cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">E25-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This study determined the prevalence and the prognostic value of the expression of microtubule components in tumors of 19 patients with non small cell lung cancer receiving taxane-based regimens.  Patient samples were stained with antibodies directed against total beta tubulin, classes I, II and III beta tubulin isotypes, delta2 alpha tubulin, tau protein, and the P-gp protein involved in the classical multidrug resistance phenotype.  All tumors were stained with pan-beta tubulin antibody and class I tubulin isotype.  A majority of the tumor samples expressed class II and class III, although the percentage of positive cells varied significantly between tumors. delta2 alpha tubulin, tau protein and Pgp protein were found in only one tumor sample each.  Progression-free survival was shorter (41 days) in patients whose tumors expressed high levels of class III tubulin isotype in comparison to patients with low levels (288 days, p = 0.02).  There were 2 responses to chemotherapy among 9 patients (22%) with high levels of class III tubulin vs. 6 among 10 patients (60%) with low levels of expression (Fisher exact test: p = 0.11).  These data suggest that high expression of class III tubulin by tumor cells is associated with poor prognosis in patients with NSCLC receiving a taxane-based regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQuPQNJ4K3goDMsgLhIoICsfW6udTcc2ebvgt9JSrGm_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7hslyntA%253D%253D&md5=db24a04afdf73ba06c4c152ecd7dc5f0</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DIsaac%26aufirst%3DS.%26aulast%3DSouquet%26aufirst%3DP.-J.%26aulast%3DBejui-Thivolet%26aufirst%3DF.%26aulast%3DPacheco%26aufirst%3DY.%26aulast%3DPeloux%26aufirst%3DN.%26aulast%3DFrankfurter%26aufirst%3DA.%26aulast%3DLuduena%26aufirst%3DR.%26aulast%3DPerol%26aufirst%3DM.%26atitle%3DExpression%2520of%2520class%2520III%2520beta%2520tubulin%2520in%2520non-small%2520cell%2520lung%2520cancer%2520is%2520correlated%2520with%2520resistance%2520to%2520taxane%2520chemotherapy%26jtitle%3DBull.%2520Cancer%26date%3D2005%26volume%3D92%26spage%3D25%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Sève, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaac, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trédan, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Souquet, P.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachéco, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérol, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafanéchère, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penet, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peiller, E.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumontet, C.</span><span> </span><span class="NLM_article-title">Expression of class III β-tubulin is predictive of patient outcome in patients with non–small cell lung cancer receiving vinorelbine-based chemotherapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5481</span><span class="NLM_x">–</span> <span class="NLM_lpage">5486</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1158%2F1078-0432.CCR-05-0285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=16061864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvFSmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=5481-5486&author=P.+S%C3%A8veauthor=S.+Isaacauthor=O.+Tr%C3%A9danauthor=P.-J.+Souquetauthor=Y.+Pach%C3%A9coauthor=M.+P%C3%A9rolauthor=L.+Lafan%C3%A9ch%C3%A8reauthor=A.+Penetauthor=E.-L.+Peillerauthor=C.+Dumontet&title=Expression+of+class+III+%CE%B2-tubulin+is+predictive+of+patient+outcome+in+patients+with+non%E2%80%93small+cell+lung+cancer+receiving+vinorelbine-based+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non-Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy</span></div><div class="casAuthors">Seve, Pascal; Isaac, Sylvie; Tredan, Olivier; Souquet, Pierre-Jean; Pacheco, Yves; Perol, Maurice; Lafanechere, Laurence; Penet, Aurelie; Peiller, Eva-Laure; Dumontet, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5481-5486</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: To det. the prevalence and the prognostic value of microtubule component expression in tumors of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).  Exptl. Design: Expression of microtubular components was immunohistochem. examd. in 93 tumor samples from untreated patients with stage III and IV NSCLC.  All patients received vinorelbine-based chemotherapy.  Response to chemotherapy, progression-free survival, and overall survival were correlated with the expression of microtubule proteins.  RESULTS: The response rate was 27.3% (21 partial responses among 77 valuable patients).  Although expression of microtubule components was not assocd. with the response rate, high class III {szligbeta}-tubulin expression was correlated with resistance to vinorelbine, defined as disease progression under treatment.  Patients whose tumors expressed high levels of class III β-tubulin isotype had shorter progression-free survival and overall survival (P = 0.002 and 0.001, resp.).  High Δ2 α-tubulin expression was assocd. with a shorter overall survival (P = 0.018).  Tubulin II levels were not found to be correlated with patient outcome.  A multivariate anal., taking into account sex, age, histol., stage, wt. loss, and class II β-tubulin, class III β-tubulin, and Δ2 α-tubulin levels, confirmed that class III {szligbeta}-tubulin expression was independently correlated with progression-free survival (P = 0.04) and overall survival (P = 0.012).  CONCLUSIONS: These findings suggest that a high level of expression of class III {szligbeta}-tubulin in tumor cells is assocd. with resistance to vinorelbine and a poor prognosis in patients with NSCLC receiving vinorelbine-based chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQLbZO_aEZCLVg90H21EOLACvtfcHk0ljSkTs6TZ8PJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvFSmtbc%253D&md5=144a54ce9966814240d86f5b92dbc2e6</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0285%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A8ve%26aufirst%3DP.%26aulast%3DIsaac%26aufirst%3DS.%26aulast%3DTr%25C3%25A9dan%26aufirst%3DO.%26aulast%3DSouquet%26aufirst%3DP.-J.%26aulast%3DPach%25C3%25A9co%26aufirst%3DY.%26aulast%3DP%25C3%25A9rol%26aufirst%3DM.%26aulast%3DLafan%25C3%25A9ch%25C3%25A8re%26aufirst%3DL.%26aulast%3DPenet%26aufirst%3DA.%26aulast%3DPeiller%26aufirst%3DE.-L.%26aulast%3DDumontet%26aufirst%3DC.%26atitle%3DExpression%2520of%2520class%2520III%2520%25CE%25B2-tubulin%2520is%2520predictive%2520of%2520patient%2520outcome%2520in%2520patients%2520with%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%2520receiving%2520vinorelbine-based%2520chemotherapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D5481%26epage%3D5486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Tommasi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacalamita, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellizzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedele, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiriatti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomssen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendzierski, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latorre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorusso, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schittulli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zito, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavallaris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paradiso, A.</span><span> </span><span class="NLM_article-title">Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β-tubulins</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">2078</span><span class="NLM_x">–</span> <span class="NLM_lpage">2085</span><span class="refDoi"> DOI: 10.1002/ijc.22557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1002%2Fijc.22557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=17285590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkt1Oitbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2007&pages=2078-2085&author=S.+Tommasiauthor=A.+Mangiaauthor=R.+Lacalamitaauthor=A.+Bellizziauthor=V.+Fedeleauthor=A.+Chiriattiauthor=C.+Thomssenauthor=N.+Kendzierskiauthor=A.+Latorreauthor=V.+Lorussoauthor=F.+Schittulliauthor=F.+Zitoauthor=M.+Kavallarisauthor=A.+Paradiso&title=Cytoskeleton+and+paclitaxel+sensitivity+in+breast+cancer%3A+The+role+of+%CE%B2-tubulins&doi=10.1002%2Fijc.22557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of β-tubulins</span></div><div class="casAuthors">Tommasi, Stefania; Mangia, Anita; Lacalamita, Rosanna; Bellizzi, Antonia; Fedele, Vita; Chiriatti, Annalisa; Thomssen, Christopher; Kendzierski, Nancy; Latorre, Agnese; Lorusso, Vito; Schittulli, Francesco; Zito, Francesco; Kavallaris, Maria; Paradiso, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2078-2085</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The antineoplastic effect of paclitaxel is mainly related to its ability to bind the β subunit of tubulin, thus preventing tubulin chain depolarization and inducing apoptosis.  The relevance of the Class 1 β-tubulin characteristics have also been confirmed in the clin. setting where mutations of paclitaxel-binding site of β-tubulin Class I have been related to paclitaxel resistance in non small cell lung and ovarian cancers.  In the present study, we verified the hypothesis of a relationship between mol. alterations of β-tubulin Class I and paclitaxel sensitivity in a panel of breast cell lines with different drug IC50.  The Class I β-tubulin gene cDNA has been sequenced detecting heterozygous missense mutations (exon 1 and 4) only in MCF-7 and SK-BR-3 lines.  Furthermore, the expression (at both mRNA and protein level) of the different isotypes have been analyzed demonstrating an assocn. between low cell sensitivity to paclitaxel and Class III β-tubulin expression increasing.  Antisense oligonucleotide (ODN) expts. confirmed that the inhibition of Class III β-tubulin could at least partially increase paclitaxel-chemosensitivity.  The hypothesis of a relationship between β-tubulin tumor expression and paclitaxel clin. response has been finally verified in a series of 92 advanced breast cancer patients treated with a first line paclitaxel-based chemotherapy.  Thirty-five percent (95% CI: 45-31) of patients with high Class III β-tubulin expression showed a disease progression vs. only 7% of patients with low expression (35% vs. 7%, p < 0.002).  Our study suggests that Class III β-tubulin tumor expression could be considered a predictive biomarker of paclitaxel-clin. resistance for breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBTFhVq0oPHrVg90H21EOLACvtfcHk0lgBt_C9Qdzy1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkt1Oitbo%253D&md5=efd1c3424ce6be7595069049392d016c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fijc.22557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.22557%26sid%3Dliteratum%253Aachs%26aulast%3DTommasi%26aufirst%3DS.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DLacalamita%26aufirst%3DR.%26aulast%3DBellizzi%26aufirst%3DA.%26aulast%3DFedele%26aufirst%3DV.%26aulast%3DChiriatti%26aufirst%3DA.%26aulast%3DThomssen%26aufirst%3DC.%26aulast%3DKendzierski%26aufirst%3DN.%26aulast%3DLatorre%26aufirst%3DA.%26aulast%3DLorusso%26aufirst%3DV.%26aulast%3DSchittulli%26aufirst%3DF.%26aulast%3DZito%26aufirst%3DF.%26aulast%3DKavallaris%26aufirst%3DM.%26aulast%3DParadiso%26aufirst%3DA.%26atitle%3DCytoskeleton%2520and%2520paclitaxel%2520sensitivity%2520in%2520breast%2520cancer%253A%2520The%2520role%2520of%2520%25CE%25B2-tubulins%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2007%26volume%3D120%26spage%3D2078%26epage%3D2085%26doi%3D10.1002%2Fijc.22557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Ferrandina, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zannoni, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paglia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallotta, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mozzetti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scambia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferlini, C.</span><span> </span><span class="NLM_article-title">Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2774</span><span class="NLM_x">–</span> <span class="NLM_lpage">2779</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-2715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1158%2F1078-0432.CCR-05-2715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=16675570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD28Xltlamsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=2774-2779&author=G.+Ferrandinaauthor=G.+F.+Zannoniauthor=E.+Martinelliauthor=A.+Pagliaauthor=V.+Gallottaauthor=S.+Mozzettiauthor=G.+Scambiaauthor=C.+Ferlini&title=Class+III+%CE%B2-tubulin+overexpression+is+a+marker+of+poor+clinical+outcome+in+advanced+ovarian+cancer+patients&doi=10.1158%2F1078-0432.CCR-05-2715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients</span></div><div class="casAuthors">Ferrandina, Gabriella; Zannoni, Gian Franco; Martinelli, Enrica; Paglia, Amelia; Gallotta, Valerio; Mozzetti, Simona; Scambia, Giovanni; Ferlini, Cristiano</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2774-2779</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Overexpression of β III tubulin has been involved in paclitaxel resistance in several exptl. models.  We investigated the role of β III tubulin as predictor of clin. outcome in ovarian cancer patients given platinum/paclitaxel treatment.  We also investigated whether β III tubulin expression could be modified after the selective pressure represented by chemotherapy in vivo.  Exptl. Design: The study was designed to include a series of consecutive ovarian cancer patients with unresectable disease at time of first surgery, who underwent interval debulking surgery with pathol. assessment of response to treatment with platinum/paclitaxel chemotherapy.  Immunostaining was done on formalin-fixed, paraffin-embedded tissue sections from pretreatment and posttreatment tissue biopsies by using the polyclonal rabbit anti-class III β-tubulin antibody.  Results: β III Tubulin immunoreaction was obsd. in 51 of 62 (82.2%) cases.  β III Tubulin positivity was neither assocd. with clinicopathol. variables nor with pathol. response to chemotherapy.  Significantly lower percentages of β III tubulin positivity were obsd. in posttreatment (range, 5-80%; median, 20%) vs. pretreatment (range 10-100%; median, 40%) tissue biopsies (P = 0.0011).  Cases with high β III tubulin expression showed a worse overall survival with respect to cases with low β III tubulin expression (median overall survival, 25 vs. 46 mo; P = 0.002).  Multivariate anal. showed that high content of β III tubulin remains independently assocd. with a worse prognosis.  Conclusions: Assessment of β III tubulin could be useful to identify poor prognosis ovarian cancer patients candidates to more aggressive and/or targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkRULoF4-0uLVg90H21EOLACvtfcHk0lgBt_C9Qdzy1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xltlamsb0%253D&md5=569d52a398426b7b06eddeb7b0e98751</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-2715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-2715%26sid%3Dliteratum%253Aachs%26aulast%3DFerrandina%26aufirst%3DG.%26aulast%3DZannoni%26aufirst%3DG.%2BF.%26aulast%3DMartinelli%26aufirst%3DE.%26aulast%3DPaglia%26aufirst%3DA.%26aulast%3DGallotta%26aufirst%3DV.%26aulast%3DMozzetti%26aufirst%3DS.%26aulast%3DScambia%26aufirst%3DG.%26aulast%3DFerlini%26aufirst%3DC.%26atitle%3DClass%2520III%2520%25CE%25B2-tubulin%2520overexpression%2520is%2520a%2520marker%2520of%2520poor%2520clinical%2520outcome%2520in%2520advanced%2520ovarian%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D2774%26epage%3D2779%26doi%3D10.1158%2F1078-0432.CCR-05-2715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Mozzetti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferlini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Concolino, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raspaglio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prislei, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranelletti, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrandina, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scambia, G.</span><span> </span><span class="NLM_article-title">Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">305</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=15671559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVegtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=298-305&author=S.+Mozzettiauthor=C.+Ferliniauthor=P.+Concolinoauthor=F.+Filippettiauthor=G.+Raspaglioauthor=S.+Prisleiauthor=D.+Galloauthor=E.+Martinelliauthor=F.+O.+Ranellettiauthor=G.+Ferrandinaauthor=G.+Scambia&title=Class+III+%CE%B2-tubulin+overexpression+is+a+prominent+mechanism+of+paclitaxel+resistance+in+ovarian+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients</span></div><div class="casAuthors">Mozzetti, Simona; Ferlini, Cristiano; Concolino, Paola; Filippetti, Flavia; Raspaglio, Giuseppina; Prislei, Silvia; Gallo, Daniela; Martinelli, Enrica; Ranelletti, Franco Oreste; Ferrandina, Gabriella; Scambia, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">298-305</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The vast majority of women with advanced ovarian cancer will ultimately relapse and develop a drug-resistant disease with an overall 5-yr survival of <50%.  Unfortunately, the mechanisms of drug resistance actually operating in patients are still unknown.  To address this issue, in 41 patients affected by advanced ovarian cancer the three main mechanisms of paclitaxel resistance were investigated: overexpression of MDR-1 gene, point mutations at prominently expressed α-tubulin and β-tubulin genes and selective alterations in the expression of β-tubulin isotypes.  MDR-1 and the β-tubulin isotypes expression were evaluated by semiquant. and real-time PCR.  On the same specimens, quant. immunohistochem. was also done in the tumor area.  No statistically significant changes of MDR-1 expression were noticed between the sensitive and resistant patients either at the mRNA or protein level.  The tubulin mutations for the ubiquitous α-tubulin and β-tubulin genes were evaluated by automated DNA sequencing, and in all patients, no mutations were detected in both resistant and sensitive cases.  With regard to the expression of tubulin isoforms, a statistically significant up-regulation of class III β-tubulin was found in the resistant subset.  It is worth noting that this statistically significant increase of the expression of class III β-tubulin was detectable at the mRNA and protein level.  By a direct comparison of the three main known mechanisms of paclitaxel resistance, this study indicates that overexpression of class III β-tubulin is the most prominent mechanism of paclitaxel resistance in ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_j0ZXNlGPW7Vg90H21EOLACvtfcHk0lgBt_C9Qdzy1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVegtrg%253D&md5=861e1e01da277ff2f4d76b458ebe5e48</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMozzetti%26aufirst%3DS.%26aulast%3DFerlini%26aufirst%3DC.%26aulast%3DConcolino%26aufirst%3DP.%26aulast%3DFilippetti%26aufirst%3DF.%26aulast%3DRaspaglio%26aufirst%3DG.%26aulast%3DPrislei%26aufirst%3DS.%26aulast%3DGallo%26aufirst%3DD.%26aulast%3DMartinelli%26aufirst%3DE.%26aulast%3DRanelletti%26aufirst%3DF.%2BO.%26aulast%3DFerrandina%26aufirst%3DG.%26aulast%3DScambia%26aufirst%3DG.%26atitle%3DClass%2520III%2520%25CE%25B2-tubulin%2520overexpression%2520is%2520a%2520prominent%2520mechanism%2520of%2520paclitaxel%2520resistance%2520in%2520ovarian%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D298%26epage%3D305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Hwang, J.-E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, W.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shim, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bae, W.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, E.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, I.-J.</span><span> </span><span class="NLM_article-title">Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1186/1471-2407-13-431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1186%2F1471-2407-13-431" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=431-431&author=J.-E.+Hwangauthor=J.-Y.+Hongauthor=K.+Kimauthor=S.-H.+Kimauthor=W.-Y.+Choiauthor=M.-J.+Kimauthor=S.-H.+Jungauthor=H.-J.+Shimauthor=W.-K.+Baeauthor=E.-C.+Hwangauthor=K.-H.+Leeauthor=J.-H.+Leeauthor=S.-H.+Choauthor=I.-J.+Chung&title=Class+III+%CE%B2-tubulin+is+a+predictive+marker+for+taxane-based+chemotherapy+in+recurrent+and+metastatic+gastric+cancer&doi=10.1186%2F1471-2407-13-431"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-13-431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-13-431%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DJ.-E.%26aulast%3DHong%26aufirst%3DJ.-Y.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DChoi%26aufirst%3DW.-Y.%26aulast%3DKim%26aufirst%3DM.-J.%26aulast%3DJung%26aufirst%3DS.-H.%26aulast%3DShim%26aufirst%3DH.-J.%26aulast%3DBae%26aufirst%3DW.-K.%26aulast%3DHwang%26aufirst%3DE.-C.%26aulast%3DLee%26aufirst%3DK.-H.%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DCho%26aufirst%3DS.-H.%26aulast%3DChung%26aufirst%3DI.-J.%26atitle%3DClass%2520III%2520%25CE%25B2-tubulin%2520is%2520a%2520predictive%2520marker%2520for%2520taxane-based%2520chemotherapy%2520in%2520recurrent%2520and%2520metastatic%2520gastric%2520cancer%26jtitle%3DBMC%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D431%26epage%3D431%26doi%3D10.1186%2F1471-2407-13-431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Stengel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leese, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, B. V. L</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purohit, A.</span><span> </span><span class="NLM_article-title">Class III β-tubulin expression and in vitro resistance to microtubule targeting agents</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">102</span><span class="NLM_x">) </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span><span class="refDoi"> DOI: 10.1038/sj.bjc.6605489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1038%2Fsj.bjc.6605489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=20029418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlKisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2010&pages=316-324&issue=102&author=C.+Stengelauthor=S.+P.+Newmanauthor=M.+P.+Leeseauthor=B.+V.+L+Potterauthor=M.+J.+Reedauthor=A.+Purohit&title=Class+III+%CE%B2-tubulin+expression+and+in+vitro+resistance+to+microtubule+targeting+agents&doi=10.1038%2Fsj.bjc.6605489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Class III β-tubulin expression and in vitro resistance to microtubule targeting agents</span></div><div class="casAuthors">Stengel, C.; Newman, S. P.; Leese, M. P.; Potter, B. V. L.; Reed, M. J.; Purohit, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">316-324</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Class III β-tubulin overexpression is a marker of resistance to microtubule disruptors in vitro, in vivo and in the clinic for many cancers, including breast cancer.  The aims of this study were to develop a new model of class III β-tubulin expression, avoiding the toxicity assocd. with chronic overexpression of class III β-tubulin, and study the efficacy of a panel of clin. and pre-clin. drugs in this model.  Methods: MCF-7 (ER+ve) and MDA-MB-231 (ER-ve) were either transfected with pALTER-TUBB3 or siRNA-tubb3 and 24 h later exposed to test compds. for a further 96 h for proliferation studies.  RT-PCR and immunoblotting were used to monitor the changes in class III β-tubulin mRNA and protein expression.  Results: The model allowed for subtle changes in class III β-tubulin expression to be achieved, which had no direct effect on the viability of the cells.  Class III β-tubulin overexpression conferred resistance to paclitaxel and vinorelbine, whereas downregulation of class III β-tubulin rendered cells more sensitive to these two drugs.  The efficacy of the colchicine-site binding agents, 2-MeOE2, colchicine, STX140, ENMD1198 and STX243 was unaffected by the changes in class III β-tubulin expression.  Conclusion: These data indicate that the effect of class III β-tubulin overexpression may depend on where the drug's binding site is located on the tubulin.  Therefore, this study highlights for the first time the potential key role of targeting the colchicine-binding site, to develop new treatment modalities for taxane-refractory breast cancer.  British Journal of Cancer (2010) 102, 316-324; doi:10.1038/sj.bjc.6605489 www.bjcancer.com Published online 22 Dec. 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hulEpiTJA7Vg90H21EOLACvtfcHk0lhekO-H2Ds0qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlKisQ%253D%253D&md5=02d84566d0f23c1781ba74a1add4fed2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605489%26sid%3Dliteratum%253Aachs%26aulast%3DStengel%26aufirst%3DC.%26aulast%3DNewman%26aufirst%3DS.%2BP.%26aulast%3DLeese%26aufirst%3DM.%2BP.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPurohit%26aufirst%3DA.%26atitle%3DClass%2520III%2520%25CE%25B2-tubulin%2520expression%2520and%2520in%2520vitro%2520resistance%2520to%2520microtubule%2520targeting%2520agents%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2010%26volume%3D102%26issue%3D102%26spage%3D316%26epage%3D324%26doi%3D10.1038%2Fsj.bjc.6605489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorpe, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disch, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey-Downs, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dybdal-Hargreaves, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohena, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangjee, A.</span><span> </span><span class="NLM_article-title">The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-<i>d</i>]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3753</span><span class="NLM_x">–</span> <span class="NLM_lpage">3772</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.04.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1016%2Fj.bmc.2014.04.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=24890652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslCns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=3753-3772&author=X.+Zhangauthor=S.+Raghavanauthor=M.+Ihnatauthor=J.+E.+Thorpeauthor=B.+C.+Dischauthor=A.+Bastianauthor=L.+C.+Bailey-Downsauthor=N.+F.+Dybdal-Hargreavesauthor=C.+C.+Rohenaauthor=E.+Hamelauthor=S.+L.+Mooberryauthor=A.+Gangjee&title=The+design+and+discovery+of+water+soluble+4-substituted-2%2C6-dimethylfuro%5B2%2C3-d%5Dpyrimidines+as+multitargeted+receptor+tyrosine+kinase+inhibitors+and+microtubule+targeting+antitumor+agents&doi=10.1016%2Fj.bmc.2014.04.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents</span></div><div class="casAuthors">Zhang, Xin; Raghavan, Sudhir; Ihnat, Michael; Thorpe, Jessica E.; Disch, Bryan C.; Bastian, Anja; Bailey-Downs, Lora C.; Dybdal-Hargreaves, Nicholas F.; Rohena, Cristina C.; Hamel, Ernest; Mooberry, Susan L.; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3753-3772</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The design, synthesis and biol. evaluations of fourteen 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidines are reported.  Four compds. inhibit vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor β (PDGFR-β), and target tubulin leading to cytotoxicity.  Compd. I has nanomolar potency, comparable to sunitinib and semaxinib, against tumor cell lines overexpressing VEGFR-2 and PDGFR-β.  Further, I binds at the colchicine site on tubulin, depolymerizes cellular microtubules and inhibits purified tubulin assembly and overcomes both βIII-tubulin and P-glycoprotein-mediated drug resistance, and initiates mitotic arrest leading to apoptosis.  In vivo, its HCl salt, I·HCl, reduced tumor size and vascularity in xenograft and allograft murine models and was superior to docetaxel and sunitinib, without overt toxicity.  Thus I·HCl affords potential combination chemotherapy in a single agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz0a4q7mfRm7Vg90H21EOLACvtfcHk0lhekO-H2Ds0qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslCns78%253D&md5=b35cd4ed7f053ea14d7ef5ee33828b38</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.04.049%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DDisch%26aufirst%3DB.%2BC.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DBailey-Downs%26aufirst%3DL.%2BC.%26aulast%3DDybdal-Hargreaves%26aufirst%3DN.%2BF.%26aulast%3DRohena%26aufirst%3DC.%2BC.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DThe%2520design%2520and%2520discovery%2520of%2520water%2520soluble%25204-substituted-2%252C6-dimethylfuro%255B2%252C3-d%255Dpyrimidines%2520as%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520and%2520microtubule%2520targeting%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D3753%26epage%3D3772%26doi%3D10.1016%2Fj.bmc.2014.04.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Risinger, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helms, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeBoeuf, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopper-Borge, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luduena, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruh, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">The taccalonolides: Microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">8881</span><span class="NLM_x">–</span> <span class="NLM_lpage">8888</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-2037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1158%2F0008-5472.CAN-08-2037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=18974132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSkur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=8881-8888&author=A.+L.+Risingerauthor=E.+M.+Jacksonauthor=L.+A.+Polinauthor=G.+L.+Helmsauthor=D.+A.+LeBoeufauthor=P.+A.+Joeauthor=E.+Hopper-Borgeauthor=R.+F.+Luduenaauthor=G.+D.+Kruhauthor=S.+L.+Mooberry&title=The+taccalonolides%3A+Microtubule+stabilizers+that+circumvent+clinically+relevant+taxane+resistance+mechanisms&doi=10.1158%2F0008-5472.CAN-08-2037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The Taccalonolides: Microtubule Stabilizers That Circumvent Clinically Relevant Taxane Resistance Mechanisms</span></div><div class="casAuthors">Risinger, April L.; Jackson, Evelyn M.; Polin, Lisa A.; Helms, Gregory L.; LeBoeuf, Desiree A.; Joe, Patrick A.; Hopper-Borge, Elizabeth; Luduena, Richard F.; Kruh, Gary D.; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8881-8888</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The taccalonolides are a class of structurally and mechanistically distinct microtubule-stabilizing agents isolated from Tacca chantrieri.  A crucial feature of the taxane family of microtubule stabilizers is their susceptibility to cellular resistance mechanisms including overexpression of P-glycoprotein (Pgp), multidrug resistance protein 7 (MRP7), and the βIII isotype of tubulin.  The ability of four taccalonolides, A, E, B, and N, to circumvent these multidrug resistance mechanisms was studied.  Taccalonolides A, E, B, and N were effective in vitro against cell lines that overexpress Pgp and MRP7.  In addn., taccalonolides A and E were highly active in vivo against a doxorubicin- and paclitaxel-resistant Pgp-expressing tumor, Mam17/ADR.  An isogenic HeLa-derived cell line that expresses the βIII isotype of tubulin was generated to evaluate the effect of βIII-tubulin on drug sensitivity.  When compared with parental HeLa cells, the βIII-tubulin-overexpressing cell line was less sensitive to paclitaxel, docetaxel, epothilone B, and vinblastine.  In striking contrast, the βIII-tubulin-overexpressing cell line showed greater sensitivity to all four taccalonolides.  These data cumulatively suggest that the taccalonolides have advantages over the taxanes in their ability to circumvent multiple drug resistance mechanisms.  The ability of the taccalonolides to overcome clin. relevant mechanisms of drug resistance in vitro and in vivo confirms that the taccalonolides represent a valuable addn. to the family of microtubule-stabilizing compds. with clin. potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAZHYmJfQNPLVg90H21EOLACvtfcHk0lhekO-H2Ds0qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSkur%252FI&md5=1f53ab12cdbebd7627482a6821f910b3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-2037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-2037%26sid%3Dliteratum%253Aachs%26aulast%3DRisinger%26aufirst%3DA.%2BL.%26aulast%3DJackson%26aufirst%3DE.%2BM.%26aulast%3DPolin%26aufirst%3DL.%2BA.%26aulast%3DHelms%26aufirst%3DG.%2BL.%26aulast%3DLeBoeuf%26aufirst%3DD.%2BA.%26aulast%3DJoe%26aufirst%3DP.%2BA.%26aulast%3DHopper-Borge%26aufirst%3DE.%26aulast%3DLuduena%26aufirst%3DR.%2BF.%26aulast%3DKruh%26aufirst%3DG.%2BD.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DThe%2520taccalonolides%253A%2520Microtubule%2520stabilizers%2520that%2520circumvent%2520clinically%2520relevant%2520taxane%2520resistance%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D8881%26epage%3D8888%26doi%3D10.1158%2F0008-5472.CAN-08-2037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="note"><p class="first last">We thank the NCI for providing the tumor cell growth inhibitory activity in the NCI 60-cell line panel for compound <b>3</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Synthesis and biological activities of (<i>R</i>)- and (<i>S</i>)-<i>N</i>-(4-methoxyphenyl)-<i>N</i>,2,6-trimethyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6151</span><span class="NLM_x">–</span> <span class="NLM_lpage">6155</span><span class="refDoi"> DOI: 10.1021/jm2007722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6151-6155&author=A.+Gangjeeauthor=Y.+Zhaoauthor=E.+Hamelauthor=C.+Westbrookauthor=S.+L.+Mooberry&title=Synthesis+and+biological+activities+of+%28R%29-+and+%28S%29-N-%284-methoxyphenyl%29-N%2C2%2C6-trimethyl-6%2C7-dihydro-5H-cyclopenta%5Bd%5Dpyrimidin-4-aminium+chloride+as+potent+cytotoxic+antitubulin+agents&doi=10.1021%2Fjm2007722"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm2007722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007722%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DWestbrook%26aufirst%3DC.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DSynthesis%2520and%2520biological%2520activities%2520of%2520%2528R%2529-%2520and%2520%2528S%2529-N-%25284-methoxyphenyl%2529-N%252C2%252C6-trimethyl-6%252C7-dihydro-5H-cyclopenta%255Bd%255Dpyrimidin-4-aminium%2520chloride%2520as%2520potent%2520cytotoxic%2520antitubulin%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6151%26epage%3D6155%26doi%3D10.1021%2Fjm2007722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. M.</span><span> </span><span class="NLM_article-title">Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4173</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1021/bi00313a026</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00313a026" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1984&pages=4173-84&author=E.+Hamelauthor=C.+M.+Lin&title=Separation+of+active+tubulin+and+microtubule-associated+proteins+by+ultracentrifugation+and+isolation+of+a+component+causing+the+formation+of+microtubule+bundles&doi=10.1021%2Fbi00313a026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fbi00313a026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00313a026%26sid%3Dliteratum%253Aachs%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DC.%2BM.%26atitle%3DSeparation%2520of%2520active%2520tubulin%2520and%2520microtubule-associated%2520proteins%2520by%2520ultracentrifugation%2520and%2520isolation%2520of%2520a%2520component%2520causing%2520the%2520formation%2520of%2520microtubule%2520bundles%26jtitle%3DBiochemistry%26date%3D1984%26volume%3D23%26spage%3D4173%26epage%3D84%26doi%3D10.1021%2Fbi00313a026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin</span> <span class="citation_source-journal">Cell Biochem. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1385/CBB:38:1:1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1385%2FCBB%3A38%3A1%3A1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=12663938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtVaisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=1-21&author=E.+Hamel&title=Evaluation+of+antimitotic+agents+by+quantitative+comparisons+of+their+effects+on+the+polymerization+of+purified+tubulin&doi=10.1385%2FCBB%3A38%3A1%3A1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin</span></div><div class="casAuthors">Hamel, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">CBBIFV</span>;
        ISSN:<span class="NLM_cas:issn">1085-9195</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Most antimitotic compds. have highly specific interactions with tubulin, the major protein component of microtubules.  It is, therefore, often desirable to characterize interactions of these agents with tubulin.  In particular, quant. comparisons between new and old ("std.") agents, between different classes of agent, and between structural analogs (e.g., for a structure-activity relationship study) are important.  Because antimitotic drugs have a variety of effects on tubulin and bind at multiple distinct sites on the protein, the tubulin assembly reaction is probably the only universally applicable reaction that can be analyzed.  In my lab., we use the assembly of purified tubulin induced by higher concns. of monosodium glutamate as our basic assay system.  This report presents a detailed description of our current routine assay, including the effects of a variety of reaction components on the reaction.  In addn., the variety of effects that reaction components can have on the quant. results obtained with drugs, using the colchicine site drug combretastatin A-4 as a model compd., is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLvDICXLUiYbVg90H21EOLACvtfcHk0lgARt4tonhYdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtVaisLY%253D&md5=c37c365cc707e237f43feffca64d706b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1385%2FCBB%3A38%3A1%3A1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FCBB%253A38%253A1%253A1%26sid%3Dliteratum%253Aachs%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DEvaluation%2520of%2520antimitotic%2520agents%2520by%2520quantitative%2520comparisons%2520of%2520their%2520effects%2520on%2520the%2520polymerization%2520of%2520purified%2520tubulin%26jtitle%3DCell%2520Biochem.%2520Biophys.%26date%3D2003%26volume%3D38%26spage%3D1%26epage%3D21%26doi%3D10.1385%2FCBB%3A38%3A1%3A1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Verdier-Pinard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, H.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagle, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falck, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerwick, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1998&pages=62-76&author=P.+Verdier-Pinardauthor=J.-Y.+Laiauthor=H.-D.+Yooauthor=J.+Yuauthor=B.+Marquezauthor=D.+G.+Nagleauthor=M.+Nambuauthor=J.+D.+Whiteauthor=J.+R.+Falckauthor=W.+H.+Gerwickauthor=B.+W.+Dayauthor=E.+Hamel&title=Structure-activity+analysis+of+the+interaction+of+curacin+A%2C+the+potent+colchicine+site+antimitotic+agent%2C+with+tubulin+and+effects+of+analogs+on+the+growth+of+MCF-7+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerdier-Pinard%26aufirst%3DP.%26aulast%3DLai%26aufirst%3DJ.-Y.%26aulast%3DYoo%26aufirst%3DH.-D.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DMarquez%26aufirst%3DB.%26aulast%3DNagle%26aufirst%3DD.%2BG.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DWhite%26aufirst%3DJ.%2BD.%26aulast%3DFalck%26aufirst%3DJ.%2BR.%26aulast%3DGerwick%26aufirst%3DW.%2BH.%26aulast%3DDay%26aufirst%3DB.%2BW.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DStructure-activity%2520analysis%2520of%2520the%2520interaction%2520of%2520curacin%2520A%252C%2520the%2520potent%2520colchicine%2520site%2520antimitotic%2520agent%252C%2520with%2520tubulin%2520and%2520effects%2520of%2520analogs%2520on%2520the%2520growth%2520of%2520MCF-7%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Pharmacol.%26date%3D1998%26volume%3D53%26spage%3D62%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Krishan, A.</span><span> </span><span class="NLM_article-title">Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">–</span> <span class="NLM_lpage">193</span><span class="refDoi"> DOI: 10.1083/jcb.66.1.188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1083%2Fjcb.66.1.188" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1975&pages=188-193&author=A.+Krishan&title=Rapid+flow+cytofluorometric+analysis+of+mammalian+cell+cycle+by+propidium+iodide&doi=10.1083%2Fjcb.66.1.188"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1083%2Fjcb.66.1.188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.66.1.188%26sid%3Dliteratum%253Aachs%26aulast%3DKrishan%26aufirst%3DA.%26atitle%3DRapid%2520flow%2520cytofluorometric%2520analysis%2520of%2520mammalian%2520cell%2520cycle%2520by%2520propidium%2520iodide%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1975%26volume%3D66%26spage%3D188%26epage%3D193%26doi%3D10.1083%2Fjcb.66.1.188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Rohena, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telang, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risinger, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sikorski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellogg, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupton, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Biological characterization of an improved pyrrole-based colchicine site agent identified through structure-based design</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">296</span><span class="refDoi"> DOI: 10.1124/mol.115.101592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1124%2Fmol.115.101592" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=287-296&author=C.+C.+Rohenaauthor=N.+S.+Telangauthor=C.+Daauthor=A.+L.+Risingerauthor=J.+A.+Sikorskiauthor=G.+E.+Kelloggauthor=J.+T.+Guptonauthor=S.+L.+Mooberry&title=Biological+characterization+of+an+improved+pyrrole-based+colchicine+site+agent+identified+through+structure-based+design&doi=10.1124%2Fmol.115.101592"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.101592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.101592%26sid%3Dliteratum%253Aachs%26aulast%3DRohena%26aufirst%3DC.%2BC.%26aulast%3DTelang%26aufirst%3DN.%2BS.%26aulast%3DDa%26aufirst%3DC.%26aulast%3DRisinger%26aufirst%3DA.%2BL.%26aulast%3DSikorski%26aufirst%3DJ.%2BA.%26aulast%3DKellogg%26aufirst%3DG.%2BE.%26aulast%3DGupton%26aufirst%3DJ.%2BT.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DBiological%2520characterization%2520of%2520an%2520improved%2520pyrrole-based%2520colchicine%2520site%2520agent%2520identified%2520through%2520structure-based%2520design%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D89%26spage%3D287%26epage%3D296%26doi%3D10.1124%2Fmol.115.101592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':[],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 20 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhen-Hua Li, Zhi-Jiang Jiang, Qiao-Ling Shao, Jin-Jing Qin, Qiang-Feng Shu, Wen-Hao Lu, <span class="NLM_string-name hlFld-ContribAuthor">Wei-Ke Su</span>. </span><span class="cited-content_cbyCitation_article-title">One-Pot Cascade Heterocyclization of γ- and β-Ketomalononitriles to 2,4-Dichloro-Substituted Pyrano[2,3-d]pyrimidines and Furo[2,3-d]pyrimidines Mediated by Triphosgene and Triphenylphosphine Oxide. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (12)
                                     , 6423-6431. <a href="https://doi.org/10.1021/acs.joc.8b00669" title="DOI URL">https://doi.org/10.1021/acs.joc.8b00669</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b00669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b00669%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne-Pot%252BCascade%252BHeterocyclization%252Bof%252B%2525CE%2525B3-%252Band%252B%2525CE%2525B2-Ketomalononitriles%252Bto%252B2%25252C4-Dichloro-Substituted%252BPyrano%25255B2%25252C3-d%25255Dpyrimidines%252Band%252BFuro%25255B2%25252C3-d%25255Dpyrimidines%252BMediated%252Bby%252BTriphosgene%252Band%252BTriphenylphosphine%252BOxide%26aulast%3DLi%26aufirst%3DZhen-Hua%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D15032018%26date%3D24052018%26date%3D21052018%26volume%3D83%26issue%3D12%26spage%3D6423%26epage%3D6431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kiran
Kumar Solingapuram Sai, Jaya Prabhakaran, Gayathri Ramanathan, Stephanie Rideout, Christopher Whitlow, Akiva Mintz, J. John Mann, <span class="NLM_string-name hlFld-ContribAuthor">J. S. Dileep Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Radiosynthesis and Evaluation of [11C]HD-800, a High Affinity Brain Penetrant PET Tracer for Imaging Microtubules. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (5)
                                     , 452-456. <a href="https://doi.org/10.1021/acsmedchemlett.8b00060" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00060%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRadiosynthesis%252Band%252BEvaluation%252Bof%252B%25255B11C%25255DHD-800%25252C%252Ba%252BHigh%252BAffinity%252BBrain%252BPenetrant%252BPET%252BTracer%252Bfor%252BImaging%252BMicrotubules%26aulast%3DSolingapuram%2BSai%26aufirst%3DKiran%2BKumar%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D07022018%26date%3D30042018%26date%3D03052018%26date%3D30042018%26volume%3D9%26issue%3D5%26spage%3D452%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Souvik  Banerjee</span>, <span class="hlFld-ContribAuthor ">Kinsie E.  Arnst</span>, <span class="hlFld-ContribAuthor ">Yuxi  Wang</span>, <span class="hlFld-ContribAuthor ">Gyanendra  Kumar</span>, <span class="hlFld-ContribAuthor ">Shanshan  Deng</span>, <span class="hlFld-ContribAuthor ">Lei  Yang</span>, <span class="hlFld-ContribAuthor ">Guo-bo  Li</span>, <span class="hlFld-ContribAuthor ">Jinliang  Yang</span>, <span class="hlFld-ContribAuthor ">Stephen W.  White</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, and <span class="hlFld-ContribAuthor ">Duane D.  Miller</span>  . </span><span class="cited-content_cbyCitation_article-title">Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (4)
                                     , 1704-1718. <a href="https://doi.org/10.1021/acs.jmedchem.7b01858" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01858</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01858%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHeterocyclic-Fused%252BPyrimidines%252Bas%252BNovel%252BTubulin%252BPolymerization%252BInhibitors%252BTargeting%252Bthe%252BColchicine%252BBinding%252BSite%25253A%252BStructural%252BBasis%252Band%252BAntitumor%252BEfficacy%26aulast%3DBanerjee%26aufirst%3DSouvik%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D21122017%26date%3D12022018%26date%3D22022018%26date%3D06022018%26volume%3D61%26issue%3D4%26spage%3D1704%26epage%3D1718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kankana  Mullick</span>, <span class="hlFld-ContribAuthor ">Sourav  Biswas</span>, <span class="hlFld-ContribAuthor ">Chiho  Kim</span>, <span class="hlFld-ContribAuthor ">Ramamurthy  Ramprasad</span>, <span class="hlFld-ContribAuthor ">Alfredo M.  Angeles-Boza</span>, and <span class="hlFld-ContribAuthor ">Steven L.  Suib</span>  . </span><span class="cited-content_cbyCitation_article-title">Ullmann Reaction Catalyzed by Heterogeneous Mesoporous Copper/Manganese Oxide: A Kinetic and Mechanistic Analysis. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2017,</strong> <em>56 </em>
                                    (17)
                                     , 10290-10297. <a href="https://doi.org/10.1021/acs.inorgchem.7b01177" title="DOI URL">https://doi.org/10.1021/acs.inorgchem.7b01177</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.inorgchem.7b01177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.inorgchem.7b01177%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DUllmann%252BReaction%252BCatalyzed%252Bby%252BHeterogeneous%252BMesoporous%252BCopper%25252FManganese%252BOxide%25253A%252BA%252BKinetic%252Band%252BMechanistic%252BAnalysis%26aulast%3DMullick%26aufirst%3DKankana%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D09052017%26date%3D11082017%26date%3D05092017%26volume%3D56%26issue%3D17%26spage%3D10290%26epage%3D10297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mu-Tian  Cui</span>, <span class="hlFld-ContribAuthor ">Li  Jiang</span>, <span class="hlFld-ContribAuthor ">Masuo  Goto</span>, <span class="hlFld-ContribAuthor ">Pei-Ling  Hsu</span>, <span class="hlFld-ContribAuthor ">Linna  Li</span>, <span class="hlFld-ContribAuthor ">Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Lei  Wei</span>, <span class="hlFld-ContribAuthor ">Shou-Jun  Yuan</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Susan L.  Morris-Natschke</span>, <span class="hlFld-ContribAuthor ">Kuo-Hsiung  Lee</span>, and <span class="hlFld-ContribAuthor ">Lan  Xie</span>  . </span><span class="cited-content_cbyCitation_article-title">In Vivo and Mechanistic Studies on Antitumor Lead 7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one and Its Modification as a Novel Class of Tubulin-Binding Tumor-Vascular Disrupting Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (13)
                                     , 5586-5598. <a href="https://doi.org/10.1021/acs.jmedchem.7b00273" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00273</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00273%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIn%252BVivo%252Band%252BMechanistic%252BStudies%252Bon%252BAntitumor%252BLead%252B7-Methoxy-4-%2525282-methylquinazolin-4-yl%252529-3%25252C4-dihydroquinoxalin-2%2525281H%252529-one%252Band%252BIts%252BModification%252Bas%252Ba%252BNovel%252BClass%252Bof%252BTubulin-Binding%252BTumor-Vascular%252BDisrupting%252BAgents%26aulast%3DCui%26aufirst%3DMu-Tian%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D21022017%26date%3D27062017%26date%3D13072017%26volume%3D60%26issue%3D13%26spage%3D5586%26epage%3D5598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Forough  Gorginpour</span>, <span class="hlFld-ContribAuthor ">Hassan  Zali-Boeini</span>. </span><span class="cited-content_cbyCitation_article-title">Synergistic effect of copper nanocrystals-nanoparticles incorporated in a porous organic polymer for the Ullmann C-O coupling r eaction. </span><span class="cited-content_cbyCitation_journal-name">Molecular Catalysis</span><span> <strong>2021,</strong> <em>504 </em>, 111460. <a href="https://doi.org/10.1016/j.mcat.2021.111460" title="DOI URL">https://doi.org/10.1016/j.mcat.2021.111460</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mcat.2021.111460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mcat.2021.111460%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Catalysis%26atitle%3DSynergistic%252Beffect%252Bof%252Bcopper%252Bnanocrystals-nanoparticles%252Bincorporated%252Bin%252Ba%252Bporous%252Borganic%252Bpolymer%252Bfor%252Bthe%252BUllmann%252BC-O%252Bcoupling%252Br%252Beaction%26aulast%3DGorginpour%26aufirst%3DForough%26date%3D2021%26volume%3D504%26spage%3D111460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Forough  Gorginpour</span>, <span class="hlFld-ContribAuthor ">Hassan  Zali-Boeini</span>, <span class="hlFld-ContribAuthor ">Hadi Amiri  Rudbari</span>. </span><span class="cited-content_cbyCitation_article-title">A quinoxaline-based porous organic polymer containing copper nanoparticles <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="286b5d66785b687905786778">[email protected]</a> as a robust nanocatalyst toward C–N coupling reaction. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2021,</strong> <em>11 </em>
                                    (6)
                                     , 3655-3665. <a href="https://doi.org/10.1039/D0RA10741G" title="DOI URL">https://doi.org/10.1039/D0RA10741G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA10741G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA10741G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DA%252Bquinoxaline-based%252Bporous%252Borganic%252Bpolymer%252Bcontaining%252Bcopper%252Bnanoparticles%252BCuNPs%252540Q-POP%252Bas%252Ba%252Brobust%252Bnanocatalyst%252Btoward%252BC%2525E2%252580%252593N%252Bcoupling%252Breaction%26aulast%3DGorginpour%26aufirst%3DForough%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D6%26spage%3D3655%26epage%3D3665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akanksha  Sharma</span>, <span class="hlFld-ContribAuthor ">Doddabasappa  Talimarada</span>, <span class="hlFld-ContribAuthor ">Umesh Prasad  Yadav</span>, <span class="hlFld-ContribAuthor ">Nidhi  Singh</span>, <span class="hlFld-ContribAuthor ">A. Sudharshan  Reddy</span>, <span class="hlFld-ContribAuthor ">Debojyoti  Bag</span>, <span class="hlFld-ContribAuthor ">Krishna  Biswas</span>, <span class="hlFld-ContribAuthor ">Amit  Baidya</span>, <span class="hlFld-ContribAuthor ">Asha N  Borale</span>, <span class="hlFld-ContribAuthor ">Dhananjay  Shinde</span>, <span class="hlFld-ContribAuthor ">Sandeep  Singh</span>, <span class="hlFld-ContribAuthor ">Harish  Holla</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of New Tubulin Polymerization Inhibitors Inspired from Combretastatin A‐4: An Anticancer Agent. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2020,</strong> <em>5 </em>
                                    (37)
                                     , 11560-11572. <a href="https://doi.org/10.1002/slct.202003170" title="DOI URL">https://doi.org/10.1002/slct.202003170</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202003170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202003170%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BNew%252BTubulin%252BPolymerization%252BInhibitors%252BInspired%252Bfrom%252BCombretastatin%252BA%2525E2%252580%2525904%25253A%252BAn%252BAnticancer%252BAgent%26aulast%3DSharma%26aufirst%3DAkanksha%26date%3D2020%26date%3D2020%26volume%3D5%26issue%3D37%26spage%3D11560%26epage%3D11572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rodolfo H. V.  Nishimura</span>, <span class="hlFld-ContribAuthor ">Valter E.  Murie</span>, <span class="hlFld-ContribAuthor ">Ricardo  Vessecchi</span>, <span class="hlFld-ContribAuthor ">Giuliano C.  Clososki</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Functionalization of Benzo‐Fused
              N
              ‐Heterocycles by Using In Situ Trapping Metalations. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2020,</strong> <em>5 </em>
                                    (36)
                                     , 11106-11111. <a href="https://doi.org/10.1002/slct.202002589" title="DOI URL">https://doi.org/10.1002/slct.202002589</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202002589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202002589%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DSelective%252BFunctionalization%252Bof%252BBenzo%2525E2%252580%252590Fused%252BN%252B%2525E2%252580%252590Heterocycles%252Bby%252BUsing%252BIn%252BSitu%252BTrapping%252BMetalations%26aulast%3DNishimura%26aufirst%3DRodolfo%2BH.%2BV.%26date%3D2020%26date%3D2020%26volume%3D5%26issue%3D36%26spage%3D11106%26epage%3D11111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammad Amjad  Kamal</span>, <span class="hlFld-ContribAuthor ">Maryam Hassan  Al-Zahrani</span>, <span class="hlFld-ContribAuthor ">Salman Hasan  Khan</span>, <span class="hlFld-ContribAuthor ">Mateen Hasan  Khan</span>, <span class="hlFld-ContribAuthor ">Hani Awad  Al-Subhi</span>, <span class="hlFld-ContribAuthor ">Abudukadeer  Kuerban</span>, <span class="hlFld-ContribAuthor ">Muhammad  Aslam</span>, <span class="hlFld-ContribAuthor ">Fahad Ahmed  Al-Abbasi</span>, <span class="hlFld-ContribAuthor ">Firoz  Anwar</span>. </span><span class="cited-content_cbyCitation_article-title">Tubulin Proteins in Cancer Resistance: A Review. </span><span class="cited-content_cbyCitation_journal-name">Current Drug Metabolism</span><span> <strong>2020,</strong> <em>21 </em>
                                    (3)
                                     , 178-185. <a href="https://doi.org/10.2174/1389200221666200226123638" title="DOI URL">https://doi.org/10.2174/1389200221666200226123638</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1389200221666200226123638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1389200221666200226123638%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Drug%2520Metabolism%26atitle%3DTubulin%252BProteins%252Bin%252BCancer%252BResistance%25253A%252BA%252BReview%26aulast%3DKamal%26aufirst%3DMohammad%2BAmjad%26date%3D2020%26volume%3D21%26issue%3D3%26spage%3D178%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shixian  Hua</span>, <span class="hlFld-ContribAuthor ">Feihong  Chen</span>, <span class="hlFld-ContribAuthor ">Shaohua  Gou</span>. </span><span class="cited-content_cbyCitation_article-title">Microtubule inhibitors containing immunostimulatory agents promote cancer immunochemotherapy by inhibiting tubulin polymerization and tryptophan-2,3-dioxygenase. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>187 </em>, 111949. <a href="https://doi.org/10.1016/j.ejmech.2019.111949" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111949</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111949%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMicrotubule%252Binhibitors%252Bcontaining%252Bimmunostimulatory%252Bagents%252Bpromote%252Bcancer%252Bimmunochemotherapy%252Bby%252Binhibiting%252Btubulin%252Bpolymerization%252Band%252Btryptophan-2%25252C3-dioxygenase%26aulast%3DHua%26aufirst%3DShixian%26date%3D2020%26volume%3D187%26spage%3D111949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bensu  Karahalil</span>, <span class="hlFld-ContribAuthor ">Sevgi  Yardım-Akaydin</span>, <span class="hlFld-ContribAuthor ">Sultan  Nacak Baytas</span>. </span><span class="cited-content_cbyCitation_article-title">An overview of microtubule targeting agents for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Archives of Industrial Hygiene and Toxicology</span><span> <strong>2019,</strong> <em>70 </em>
                                    (3)
                                     , 160-172. <a href="https://doi.org/10.2478/aiht-2019-70-3258" title="DOI URL">https://doi.org/10.2478/aiht-2019-70-3258</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2478/aiht-2019-70-3258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2478%2Faiht-2019-70-3258%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Industrial%2520Hygiene%2520and%2520Toxicology%26atitle%3DAn%252Boverview%252Bof%252Bmicrotubule%252Btargeting%252Bagents%252Bfor%252Bcancer%252Btherapy%26aulast%3DKarahalil%26aufirst%3DBensu%26date%3D2019%26date%3D2019%26volume%3D70%26issue%3D3%26spage%3D160%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenlong  Li</span>, <span class="hlFld-ContribAuthor ">Ying  Yin</span>, <span class="hlFld-ContribAuthor ">Wen  Shuai</span>, <span class="hlFld-ContribAuthor ">Feijie  Xu</span>, <span class="hlFld-ContribAuthor ">Hong  Yao</span>, <span class="hlFld-ContribAuthor ">Jie  Liu</span>, <span class="hlFld-ContribAuthor ">Keguang  Cheng</span>, <span class="hlFld-ContribAuthor ">Jinyi  Xu</span>, <span class="hlFld-ContribAuthor ">Zheying  Zhu</span>, <span class="hlFld-ContribAuthor ">Shengtao  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel quinazolines as potential anti-tubulin agents occupying three zones of colchicine domain. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>83 </em>, 380-390. <a href="https://doi.org/10.1016/j.bioorg.2018.10.027" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.10.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.10.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.10.027%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bquinazolines%252Bas%252Bpotential%252Banti-tubulin%252Bagents%252Boccupying%252Bthree%252Bzones%252Bof%252Bcolchicine%252Bdomain%26aulast%3DLi%26aufirst%3DWenlong%26date%3D2019%26volume%3D83%26spage%3D380%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roheeth Kumar  Pavana</span>, <span class="hlFld-ContribAuthor ">Khushbu  Shah</span>, <span class="hlFld-ContribAuthor ">Taylor  Gentile</span>, <span class="hlFld-ContribAuthor ">Nicholas F.  Dybdal-Hargreaves</span>, <span class="hlFld-ContribAuthor ">April L.  Risinger</span>, <span class="hlFld-ContribAuthor ">Susan L.  Mooberry</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>. </span><span class="cited-content_cbyCitation_article-title">Sterically induced conformational restriction: Discovery and preclinical evaluation of novel pyrrolo[3,2-d]pyrimidines as microtubule targeting agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (20)
                                     , 5470-5478. <a href="https://doi.org/10.1016/j.bmc.2018.09.025" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.09.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.09.025%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSterically%252Binduced%252Bconformational%252Brestriction%25253A%252BDiscovery%252Band%252Bpreclinical%252Bevaluation%252Bof%252Bnovel%252Bpyrrolo%25255B3%25252C2-d%25255Dpyrimidines%252Bas%252Bmicrotubule%252Btargeting%252Bagents%26aulast%3DPavana%26aufirst%3DRoheeth%2BKumar%26date%3D2018%26volume%3D26%26issue%3D20%26spage%3D5470%26epage%3D5478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ravi Kumar Vyas  Devambatla</span>, <span class="hlFld-ContribAuthor ">Shruti  Choudhary</span>, <span class="hlFld-ContribAuthor ">Michael  Ihnat</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Susan L.  Mooberry</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and preclinical evaluation of 5-methyl-N4-aryl-furo[2,3-d]pyrimidines as single agents with combination chemotherapy potential. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (18)
                                     , 3085-3093. <a href="https://doi.org/10.1016/j.bmcl.2018.07.039" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.07.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.07.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.07.039%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bpreclinical%252Bevaluation%252Bof%252B5-methyl-N4-aryl-furo%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252Bsingle%252Bagents%252Bwith%252Bcombination%252Bchemotherapy%252Bpotential%26aulast%3DDevambatla%26aufirst%3DRavi%2BKumar%2BVyas%26date%3D2018%26volume%3D28%26issue%3D18%26spage%3D3085%26epage%3D3093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenlong  Li</span>, <span class="hlFld-ContribAuthor ">Honghao  Sun</span>, <span class="hlFld-ContribAuthor ">Shengtao  Xu</span>, <span class="hlFld-ContribAuthor ">Zheying  Zhu</span>, <span class="hlFld-ContribAuthor ">Jinyi  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2017,</strong> <em>9 </em>
                                    (15)
                                     , 1765-1794. <a href="https://doi.org/10.4155/fmc-2017-0100" title="DOI URL">https://doi.org/10.4155/fmc-2017-0100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2017-0100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2017-0100%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DTubulin%252Binhibitors%252Btargeting%252Bthe%252Bcolchicine%252Bbinding%252Bsite%25253A%252Ba%252Bperspective%252Bof%252Bprivileged%252Bstructures%26aulast%3DLi%26aufirst%3DWenlong%26date%3D2017%26volume%3D9%26issue%3D15%26spage%3D1765%26epage%3D1794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhong-Zhen  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiu-Dong  Shi</span>, <span class="hlFld-ContribAuthor ">Hong-Fang  Feng</span>, <span class="hlFld-ContribAuthor ">Yu-Fang  Cheng</span>, <span class="hlFld-ContribAuthor ">Hai-Tao  Wang</span>, <span class="hlFld-ContribAuthor ">Jiang-Ping  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 9 H -purins as potential tubulin polymerization inhibitors: Synthesis, biological evaluation and structure−activity relationships. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>138 </em>, 1126-1134. <a href="https://doi.org/10.1016/j.ejmech.2017.07.054" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.07.054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.07.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.07.054%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B9%252BH%252B-purins%252Bas%252Bpotential%252Btubulin%252Bpolymerization%252Binhibitors%25253A%252BSynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bstructure%2525E2%252588%252592activity%252Brelationships%26aulast%3DZhou%26aufirst%3DZhong-Zhen%26date%3D2017%26volume%3D138%26spage%3D1126%26epage%3D1134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ravi Kumar Vyas  Devambatla</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Nilesh  Zaware</span>, <span class="hlFld-ContribAuthor ">Shruti  Choudhary</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Susan L.  Mooberry</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and structure–activity relationships of pyrimido[4,5- b ]indole-4-amines as microtubule depolymerizing agents that are effective against multidrug resistant cells. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (15)
                                     , 3423-3430. <a href="https://doi.org/10.1016/j.bmcl.2017.05.085" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.05.085</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.05.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.05.085%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bstructure%2525E2%252580%252593activity%252Brelationships%252Bof%252Bpyrimido%25255B4%25252C5-%252Bb%252B%25255Dindole-4-amines%252Bas%252Bmicrotubule%252Bdepolymerizing%252Bagents%252Bthat%252Bare%252Beffective%252Bagainst%252Bmultidrug%252Bresistant%252Bcells%26aulast%3DDevambatla%26aufirst%3DRavi%2BKumar%2BVyas%26date%3D2017%26volume%3D27%26issue%3D15%26spage%3D3423%26epage%3D3430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristina  Rohena</span>, <span class="hlFld-ContribAuthor ">April  Risinger</span>, <span class="hlFld-ContribAuthor ">Ravi  Devambatla</span>, <span class="hlFld-ContribAuthor ">Nicholas  Dybdal-Hargreaves</span>, <span class="hlFld-ContribAuthor ">Roma  Kaul</span>, <span class="hlFld-ContribAuthor ">Shruti  Choudhary</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>, <span class="hlFld-ContribAuthor ">Susan  Mooberry</span>. </span><span class="cited-content_cbyCitation_article-title">Janus Compounds, 5-Chloro-N4-methyl-N4-aryl-9H-pyrimido[4,5-b]indole-2,4-diamines, Cause Both Microtubule Depolymerizing and Stabilizing Effects. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2016,</strong> <em>21 </em>
                                    (12)
                                     , 1661. <a href="https://doi.org/10.3390/molecules21121661" title="DOI URL">https://doi.org/10.3390/molecules21121661</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules21121661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules21121661%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DJanus%252BCompounds%25252C%252B5-Chloro-N4-methyl-N4-aryl-9H-pyrimido%25255B4%25252C5-b%25255Dindole-2%25252C4-diamines%25252C%252BCause%252BBoth%252BMicrotubule%252BDepolymerizing%252Band%252BStabilizing%252BEffects%26aulast%3DRohena%26aufirst%3DCristina%26date%3D2016%26date%3D2016%26volume%3D21%26issue%3D12%26spage%3D1661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shun  Zhang</span>, <span class="hlFld-ContribAuthor ">Baijiao  An</span>, <span class="hlFld-ContribAuthor ">Jun  Yan</span>, <span class="hlFld-ContribAuthor ">Ling  Huang</span>, <span class="hlFld-ContribAuthor ">Xingshu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">The synthesis and evaluation of new benzophenone derivatives as tubulin polymerization inhibitors. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (91)
                                     , 88453-88462. <a href="https://doi.org/10.1039/C6RA16948A" title="DOI URL">https://doi.org/10.1039/C6RA16948A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA16948A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA16948A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DThe%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bnew%252Bbenzophenone%252Bderivatives%252Bas%252Btubulin%252Bpolymerization%252Binhibitors%26aulast%3DZhang%26aufirst%3DShun%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D91%26spage%3D88453%26epage%3D88462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative microtubule targeting agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Parent 5-methyl-cyclopenta[2,3-<i>d</i>]pyrimidine (±)-<b>1</b> and target 5-methyl-furo[2,3-<i>d</i>]pyrimidines <b>2</b> and <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Superimposition of the docked pose of <b>3</b> (green) in the colchicine site (colchicine in orange) of tubulin (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B">4O2B</a><a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Target compounds <b>4</b>–<b>9</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0014.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Target Compounds <b>2</b> and <b>3</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0015.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Target Compounds <b>4</b>–<b>7</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0016.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Target Compounds <b>8</b> and <b>9</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of compounds <b>3</b>, <b>4</b>, and <b>6</b>–<b>9</b> on cellular microtubules. A-10 cells were treated for 18 h with 2× the EC<sub>50</sub>, and cellular microtubules were visualized by indirect immunofluorescence with a β-tubulin antibody.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of compounds <b>3</b>, <b>4</b>, and <b>6</b>–<b>9</b> on mitotic spindles. HeLa cells were treated for 18 h with a concentration five-times the respective IC<sub>50</sub>, and cellular microtubules and mitotic spindles were visualized by indirect immunofluorescence techniques with a β-tubulin antibody.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cell cycle analysis of HeLa cells treated with <b>3</b>, <b>4</b>, and <b>6</b>–<b>9</b>. (A) Cell cycle distribution profiles of cells treated for 18 h with five-times the IC<sub>50</sub> of each compound. (B) Table showing the percent of cells in G<sub>2</sub>/M in each treatment group. Values are reported as the mean ± SD from two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Conformational restriction of C4–N and N–C1′ bonds in the presence of the <i>N</i>-Me moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0010.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Conformations and <sup>1</sup>H NMR analyses of <b>2</b> (A) and <b>3</b> (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0011.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. δ values (<sup>1</sup>H NMR) for compounds <b>2</b>–<b>9</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0012.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Docked pose of <b>3</b> without the protein showing the distance (in Å) between 5-Me and the closest carbons on the phenyl ring. (B) Stereoview. Superimposition of docked poses of <b>3</b> (green), <b>4</b> (magenta), <b>5</b> (yellow), <b>6</b> (blue), <b>7</b> (brown), <b>8</b> (orange), and <b>9</b> (cyan) in the colchicine site of tubulin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/medium/jm-2016-002373_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0013.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Effect of <b>3</b> and paclitaxel (PTX) on MDA-MB-435 tumor growth. Nude mice bilaterally implanted with MDA-MB-435 tumor fragments were dosed with 60 mg/kg of <b>3</b> on days 0 and 2; and 50 mg/kg of <b>3</b> on day 8 or PTX at 20 mg/kg on days 0, 2, 4, 6, 8, and 11 as a positive control. (A) The average tumor volume is graphed with error bars representing the standard deviation. (B) The final tumor volumes are plotted with lines representing the mean and 95% confidence intervals. *<i>p</i> = 0.0425 and **<i>p</i> = 0.0014.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00237/20160617/images/large/jm-2016-002373_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00237&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i54">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70718" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70718" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 52 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Dumontet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, M. A.</span><span> </span><span class="NLM_article-title">Microtubule-binding agents: A dynamic field of cancer therapeutics</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">790</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span><span class="refDoi"> DOI: 10.1038/nrd3253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1038%2Fnrd3253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=20885410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=790-803&author=C.+Dumontetauthor=M.+A.+Jordan&title=Microtubule-binding+agents%3A+A+dynamic+field+of+cancer+therapeutics&doi=10.1038%2Fnrd3253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-binding agents: a dynamic field of cancer therapeutics</span></div><div class="casAuthors">Dumontet, Charles; Jordan, Mary Ann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">790-803</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an important therapeutic target in tumor cells.  Agents that bind to microtubules have been part of the pharmacopoeia of anticancer therapy for decades and until the advent of targeted therapy, microtubules were the only alternative to DNA as a therapeutic target in cancer.  The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties.  In the current search for novel microtubule-binding agents, enhanced tumor specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms are the three main objectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ43DyXjdN7rVg90H21EOLACvtfcHk0lgRsxZNpvZsxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI&md5=9fc6fd966859785605936ecbe6dca44e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd3253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3253%26sid%3Dliteratum%253Aachs%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DM.%2BA.%26atitle%3DMicrotubule-binding%2520agents%253A%2520A%2520dynamic%2520field%2520of%2520cancer%2520therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D790%26epage%3D803%26doi%3D10.1038%2Fnrd3253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Risinger, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Microtubule dynamics as a target in oncology</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2008.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1016%2Fj.ctrv.2008.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=19117686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVantrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=255-261&author=A.+L.+Risingerauthor=F.+J.+Gilesauthor=S.+L.+Mooberry&title=Microtubule+dynamics+as+a+target+in+oncology&doi=10.1016%2Fj.ctrv.2008.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule dynamics as a target in oncology</span></div><div class="casAuthors">Risinger, April L.; Giles, Francis J.; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-261</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Drugs that affect microtubule dynamics, including the taxanes and vinca alkaloids, have been a mainstay in the treatment of leukemias and solid tumors for decades.  New, more effective microtubule-targeting agents continue to enter into clin. trials and some, including the epothilone ixapebilone, have been approved for use.  In contrast, several other drugs of this class with promising preclin. data were later shown to be ineffective or intolerable in animal models or clin. trials.  In this review, we discuss the mol. mechanisms as well as preclin. and clin. results for a variety of microtubule-targeting agents in various stages of development.  We also offer a frank discussion of which microtubule-targeting agents are amenable to further development based on their availability, efficacy and toxic profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh2wR_5ls3DLVg90H21EOLACvtfcHk0lgRsxZNpvZsxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVantrg%253D&md5=2d18cb599b5c35f1e0bc0292c183826f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2008.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2008.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DRisinger%26aufirst%3DA.%2BL.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DMicrotubule%2520dynamics%2520as%2520a%2520target%2520in%2520oncology%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2009%26volume%3D35%26spage%3D255%26epage%3D261%26doi%3D10.1016%2Fj.ctrv.2008.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Stanton, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gernert, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aneja, R.</span><span> </span><span class="NLM_article-title">Drugs that target dynamic microtubules: A new molecular perspective</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">481</span><span class="refDoi"> DOI: 10.1002/med.20242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1002%2Fmed.20242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=21381049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksVKlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=443-481&author=R.+A.+Stantonauthor=K.+M.+Gernertauthor=J.+H.+Nettlesauthor=R.+Aneja&title=Drugs+that+target+dynamic+microtubules%3A+A+new+molecular+perspective&doi=10.1002%2Fmed.20242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs that target dynamic microtubules: A new molecular perspective</span></div><div class="casAuthors">Stanton, Richard A.; Gernert, Kim M.; Nettles, James H.; Aneja, Ritu</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">443-481</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Microtubules have long been considered an ideal target for anticancer drugs because of the essential role they play in mitosis, forming the dynamic spindle app.  As such, there is a wide variety of compds. currently in clin. use and in development that act as antimitotic agents by altering microtubule dynamics.  Although these diverse mols. are known to affect microtubule dynamics upon binding to one of the three established drug domains (taxane, vinca alkaloid, or colchicine site), the exact mechanism by which each drug works is still an area of intense speculation and research.  In this study, we review the effects of microtubule-binding chemotherapeutic agents from a new perspective, considering how their mode of binding induces conformational changes and alters biol. function relative to the mol. vectors of microtubule assembly or disassembly.  These "biol. vectors" can thus be used as a spatiotemporal context to describe mol. mechanisms by which microtubule-targeting drugs work. © 2011 Wiley Periodicals, Inc.  Med Res Rev, 31, No. 3, 443-481, 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB6_lcUQbXYrVg90H21EOLACvtfcHk0lhOsj20TzxeMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksVKlsLs%253D&md5=acce5b9cc89581a7dab0236072b68c72</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fmed.20242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20242%26sid%3Dliteratum%253Aachs%26aulast%3DStanton%26aufirst%3DR.%2BA.%26aulast%3DGernert%26aufirst%3DK.%2BM.%26aulast%3DNettles%26aufirst%3DJ.%2BH.%26aulast%3DAneja%26aufirst%3DR.%26atitle%3DDrugs%2520that%2520target%2520dynamic%2520microtubules%253A%2520A%2520new%2520molecular%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2011%26volume%3D31%26spage%3D443%26epage%3D481%26doi%3D10.1002%2Fmed.20242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span> </span><span class="NLM_article-title">Targeting p53 for novel anticancer therapy</span> <span class="citation_source-journal">Transl. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1593/tlo.09250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1593%2Ftlo.09250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=20165689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A280%3ADC%252BC3c7hsFOgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=1-12&author=Z.+Wangauthor=Y.+Sun&title=Targeting+p53+for+novel+anticancer+therapy&doi=10.1593%2Ftlo.09250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting p53 for Novel Anticancer Therapy</span></div><div class="casAuthors">Wang Zhen; Sun Yi</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Carcinogenesis is a multistage process, involving oncogene activation and tumor suppressor gene inactivation as well as complex interactions between tumor and host tissues, leading ultimately to an aggressive metastatic phenotype.  Among many genetic lesions, mutational inactivation of p53 tumor suppressor, the "guardian of the genome," is the most frequent event found in 50% of human cancers. p53 plays a critical role in tumor suppression mainly by inducing growth arrest, apoptosis, and senescence, as well as by blocking angiogenesis.  In addition, p53 generally confers the cancer cell sensitivity to chemoradiation.  Thus, p53 becomes the most appealing target for mechanism-driven anticancer drug discovery.  This review will focus on the approaches currently undertaken to target p53 and its regulators with an overall goal either to activate p53 in cancer cells for killing or to inactivate p53 temporarily in normal cells for chemoradiation protection.  The compounds that activate wild type (wt) p53 would have an application for the treatment of wt p53-containing human cancer.  Likewise, the compounds that change p53 conformation from mutant to wt p53 (p53 reactivation) or that kill the cancer cells with mutant p53 using a synthetic lethal mechanism can be used to selectively treat human cancer harboring a mutant p53.  The inhibitors of wt p53 can be used on a temporary basis to reduce the normal cell toxicity derived from p53 activation.  Thus, successful development of these three classes of p53 modulators, to be used alone or in combination with chemoradiation, will revolutionize current anticancer therapies and benefit cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTeSdXZp7lZxNNTrvPZP1IpfW6udTcc2eZ7sx414GU3iLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7hsFOgtw%253D%253D&md5=4f0975ff3e93a1dd766084db4eb06158</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1593%2Ftlo.09250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Ftlo.09250%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DTargeting%2520p53%2520for%2520novel%2520anticancer%2520therapy%26jtitle%3DTransl.%2520Oncol.%26date%3D2010%26volume%3D3%26spage%3D1%26epage%3D12%26doi%3D10.1593%2Ftlo.09250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">O’Connor, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bae, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutoh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scudiero, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friend, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fornace, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohn, K. W.</span><span> </span><span class="NLM_article-title">Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4285</span><span class="NLM_x">–</span> <span class="NLM_lpage">4300</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=4285-4300&author=P.+M.+O%E2%80%99Connorauthor=J.+Jackmanauthor=I.+Baeauthor=T.+G.+Myersauthor=S.+Fanauthor=M.+Mutohauthor=D.+A.+Scudieroauthor=A.+Monksauthor=E.+A.+Sausvilleauthor=J.+N.+Weinsteinauthor=S.+Friendauthor=A.+J.+Fornaceauthor=K.+W.+Kohn&title=Characterization+of+the+p53+tumor+suppressor+pathway+in+cell+lines+of+the+National+Cancer+Institute+anticancer+drug+screen+and+correlations+with+the+growth-inhibitory+potency+of+123+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DP.%2BM.%26aulast%3DJackman%26aufirst%3DJ.%26aulast%3DBae%26aufirst%3DI.%26aulast%3DMyers%26aufirst%3DT.%2BG.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DMutoh%26aufirst%3DM.%26aulast%3DScudiero%26aufirst%3DD.%2BA.%26aulast%3DMonks%26aufirst%3DA.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26aulast%3DFriend%26aufirst%3DS.%26aulast%3DFornace%26aufirst%3DA.%2BJ.%26aulast%3DKohn%26aufirst%3DK.%2BW.%26atitle%3DCharacterization%2520of%2520the%2520p53%2520tumor%2520suppressor%2520pathway%2520in%2520cell%2520lines%2520of%2520the%2520National%2520Cancer%2520Institute%2520anticancer%2520drug%2520screen%2520and%2520correlations%2520with%2520the%2520growth-inhibitory%2520potency%2520of%2520123%2520anticancer%2520agents%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D4285%26epage%3D4300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Komlodi-Pasztor, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sackett, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkerson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fojo, T.</span><span> </span><span class="NLM_article-title">Mitosis is not a key target of microtubule agents in patient tumors</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">244</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2010.228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1038%2Fnrclinonc.2010.228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=21283127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFKlsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=244-250&author=E.+Komlodi-Pasztorauthor=D.+Sackettauthor=J.+Wilkersonauthor=T.+Fojo&title=Mitosis+is+not+a+key+target+of+microtubule+agents+in+patient+tumors&doi=10.1038%2Fnrclinonc.2010.228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Mitosis is not a key target of microtubule agents in patient tumors</span></div><div class="casAuthors">Komlodi-Pasztor, Edina; Sackett, Dan; Wilkerson, Julia; Fojo, Tito</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">244-250</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In this Perspective, the clin. disappointment of mitosis-specific agents is explained in the context of the mechanism of action of microtubule-targeting agents.  The authors propose a new paradigm for the anticancer activity of microtubule-targeting agents and suggest that mitosis-specific inhibitors will not result in significant clin. impact.  Mitosis-specific agents have, to date, not been clin. successful.  By contrast, microtubule-targeting agents (MTAs) have a long record of success, usually attributed to the induction of mitotic arrest.  Indeed, it was this success that led to the search for mitosis-specific inhibitors.  We believe the clin. disappointment of mitosis-specific inhibitors stands as evidence that MTAs have been successful not only by interfering with mitosis but, more importantly, by disrupting essential interphase cellular mechanisms.  In this Perspective we will review literature that supports a paradigm shift in how we think about one of our most widely used classes of chemotherapeutics-MTAs.  We believe that the steady presence and const. physiol. role of microtubules are responsible for the overall success of MTAs.  While mitosis-specific inhibitors are effective on only a small fraction of the tumor mass (dividing cells), MTAs target tubulin, a protein that has crucial roles in both mitotic and non-mitotic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYOmCILGEs2LVg90H21EOLACvtfcHk0lhOsj20TzxeMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFKlsLY%253D&md5=2a72541e9b990534b74e88c18265e4c8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2010.228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2010.228%26sid%3Dliteratum%253Aachs%26aulast%3DKomlodi-Pasztor%26aufirst%3DE.%26aulast%3DSackett%26aufirst%3DD.%26aulast%3DWilkerson%26aufirst%3DJ.%26aulast%3DFojo%26aufirst%3DT.%26atitle%3DMitosis%2520is%2520not%2520a%2520key%2520target%2520of%2520microtubule%2520agents%2520in%2520patient%2520tumors%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D8%26spage%3D244%26epage%3D250%26doi%3D10.1038%2Fnrclinonc.2010.228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Löwe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nogales, E.</span><span> </span><span class="NLM_article-title">Refined structure of αβ-tubulin at 3.5 Å resolution</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">1045</span><span class="NLM_x">–</span> <span class="NLM_lpage">1057</span><span class="refDoi"> DOI: 10.1006/jmbi.2001.5077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1006%2Fjmbi.2001.5077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=11700061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A280%3ADC%252BD3Mnksl2muw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2001&pages=1045-1057&author=J.+L%C3%B6weauthor=H.+Liauthor=K.+H.+Downingauthor=E.+Nogales&title=Refined+structure+of+%CE%B1%CE%B2-tubulin+at+3.5+%C3%85+resolution&doi=10.1006%2Fjmbi.2001.5077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Refined structure of alpha beta-tubulin at 3.5 A resolution</span></div><div class="casAuthors">Lowe J; Li H; Downing K H; Nogales E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of molecular biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1045-57</span>
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    </div><div class="casAbstract">We present a refined model of the alpha beta-tubulin dimer to 3.5 A resolution.  An improved experimental density for the zinc-induced tubulin sheets was obtained by adding 114 electron diffraction patterns at 40-60 degrees tilt and increasing the completeness of structure factor amplitudes to 84.7 %.  The refined structure was obtained using maximum-likelihood including phase information from experimental images, and simulated annealing Cartesian refinement to an R-factor of 23.2 and free R-factor of 29.7.  The current model includes residues alpha:2-34, alpha:61-439, beta:2-437, one molecule of GTP, one of GDP, and one of taxol, as well as one magnesium ion at the non-exchangeable nucleotide site, and one putative zinc ion near the M-loop in the alpha-tubulin subunit.  The acidic C-terminal tails could not be traced accurately, neither could the N-terminal loop including residues 35-60 in the alpha-subunit.  There are no major changes in the overall fold of tubulin with respect to the previous structure, testifying to the quality of the initial experimental phases.  The overall geometry of the model is, however, greatly improved, and the position of side-chains, especially those of exposed polar/charged groups, is much better defined.  Three short protein sequence frame shifts were detected with respect to the non-refined structure.  In light of the new model we discuss details of the tubulin structure such as nucleotide and taxol binding sites, lateral contacts in zinc-sheets, and the significance of the location of highly conserved residues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDXIwG-_BEjn6HPRus0rAafW6udTcc2eb-sx7P3wXOJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3Mnksl2muw%253D%253D&md5=f791000e3cfbfdc2eff7a032ec58b60b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.2001.5077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.2001.5077%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6we%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DDowning%26aufirst%3DK.%2BH.%26aulast%3DNogales%26aufirst%3DE.%26atitle%3DRefined%2520structure%2520of%2520%25CE%25B1%25CE%25B2-tubulin%2520at%25203.5%2520%25C3%2585%2520resolution%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2001%26volume%3D313%26spage%3D1045%26epage%3D1057%26doi%3D10.1006%2Fjmbi.2001.5077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Rao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ojima, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horwitz, S. B.</span><span> </span><span class="NLM_article-title">Characterization of the taxol binding site on the microtubule. Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of taxol</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">37990</span><span class="NLM_x">–</span> <span class="NLM_lpage">37994</span><span class="refDoi"> DOI: 10.1074/jbc.274.53.37990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1074%2Fjbc.274.53.37990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10608867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkt1Gltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=37990-37994&author=S.+Raoauthor=L.+Heauthor=S.+Chakravartyauthor=I.+Ojimaauthor=G.+A.+Orrauthor=S.+B.+Horwitz&title=Characterization+of+the+taxol+binding+site+on+the+microtubule.+Identification+of+Arg%28282%29+in+beta-tubulin+as+the+site+of+photoincorporation+of+a+7-benzophenone+analogue+of+taxol&doi=10.1074%2Fjbc.274.53.37990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Taxol binding site on the microtubule: Identification of Arg282 in β-tubulin as the site of photoincorporation of a 7-benzophenone analogue of taxol</span></div><div class="casAuthors">Rao, Srinivasa; He, Lifeng; Chakravarty, Subrata; Ojima, Iwao; Orr, George A.; Horwitz, Susan Band</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">53</span>),
    <span class="NLM_cas:pages">37990-37994</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Photoaffinity labeling methods have allowed a definition of the sites of interaction between Taxol and its cellular target, the microtubule, specifically β-tubulin.  Our previous studies have indicated that [3H]3'-(p-azidobenzamido)Taxol photolabels the N-terminal 31 amino acids of β-tubulin and [3H]2-(m-azidobenzoyl)Taxol photolabels a peptide contg. amino acid residues 217-233 of β-tubulin.  The site of photoincorporation of a third photoaffinity analog of Taxol, [3H]7-(benzoyldihydrocinnamoyl) Taxol, has been detd.  This analog stabilizes microtubules polymd. in the presence of GTP, but in contrast to Taxol, does not by itself enhance the polymn. of tubulin to its polymer form.  CNBr digestion of [3H]7-(benzoyldihydrocinnamoyl)Taxol-labeled tubulin, with further arginine-specific cleavage by clostripain resulted in the isolation of a peptide contg. amino acid residues 277-293.  Amino acid sequence anal. indicated that the photoaffinity analog crosslinks to Arg282 in β-tubulin.  Advances made by electron crystallog. in understanding the structure of the tubulin dimer have allowed us to visualize the three sites of photoincorporation by mol. modeling.  There is good agreement between the binding site of Taxol in β-tubulin as detd. by photoaffinity labeling and electron crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKSE1QG2SG7LVg90H21EOLACvtfcHk0ljcVlOFUBM9fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkt1Gltw%253D%253D&md5=81a886bb1b567132079be101f5900149</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.53.37990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.53.37990%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DChakravarty%26aufirst%3DS.%26aulast%3DOjima%26aufirst%3DI.%26aulast%3DOrr%26aufirst%3DG.%2BA.%26aulast%3DHorwitz%26aufirst%3DS.%2BB.%26atitle%3DCharacterization%2520of%2520the%2520taxol%2520binding%2520site%2520on%2520the%2520microtubule.%2520Identification%2520of%2520Arg%2528282%2529%2520in%2520beta-tubulin%2520as%2520the%2520site%2520of%2520photoincorporation%2520of%2520a%25207-benzophenone%2520analogue%2520of%2520taxol%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D37990%26epage%3D37994%26doi%3D10.1074%2Fjbc.274.53.37990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Lee, J. F.; Harris, L. N.</span><span> </span><span class="NLM_article-title">Antimicrotubule Agents</span>. In  <span class="citation_source-book">Cancer: Principles & Practice of Oncology</span>, <span class="NLM_edition">8</span>th ed.; <span class="NLM_contrib-group">DeVita, V. T.,  Jr.; Lawrence, T. S.; Rosenberg, S. A.</span> Eds.; <span class="NLM_publisher-name">Lippincott Williams & Wilkins</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">447</span><span class="NLM_x">–</span> <span class="NLM_lpage">456</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=447-456&author=J.+F.+Lee&author=L.+N.+Harrisauthor=V.+T.+DeVita&author=T.+S.+Lawrence&author=S.+A.+Rosenberg&title=Cancer%3A+Principles+%26+Practice+of+Oncology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BF.%26atitle%3DAntimicrotubule%2520Agents%26btitle%3DCancer%253A%2520Principles%2520%2526%2520Practice%2520of%2520Oncology%26aulast%3DDeVita%26aufirst%3DV.%2BT.%26pub%3DLippincott%2520Williams%2520%2526%2520Wilkins%26date%3D2008%26spage%3D447%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Altmann, K.-H.</span><span> </span><span class="NLM_article-title">Microtubule-stabilizing agents: A growing class of important anticancer drugs</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">424</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1016/S1367-5931(00)00225-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1016%2FS1367-5931%2800%2900225-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=11470606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltlyqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2001&pages=424-431&author=K.-H.+Altmann&title=Microtubule-stabilizing+agents%3A+A+growing+class+of+important+anticancer+drugs&doi=10.1016%2FS1367-5931%2800%2900225-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-stabilizing agents: a growing class of important anticancer drugs</span></div><div class="casAuthors">Altmann, K.-H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">424-431</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  Microtubule-stabilizing agents continue to play an important role in anticancer drug discovery and development.  New agents were again discovered in the past year, including small synthetic mols.  At least three new taxanes and two compds. of the epothilone class of natural products underwent clin. trials in 2000.  Unexpected new findings about synergistic effects between different microtubule-stabilizing agents in vitro raise new prospects for combination chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEbKmPFiPGKbVg90H21EOLACvtfcHk0ljcVlOFUBM9fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltlyqsLg%253D&md5=dcdbd861319db7538654e2e9244d522e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS1367-5931%2800%2900225-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1367-5931%252800%252900225-8%26sid%3Dliteratum%253Aachs%26aulast%3DAltmann%26aufirst%3DK.-H.%26atitle%3DMicrotubule-stabilizing%2520agents%253A%2520A%2520growing%2520class%2520of%2520important%2520anticancer%2520drugs%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2001%26volume%3D5%26spage%3D424%26epage%3D431%26doi%3D10.1016%2FS1367-5931%2800%2900225-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Prota, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargsten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northcote, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altmann, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díaz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span> </span><span class="NLM_article-title">Structural basis of microtubule stabilization by laulimalide and peloruside A</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1621</span><span class="NLM_x">–</span> <span class="NLM_lpage">1625</span><span class="refDoi"> DOI: 10.1002/anie.201307749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1002%2Fanie.201307749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlegt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1621-1625&author=A.+E.+Protaauthor=K.+Bargstenauthor=P.+T.+Northcoteauthor=M.+Marshauthor=K.-H.+Altmannauthor=J.+H.+Millerauthor=J.+F.+D%C3%ADazauthor=M.+O.+Steinmetz&title=Structural+basis+of+microtubule+stabilization+by+laulimalide+and+peloruside+A&doi=10.1002%2Fanie.201307749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Microtubule Stabilization by Laulimalide and Peloruside A</span></div><div class="casAuthors">Prota, Andrea E.; Bargsten, Katja; Northcote, Peter T.; Marsh, May; Altmann, Karl-Heinz; Miller, John H.; Diaz, Jose Fernando; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1621-1625</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Laulimalide and peloruside A are microtubule-stabilizing agents (MSAs), the mechanism of action on microtubules of which is poorly defined.  Here, using X-ray crystallog. it is shown that laulimalide and peloruside A bind to a unique non-taxane site on β-tubulin and use their resp. macrolide core structures to interact with a second tubulin dimer across protofilaments.  At the same time, they allosterically stabilize the taxane-site M-loop that establishes lateral tubulin contacts in microtubules.  Structures of ternary complexes of tubulin with laulimalide/peloruside A and epothilone A are also solved, and a crosstalk between the laulimalide/peloruside and taxane sites via the M-loop of β-tubulin is found.  Together, the data define the mechanism of action of laulimalide and peloruside A on tubulin and microtubules.  The data further provide a structural framework for understanding the synergy obsd. between two classes of MSAs in tubulin assembly and the inhibition of cancer cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0Dd_nMEpmVrVg90H21EOLACvtfcHk0lioT_GMiJx0kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlegt74%253D&md5=add9ce5e97ae55ad70d04ebc58245728</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fanie.201307749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201307749%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DNorthcote%26aufirst%3DP.%2BT.%26aulast%3DMarsh%26aufirst%3DM.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DMiller%26aufirst%3DJ.%2BH.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DStructural%2520basis%2520of%2520microtubule%2520stabilization%2520by%2520laulimalide%2520and%2520peloruside%2520A%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D1621%26epage%3D1625%26doi%3D10.1002%2Fanie.201307749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Prota, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargsten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuevas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liniger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuhaus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altmann, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span> </span><span class="NLM_article-title">A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">13817</span><span class="NLM_x">–</span> <span class="NLM_lpage">13821</span><span class="refDoi"> DOI: 10.1073/pnas.1408124111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1073%2Fpnas.1408124111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=25114240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCju7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=13817-13821&author=A.+E.+Protaauthor=K.+Bargstenauthor=J.+F.+Diazauthor=M.+Marshauthor=C.+Cuevasauthor=M.+Linigerauthor=C.+Neuhausauthor=J.+M.+Andreuauthor=K.-H.+Altmannauthor=M.+O.+Steinmetz&title=A+new+tubulin-binding+site+and+pharmacophore+for+microtubule-destabilizing+anticancer+drugs&doi=10.1073%2Fpnas.1408124111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</span></div><div class="casAuthors">Prota, Andrea E.; Bargsten, Katja; Diaz, J. Fernando; Marsh, May; Cuevas, Carmen; Liniger, Marc; Neuhaus, Christian; Andreu, Jose M.; Altmann, Karl-Heinz; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">13817-13821</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The recent success of antibody-drug conjugates (ADCs) in the treatment of cancer has led to a revived interest in microtubule-destabilizing agents.  Here, we detd. the high-resoln. crystal structure of the complex between tubulin and maytansine, which is part of an ADC that is approved by the US Food and Drug Administration (FDA) for the treatment of advanced breast cancer.  We found that the drug binds to a site on β-tubulin that is distinct from the vinca domain and that blocks the formation of longitudinal tubulin interactions in microtubules.  We also solved crystal structures of tubulin in complex with both a variant of rhizoxin and the phase 1 drug PM060184.  Consistent with biochem. and mutagenesis data, we found that the two compds. bound to the same site as maytansine and that the structures revealed a common pharmacophore for the three ligands.  Our results delineate a distinct mol. mechanism of action for the inhibition of microtubule assembly by clin. relevant agents.  They further provide a structural basis for the rational design of potent microtubule-destabilizing agents, thus opening opportunities for the development of next-generation ADCs for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX4icqk698gLVg90H21EOLACvtfcHk0lioT_GMiJx0kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCju7vM&md5=798cae320e427ff76c2099387d9e6ba4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1408124111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1408124111%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DDiaz%26aufirst%3DJ.%2BF.%26aulast%3DMarsh%26aufirst%3DM.%26aulast%3DCuevas%26aufirst%3DC.%26aulast%3DLiniger%26aufirst%3DM.%26aulast%3DNeuhaus%26aufirst%3DC.%26aulast%3DAndreu%26aufirst%3DJ.%2BM.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DA%2520new%2520tubulin-binding%2520site%2520and%2520pharmacophore%2520for%2520microtubule-destabilizing%2520anticancer%2520drugs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D13817%26epage%3D13821%26doi%3D10.1073%2Fpnas.1408124111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Verma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welslau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diéras, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guardino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwell, K.</span><span> </span><span class="NLM_article-title">Trastuzumab emtansine for HER2-positive advanced breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">1783</span><span class="NLM_x">–</span> <span class="NLM_lpage">1791</span><span class="refDoi"> DOI: 10.1056/NEJMoa1209124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1056%2FNEJMoa1209124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=23020162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1783-1791&author=S.+Vermaauthor=D.+Milesauthor=L.+Gianniauthor=I.+E.+Kropauthor=M.+Welslauauthor=J.+Baselgaauthor=M.+Pegramauthor=D.-Y.+Ohauthor=V.+Di%C3%A9rasauthor=E.+Guardinoauthor=L.+Fangauthor=M.+W.+Luauthor=S.+Olsenauthor=K.+Blackwell&title=Trastuzumab+emtansine+for+HER2-positive+advanced+breast+cancer&doi=10.1056%2FNEJMoa1209124"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab emtansine for HER2-positive advanced breast cancer</span></div><div class="casAuthors">Verma, Sunil; Miles, David; Gianni, Luca; Krop, Ian E.; Welslau, Manfred; Baselga, Jose; Pegram, Mark; Oh, Do-Youn; Dieras, Veronique; Guardino, Ellie; Fang, Liang; Lu, Michael W.; Olsen, Steven; Blackwell, Kim</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1783-1791</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.  The antibody and the cytotoxic agent are conjugated by means of a stable linker.  METHODS: We randomly assigned patients with HER2-pos. advanced breast cancer, who had previously been treated with trastuzumab and a taxane, to T-DM1 or lapatinib plus capecitabine.  The primary end points were progression-free survival (as assessed by independent review), overall survival, and safety.  Secondary end points included progression-free survival (investigator-assessed), the objective response rate, and the time to symptom progression.  Two interim analyses of overall survival were conducted.  RESULTS: Among 991 randomly assigned patients, median progression-free survival as assessed by independent review was 9.6 mo with T-DM1 vs. 6.4 mo with lapatinib plus capecitabine (hazard ratio for progression or death from any cause, 0.65; 95% confidence interval [CI], 0.55 to 0.77; P<0.001), and median overall survival at the second interim anal. crossed the stopping boundary for efficacy (30.9 mo vs. 25.1 mo; hazard ratio for death from any cause, 0.68; 95% CI, 0.55 to 0.85; P<0.001).  The objective response rate was higher with T-DM1 (43.6%, vs. 30.8% with lapatinib plus capecitabine; P<0.001); results for all addnl. secondary end points favored T-DM1.  Rates of grade 3 or above were higher with lapatinib plus capecitabine than with T-DM1 (57% vs. 41%).  The incidences of thrombocytopenia and increased serum aminotransferase levels were higher with T-DM1, whereas the incidences of diarrhea, nausea, vomiting, and palmar-plantar erythrodysesthesia were higher with lapatinib plus capecitabine.  CONCLUSIONS: T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-pos. advanced breast cancer previously treated with trastuzumab and a taxane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGRhxRQ7JSJrVg90H21EOLACvtfcHk0lgekQwotnmc1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73M&md5=3be5bac27a81b530442dc8a6b4a1f82e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1209124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1209124%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DS.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DGianni%26aufirst%3DL.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DWelslau%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DPegram%26aufirst%3DM.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26aulast%3DGuardino%26aufirst%3DE.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DS.%26aulast%3DBlackwell%26aufirst%3DK.%26atitle%3DTrastuzumab%2520emtansine%2520for%2520HER2-positive%2520advanced%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1783%26epage%3D1791%26doi%3D10.1056%2FNEJMoa1209124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D.</span><span> </span><span class="NLM_article-title">An overview of tubulin inhibitors that interact with the colchicine binding site</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2943</span><span class="NLM_x">–</span> <span class="NLM_lpage">2971</span><span class="refDoi"> DOI: 10.1007/s11095-012-0828-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1007%2Fs11095-012-0828-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=22814904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOis7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=2943-2971&author=Y.+Luauthor=J.+Chenauthor=M.+Xiaoauthor=W.+Liauthor=D.+Miller&title=An+overview+of+tubulin+inhibitors+that+interact+with+the+colchicine+binding+site&doi=10.1007%2Fs11095-012-0828-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site</span></div><div class="casAuthors">Lu, Yan; Chen, Jianjun; Xiao, Min; Li, Wei; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2943-2971</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Tubulin dynamics is a promising target for new chemotherapeutic agents.  The colchicine binding site is one of the most important pockets for potential tubulin polymn. destabilizers.  Colchicine binding site inhibitors (CBSI) exert their biol. effects by inhibiting tubulin assembly and suppressing microtubule formation.  A large no. of mols. interacting with the colchicine binding site have been designed and synthesized with significant structural diversity.  CBSIs have been modified as to chem. structure as well as pharmacokinetic properties, and tested in order to find a highly potent, low toxicity agent for treatment of cancers.  CBSIs are believed to act by a common mechanism via binding to the colchicine site on tubulin.  The present review is a synopsis of compds. that have been reported in the past decade that have provided an increase in our understanding of the actions of CBSIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFrFQVgeCbBbVg90H21EOLACvtfcHk0lgekQwotnmc1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOis7vN&md5=dfe42e8eb1f0ff22b256641aaa8c17ab</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs11095-012-0828-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-012-0828-z%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%26atitle%3DAn%2520overview%2520of%2520tubulin%2520inhibitors%2520that%2520interact%2520with%2520the%2520colchicine%2520binding%2520site%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26spage%3D2943%26epage%3D2971%26doi%3D10.1007%2Fs11095-012-0828-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Massarotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coluccia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvestri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorba, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brancale, A.</span><span> </span><span class="NLM_article-title">The tubulin colchicine domain: A molecular modeling perspective</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span><span class="refDoi"> DOI: 10.1002/cmdc.201100361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1002%2Fcmdc.201100361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=21990124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12qt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=33-42&author=A.+Massarottiauthor=A.+Colucciaauthor=R.+Silvestriauthor=G.+Sorbaauthor=A.+Brancale&title=The+tubulin+colchicine+domain%3A+A+molecular+modeling+perspective&doi=10.1002%2Fcmdc.201100361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The Tubulin Colchicine Domain: a Molecular Modeling Perspective</span></div><div class="casAuthors">Massarotti, Alberto; Coluccia, Antonio; Silvestri, Romano; Sorba, Giovanni; Brancale, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-42</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Computational approaches have been increasingly applied to drug design over the past three decades and have already provided some useful results in the discovery of anticancer drugs.  Given the increased availability of crystal structures in recent years, a growing no. of mol. modeling studies on tubulin have been reported.  Herein we present a brief overview of the role played by computational methods in anti-tubulin research, specifically in the context of colchicine binding agent research.  An overview of current structures is reported, along with a brief discussion on the issues assocd. with the various tubulin isotypes.  Finally, a summary of the most recent and relevant results is presented, highlighting the challenges and opportunities faced by researchers in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpomkM8Gy2eS7Vg90H21EOLACvtfcHk0lj3WfqA2SVfyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12qt7zO&md5=84b4f8c78b635c2b7df31bbd1e4a89de</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100361%26sid%3Dliteratum%253Aachs%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DSilvestri%26aufirst%3DR.%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DBrancale%26aufirst%3DA.%26atitle%3DThe%2520tubulin%2520colchicine%2520domain%253A%2520A%2520molecular%2520modeling%2520perspective%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D33%26epage%3D42%26doi%3D10.1002%2Fcmdc.201100361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baichwal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skvortsova, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skvortsov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">English, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisoma, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pervin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pleiman, C. M.</span><span> </span><span class="NLM_article-title">MPC-6827: A small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">5865</span><span class="NLM_x">–</span> <span class="NLM_lpage">5871</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-0127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1158%2F0008-5472.CAN-07-0127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=17575155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFCqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=5865-5871&author=S.+Kasibhatlaauthor=V.+Baichwalauthor=S.+X.+Caiauthor=B.+Rothauthor=I.+Skvortsovaauthor=S.+Skvortsovauthor=P.+Lukasauthor=N.+M.+Englishauthor=N.+Sirisomaauthor=J.+Dreweauthor=A.+Pervinauthor=B.+Tsengauthor=R.+O.+Carlsonauthor=C.+M.+Pleiman&title=MPC-6827%3A+A+small-molecule+inhibitor+of+microtubule+formation+that+is+not+a+substrate+for+multidrug+resistance+pumps&doi=10.1158%2F0008-5472.CAN-07-0127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">MPC-6827: A small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps</span></div><div class="casAuthors">Kasibhatla, Shailaja; Baichwal, Vijay; Cai, Sui Xiong; Roth, Bruce; Skvortsova, Ira; Skvortsov, Sergej; Lukas, Peter; English, Nicole M.; Sirisoma, Nilantha; Drewe, John; Pervin, Azra; Tseng, Ben; Carlson, Robert O.; Pleiman, Christopher M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5865-5871</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A novel series of 4-arylaminoquinazolines were identified from a cell-based screening assay as potent apoptosis inducers.  Through structure-activity relationship studies, MPC-6827 and its close structural analog, MPI-0441138, were discovered as proapoptotic mols. and mitotic inhibitors with potencies at low nanomolar concns. in multiple tumor cell lines.  Photoaffinity and radiolabeled analogs of MPC-6827 were found to bind a 55-kDa protein, and this binding was competed by MPC-6827, paclitaxel, and colchicine, but not vinblastine.  MPC-6827 effectively inhibited the polymn. of tubulin in vitro, competed with colchicine binding, and disrupted the formation of microtubules in a variety of tumor cell lines, which together showed the mol. target as tubulin.  Treatment of MCF-7 breast carcinoma or Jurkat leukemia cells with MPC-6827 led to pronounced G2-M cell cycle arrest followed by apoptosis.  Apoptosis, as detd. by terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay, was preceded by loss of mitochondrial membrane potential, cytochrome c translocation from mitochondria to nuclei, activation of caspase-3, and cleavage of poly(ADP-ribose) polymerase.  MPC-6827 was equipotent in an in vitro growth inhibition assay in several cancer cell lines regardless of the expression levels of the multidrug resistance ABC transporters MDR-1 (Pgp-1), MRP-1, and BCRP-1.  In B16-F1 allografts and in OVCAR-3, MIAPaCa-2, MCF-7, HT-29, MDA-MB-435, and MX-1 xenografts, statistically significant tumor growth inhibition was obsd. with MPC-6827.  These studies show that MPC-6827 is a microtubule-disrupting agent with potent and broad-spectrum in vitro and in vivo cytotoxic activities and, therefore, MPC-6827 is a promising candidate for development as a novel therapeutic for multiple cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo-qab7pG6E7Vg90H21EOLACvtfcHk0lj3WfqA2SVfyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFCqtrg%253D&md5=3ce57c281fdc663115a794ac7e91f177</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-0127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-0127%26sid%3Dliteratum%253Aachs%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DBaichwal%26aufirst%3DV.%26aulast%3DCai%26aufirst%3DS.%2BX.%26aulast%3DRoth%26aufirst%3DB.%26aulast%3DSkvortsova%26aufirst%3DI.%26aulast%3DSkvortsov%26aufirst%3DS.%26aulast%3DLukas%26aufirst%3DP.%26aulast%3DEnglish%26aufirst%3DN.%2BM.%26aulast%3DSirisoma%26aufirst%3DN.%26aulast%3DDrewe%26aufirst%3DJ.%26aulast%3DPervin%26aufirst%3DA.%26aulast%3DTseng%26aufirst%3DB.%26aulast%3DCarlson%26aufirst%3DR.%2BO.%26aulast%3DPleiman%26aufirst%3DC.%2BM.%26atitle%3DMPC-6827%253A%2520A%2520small-molecule%2520inhibitor%2520of%2520microtubule%2520formation%2520that%2520is%2520not%2520a%2520substrate%2520for%2520multidrug%2520resistance%2520pumps%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D5865%26epage%3D5871%26doi%3D10.1158%2F0008-5472.CAN-07-0127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Tsimberidou, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akerley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schabel, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehara, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chhabra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mather, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodland, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swabb, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span> </span><span class="NLM_article-title">Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">3410</span><span class="NLM_x">–</span> <span class="NLM_lpage">3419</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1158%2F1535-7163.MCT-10-0516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=21159616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGrsLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=3410-3419&author=A.-M.+Tsimberidouauthor=W.+Akerleyauthor=M.+C.+Schabelauthor=D.+S.+Hongauthor=C.+Ueharaauthor=A.+Chhabraauthor=T.+Warrenauthor=G.+G.+Matherauthor=B.+A.+Evansauthor=D.+P.+Woodlandauthor=E.+A.+Swabbauthor=R.+Kurzrock&title=Phase+I+clinical+trial+of+MPC-6827+%28Azixa%29%2C+a+microtubule+destabilizing+agent%2C+in+patients+with+advanced+cancer&doi=10.1158%2F1535-7163.MCT-10-0516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer</span></div><div class="casAuthors">Tsimberidou, Apostolia-Maria; Akerley, Wallace; Schabel, Matthias C.; Hong, David S.; Uehara, Cynthia; Chhabra, Anil; Warren, Terri; Mather, Gary G.; Evans, Brent A.; Woodland, Deane P.; Swabb, Edward A.; Kurzrock, Razelle</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3410-3419</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">MPC-6827 (Azixa) is a small-mol. microtubule-destabilizing agent that binds to the same (or nearby) sites on β-tubulin as colchicine.  This phase I study was designed to det. the dose-limiting toxicities (DLT), max. tolerated dose (MTD), and pharmacokinetics (PK) of MPC-6827 in patients with solid tumors.  Patients with advanced/metastatic cancer were treated with once-weekly, 1- to 2-h i.v. administration of MPC-6827 for 3 consecutive weeks every 28 days (1 cycle).  Dose escalation began with 0.3, 0.6, 1, and 1.5 mg/m2, with subsequent increments of 0.6 mg/m2 until the MTD was detd.  A 3 + 3 design was used.  Pharmacokinetics of MPC-6827 and its metabolite MPI-0440627 were evaluated.  Forty-eight patients received therapy; 79 cycles were completed (median, 1; range, 1-10).  The most common adverse events were nausea, fatigue, flushing, and hyperglycemia.  The DLT was nonfatal grade 3 myocardial infarction at 3.9 mg/m2 (1/6 patients) and at 4.5 mg/m2 (1/7 patients).  The MTD was detd. to be 3.3 mg/m2 (0/13 patients had a DLT).  Five (10.4%) of the 48 patients achieved stable disease (Response Evaluation Criteria in Solid Tumors) for 4 mo or greater.  MPC-6827 has a high vol. of distribution and clearance.  Half-life ranged from 3.8 to 7.5 h.  In conclusion, MPC-6827 administered i.v. over 2 h at a dose of 3.3 mg/m2 once weekly for 3 wk every 28 days was safe in patients with heavily pretreated cancer.  Clin. trials with MPC-6827 and chemotherapy are ongoing.  Mol Cancer Ther; 9(12); 3410-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQxB3bYYYZ1rVg90H21EOLACvtfcHk0lj3WfqA2SVfyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGrsLjN&md5=97b0a255d67eec98f8bd7c3709cdcf6c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0516%26sid%3Dliteratum%253Aachs%26aulast%3DTsimberidou%26aufirst%3DA.-M.%26aulast%3DAkerley%26aufirst%3DW.%26aulast%3DSchabel%26aufirst%3DM.%2BC.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DUehara%26aufirst%3DC.%26aulast%3DChhabra%26aufirst%3DA.%26aulast%3DWarren%26aufirst%3DT.%26aulast%3DMather%26aufirst%3DG.%2BG.%26aulast%3DEvans%26aufirst%3DB.%2BA.%26aulast%3DWoodland%26aufirst%3DD.%2BP.%26aulast%3DSwabb%26aufirst%3DE.%2BA.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DPhase%2520I%2520clinical%2520trial%2520of%2520MPC-6827%2520%2528Azixa%2529%252C%2520a%2520microtubule%2520destabilizing%2520agent%252C%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D3410%26epage%3D3419%26doi%3D10.1158%2F1535-7163.MCT-10-0516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Harrison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pili, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnott, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidor, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span> </span><span class="NLM_article-title">A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1465</span><span class="NLM_x">–</span> <span class="NLM_lpage">1474</span><span class="refDoi"> DOI: 10.1007/s10637-010-9455-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1007%2Fs10637-010-9455-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1465-1474&author=M.+Harrisonauthor=N.+Hahnauthor=R.+Piliauthor=W.+Ohauthor=H.+Hammersauthor=C.+Sweeneyauthor=K.+Kimauthor=S.+Perlmanauthor=J.+Arnottauthor=C.+Sidorauthor=G.+Wildingauthor=G.+Liu&title=A+phase+II+study+of+2-methoxyestradiol+%282ME2%29+NanoCrystal%C2%AE+dispersion+%28NCD%29+in+patients+with+taxane-refractory%2C+metastatic+castrate-resistant+prostate+cancer+%28CRPC%29&doi=10.1007%2Fs10637-010-9455-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs10637-010-9455-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-010-9455-x%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DM.%26aulast%3DHahn%26aufirst%3DN.%26aulast%3DPili%26aufirst%3DR.%26aulast%3DOh%26aufirst%3DW.%26aulast%3DHammers%26aufirst%3DH.%26aulast%3DSweeney%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DPerlman%26aufirst%3DS.%26aulast%3DArnott%26aufirst%3DJ.%26aulast%3DSidor%26aufirst%3DC.%26aulast%3DWilding%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DG.%26atitle%3DA%2520phase%2520II%2520study%2520of%25202-methoxyestradiol%2520%25282ME2%2529%2520NanoCrystal%25C2%25AE%2520dispersion%2520%2528NCD%2529%2520in%2520patients%2520with%2520taxane-refractory%252C%2520metastatic%2520castrate-resistant%2520prostate%2520cancer%2520%2528CRPC%2529%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2011%26volume%3D29%26spage%3D1465%26epage%3D1474%26doi%3D10.1007%2Fs10637-010-9455-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Bruce, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eickhoff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pili, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carducci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnott, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span> </span><span class="NLM_article-title">A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">794</span><span class="NLM_x">–</span> <span class="NLM_lpage">802</span><span class="refDoi"> DOI: 10.1007/s10637-010-9618-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1007%2Fs10637-010-9618-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=794-802&author=J.+Bruceauthor=J.+Eickhoffauthor=R.+Piliauthor=T.+Loganauthor=M.+Carducciauthor=J.+Arnottauthor=A.+Trestonauthor=G.+Wildingauthor=G.+Liu&title=A+phase+II+study+of+2-methoxyestradiol+nanocrystal+colloidal+dispersion+alone+and+in+combination+with+sunitinib+malate+in+patients+with+metastatic+renal+cell+carcinoma+progressing+on+sunitinib+malate&doi=10.1007%2Fs10637-010-9618-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs10637-010-9618-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-010-9618-9%26sid%3Dliteratum%253Aachs%26aulast%3DBruce%26aufirst%3DJ.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DPili%26aufirst%3DR.%26aulast%3DLogan%26aufirst%3DT.%26aulast%3DCarducci%26aufirst%3DM.%26aulast%3DArnott%26aufirst%3DJ.%26aulast%3DTreston%26aufirst%3DA.%26aulast%3DWilding%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DG.%26atitle%3DA%2520phase%2520II%2520study%2520of%25202-methoxyestradiol%2520nanocrystal%2520colloidal%2520dispersion%2520alone%2520and%2520in%2520combination%2520with%2520sunitinib%2520malate%2520in%2520patients%2520with%2520metastatic%2520renal%2520cell%2520carcinoma%2520progressing%2520on%2520sunitinib%2520malate%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D794%26epage%3D802%26doi%3D10.1007%2Fs10637-010-9618-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span> </span><span class="NLM_article-title">A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">462</span><span class="NLM_x">–</span> <span class="NLM_lpage">471</span><span class="refDoi"> DOI: 10.1097/CAD.0000000000000070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1097%2FCAD.0000000000000070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=24500030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1SksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=462-471&author=P.+Liuauthor=Y.+Qinauthor=L.+Wuauthor=S.+Yangauthor=N.+Liauthor=H.+Wangauthor=H.+Xuauthor=K.+Sunauthor=S.+Zhangauthor=X.+Hanauthor=Y.+Sunauthor=Y.+Shi&title=A+phase+I+clinical+trial+assessing+the+safety+and+tolerability+of+combretastatin+A4+phosphate+injections&doi=10.1097%2FCAD.0000000000000070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections</span></div><div class="casAuthors">Liu, Peng; Qin, Yan; Wu, Lingying; Yang, Sheng; Li, Nan; Wang, Haijun; Xu, Haiyan; Sun, Kelin; Zhang, Shuxiang; Han, Xiaohong; Sun, Yan; Shi, Yuankai</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">462-471</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Combretastatin A4 phosphate (CA4P) is a prodrug that selectively destroys tumor blood vessels, and has shown efficacy as a targeted anticancer drug in both animal models and clin. trials.  The aims of this single-center, open label, phase I clin. trial were to investigate the safety and tolerability of CA4P administered i.v. to patients aged 18-65 years with advanced solid tumors.  Using a dose-escalation protocol, patients were assigned to five groups that received injections with 20 (n=3), 33 (n=3), 50 (n=11), 65 (n=6), or 85 (n=2) mg/m CA4P.  Patients in the 20 and 85 mg/m groups received a single dose and the other groups received multiple doses.  Adverse events (AE), cardiovascular parameters, and biochem. investigations were studied, and the max. tolerated dose was detd.  Of twenty-five patients enrolled, eight were withdrawn/excluded (not because of AE).  There were no deaths.  A total of 394 AE occurred in the 25 patients, with 89.3% considered related/possibly related to the drug.  AE included headache and dizziness (19.8%), tumor-induced pain (14.2%), vascular vagal excitation (10.7%), and vomiting (9.4%).  Ninety-five percent of AE were mild (grades 0-II), with only 5% being grade III-IV.  Drug administration was assocd. with biphasic changes in heart rate and blood pressure, and only limited abnormalities in the lab. investigations performed.  The max. tolerated dose was 65 mg/m.  We conclude that CA4P is generally well tolerated, with the vast majority of AE that occurred being of mild severity.  Further studies will establish the role of CA4P in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobvmdFO81FLLVg90H21EOLACvtfcHk0lirdjtj2i6Eig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1SksLg%253D&md5=1573e6f13d625ddc78fdac4ffff13181</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000070%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DA%2520phase%2520I%2520clinical%2520trial%2520assessing%2520the%2520safety%2520and%2520tolerability%2520of%2520combretastatin%2520A4%2520phosphate%2520injections%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2014%26volume%3D25%26spage%3D462%26epage%3D471%26doi%3D10.1097%2FCAD.0000000000000070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Ng, Q.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandeville, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padhani, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saunders, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoskin, P. J.</span><span> </span><span class="NLM_article-title">Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">237</span><span class="refDoi"> DOI: 10.1093/annonc/mdr332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1093%2Fannonc%2Fmdr332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=21765046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FptVClsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=231-237&author=Q.-S.+Ngauthor=H.+Mandevilleauthor=V.+Gohauthor=R.+Alonziauthor=J.+Milnerauthor=D.+Carnellauthor=K.+Meerauthor=A.+R.+Padhaniauthor=M.+I.+Saundersauthor=P.+J.+Hoskin&title=Phase+Ib+trial+of+radiotherapy+in+combination+with+combretastatin-A4-phosphate+in+patients+with+non-small-cell+lung+cancer%2C+prostate+adenocarcinoma%2C+and+squamous+cell+carcinoma+of+the+head+and+neck&doi=10.1093%2Fannonc%2Fmdr332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck</span></div><div class="casAuthors">Ng Q-S; Mandeville H; Goh V; Alonzi R; Milner J; Carnell D; Meer K; Padhani A R; Saunders M I; Hoskin P J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">231-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The vascular disrupting agent combretastatin-A4-phosphate (CA4P) demonstrated antitumour activity in preclinical studies when combined with radiation.  METHODS:  Patients with non-small-cell lung cancer (NSCLC), prostate adenocarcinoma, and squamous cell carcinoma of the head and neck (SCCHN) received 27 Gy in 6 fractions treating twice weekly over 3 weeks, 55 Gy in 20 fractions over 4 weeks, and 66 Gy in 33 fractions over 6 weeks respectively.  CA4P was escalated from 50 mg/m2 to 63 mg/m2.  CA4P exposure was further increased from one to three to six doses.  Patients with SCCHN received cetuximab in addition.  RESULTS:  Thirty-nine patients received 121 doses of CA4P.  Dose-limiting toxic effects (DLTs) of reversible ataxia and oculomotor nerve palsy occurred in two patients with prostate cancer receiving weekly CA4P at 63 mg/m2.  DLT of cardiac ischaemia occurred in two patients with SCCHN at a weekly dose of 50 mg/m2 in combination with cetuximab.  Three patients developed grade 3 hypertension.  Responses were seen in 7 of 18 patients with NSCLC.  At 3 years, 3 of 18 patients with prostate cancer had prostate-specific antigen relapse.  CONCLUSIONS:  Radiotherapy with CA4P appears well tolerated in most patients.  The combination of CA4P, cetuximab, and radiotherapy needs further scrutiny before it can be recommended for clinical studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUpqvW00Wv3kkUaC_kzhvyfW6udTcc2eYWY4x5_XKH0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FptVClsA%253D%253D&md5=81485b098f126d9a1f6355dd440b28f9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdr332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdr332%26sid%3Dliteratum%253Aachs%26aulast%3DNg%26aufirst%3DQ.-S.%26aulast%3DMandeville%26aufirst%3DH.%26aulast%3DGoh%26aufirst%3DV.%26aulast%3DAlonzi%26aufirst%3DR.%26aulast%3DMilner%26aufirst%3DJ.%26aulast%3DCarnell%26aufirst%3DD.%26aulast%3DMeer%26aufirst%3DK.%26aulast%3DPadhani%26aufirst%3DA.%2BR.%26aulast%3DSaunders%26aufirst%3DM.%2BI.%26aulast%3DHoskin%26aufirst%3DP.%2BJ.%26atitle%3DPhase%2520Ib%2520trial%2520of%2520radiotherapy%2520in%2520combination%2520with%2520combretastatin-A4-phosphate%2520in%2520patients%2520with%2520non-small-cell%2520lung%2520cancer%252C%2520prostate%2520adenocarcinoma%252C%2520and%2520squamous%2520cell%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26spage%3D231%26epage%3D237%26doi%3D10.1093%2Fannonc%2Fmdr332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Zweifel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayson, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeves, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkissoon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span> </span><span class="NLM_article-title">Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2036</span><span class="NLM_x">–</span> <span class="NLM_lpage">2041</span><span class="refDoi"> DOI: 10.1093/annonc/mdq708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1093%2Fannonc%2Fmdq708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=21273348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A280%3ADC%252BC3MjpvVSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=2036-2041&author=M.+Zweifelauthor=G.+C.+Jaysonauthor=N.+S.+Reedauthor=R.+Osborneauthor=B.+Hassanauthor=J.+Ledermannauthor=G.+Shreevesauthor=L.+Poupardauthor=S.-P.+Luauthor=J.+Balkissoonauthor=D.+J.+Chaplinauthor=G.+J.+S.+Rustin&title=Phase+II+trial+of+combretastatin+A4+phosphate%2C+carboplatin%2C+and+paclitaxel+in+patients+with+platinum-resistant+ovarian+cancer&doi=10.1093%2Fannonc%2Fmdq708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer</span></div><div class="casAuthors">Zweifel M; Jayson G C; Reed N S; Osborne R; Hassan B; Ledermann J; Shreeves G; Poupard L; Lu S-P; Balkissoon J; Chaplin D J; Rustin G J S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2036-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer.  PATIENTS AND METHODS:  Patients with ovarian cancer that had relapsed and who could start trial therapy within 6 months of their last platinum chemotherapy were given CA4P 63 mg/m(2) minimum 18 h before paclitaxel 175 mg/m(2) and carboplatin AUC (area under the concentration curve) 5, repeated every 3 weeks.  RESULTS:  Five of the first 18 patients' disease responded, so the study was extended and closed after 44 patients were recruited.  Grade ≥2 toxic effects were neutropenia in 75% and thrombocytopenia in 9% of patients (weekly blood counts), tumour pain, fatigue, and neuropathy, with one patient with rapidly reversible ataxia.  Hypertension (23% of patients) was controlled by glyceryl trinitrate or prophylactic amlodipine.  The response rate by RECIST was 13.5% and by Gynecologic Cancer InterGroup CA 125 criteria 34%.  CONCLUSIONS:  The addition of CA4P to paclitaxel and carboplatin is well tolerated and appears to produce a higher response rate in this patient population than if the chemotherapy was given without CA4P.  A planned randomised trial will test this hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKPQKWSYY7Sqe0F5ixvZgXfW6udTcc2eaXR-oHyFrDwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjpvVSrsQ%253D%253D&md5=6b960ad4dcccdbbc67ffa9398e85d2be</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdq708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdq708%26sid%3Dliteratum%253Aachs%26aulast%3DZweifel%26aufirst%3DM.%26aulast%3DJayson%26aufirst%3DG.%2BC.%26aulast%3DReed%26aufirst%3DN.%2BS.%26aulast%3DOsborne%26aufirst%3DR.%26aulast%3DHassan%26aufirst%3DB.%26aulast%3DLedermann%26aufirst%3DJ.%26aulast%3DShreeves%26aufirst%3DG.%26aulast%3DPoupard%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DS.-P.%26aulast%3DBalkissoon%26aufirst%3DJ.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26atitle%3DPhase%2520II%2520trial%2520of%2520combretastatin%2520A4%2520phosphate%252C%2520carboplatin%252C%2520and%2520paclitaxel%2520in%2520patients%2520with%2520platinum-resistant%2520ovarian%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26spage%3D2036%26epage%3D2041%26doi%3D10.1093%2Fannonc%2Fmdq708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Nathan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweifel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padhani, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, D.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smythe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirling, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3428</span><span class="NLM_x">–</span> <span class="NLM_lpage">3439</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-3376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1158%2F1078-0432.CCR-11-3376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=22645052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1Oks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3428-3439&author=P.+Nathanauthor=M.+Zweifelauthor=A.+R.+Padhaniauthor=D.-M.+Kohauthor=M.+Ngauthor=D.+J.+Collinsauthor=A.+Harrisauthor=C.+Cardenauthor=J.+Smytheauthor=N.+Fisherauthor=N.+J.+Taylorauthor=J.+J.+Stirlingauthor=S.-P.+Luauthor=M.+O.+Leachauthor=G.+J.+S.+Rustinauthor=I.+Judson&title=Phase+I+trial+of+combretastatin+A4+phosphate+%28CA4P%29+in+combination+with+bevacizumab+in+patients+with+advanced+cancer&doi=10.1158%2F1078-0432.CCR-11-3376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer</span></div><div class="casAuthors">Nathan, Paul; Zweifel, Martin; Padhani, Anwar R.; Koh, Dow-Mu; Ng, Matthew; Collins, David J.; Harris, Adrian; Carden, Craig; Smythe, Jon; Fisher, Nita; Taylor, N. Jane; Stirling, J. James; Lu, Shiao-Ping; Leach, Martin O.; Rustin, Gordon J. S.; Judson, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3428-3439</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The vascular disrupting agent (VDA) combretastatin A4 phosphate (CA4P) induces significant tumor necrosis as a single agent.  Preclin. models have shown that the addn. of an anti-VEGF antibody to a VDA attenuates the revascularization of the surviving tumor rim and thus significantly increases antitumor activity.  Exptl. Design: Patients with advanced solid malignancies received CA4P at 45, 54, or 63 mg/m2 on day 1, day 8, and then every 14 days.  Bevacizumab 10 mg/kg was given on day 8 and at subsequent cycles four hours after CA4P.  Functional imaging with dynamic contrast enhanced-MRI (DCE-MRI) was conducted at baseline, after CA4P alone, and after cycle 1 CA4P + bevacizumab.  Results: A total of 63 mg/m2 CA4P + 10 mg/kg bevacizumab q14 is the recommended phase II dose.  A total of 15 patients were enrolled.  Dose-limiting toxicities were grade III asymptomatic atrial fibrillation and grade IV liver hemorrhage in a patient with a history of hemorrhage.  Most common toxicities were hypertension, headache, lymphopenia, pruritus, and pyrexia.  Asymptomatic electrocardiog. changes were seen in five patients.  Nine of 14 patients experienced disease stabilization.  A patient with ovarian cancer had a CA125 response lasting for more than a year.  DCE-MRI showed statistically significant redns. in tumor perfusion/vascular permeability, which reversed after CA4P alone but which were sustained following bevacizumab.  Circulating CD34+ and CD133+ bone marrow progenitors increased following CA4P as did VEGF and granulocyte colony-stimulating factor levels.  Conclusions: CA4P in combination with bevacizumab appears safe and well tolerated in this dosing schedule.  CA4P induced profound vascular changes, which were maintained by the presence of bevacizumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDhWR6xfmKNbVg90H21EOLACvtfcHk0lhyGH0kaGLV2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1Oks70%253D&md5=b7d93331d8ad4e6d21fff0ddf35fe461</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3376%26sid%3Dliteratum%253Aachs%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DZweifel%26aufirst%3DM.%26aulast%3DPadhani%26aufirst%3DA.%2BR.%26aulast%3DKoh%26aufirst%3DD.-M.%26aulast%3DNg%26aufirst%3DM.%26aulast%3DCollins%26aufirst%3DD.%2BJ.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DCarden%26aufirst%3DC.%26aulast%3DSmythe%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DN.%2BJ.%26aulast%3DStirling%26aufirst%3DJ.%2BJ.%26aulast%3DLu%26aufirst%3DS.-P.%26aulast%3DLeach%26aufirst%3DM.%2BO.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DPhase%2520I%2520trial%2520of%2520combretastatin%2520A4%2520phosphate%2520%2528CA4P%2529%2520in%2520combination%2520with%2520bevacizumab%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3428%26epage%3D3439%26doi%3D10.1158%2F1078-0432.CCR-11-3376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Patterson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweifel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halford, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkissoon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padhani, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span> </span><span class="NLM_article-title">Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1415</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1158%2F1078-0432.CCR-11-2414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=22235096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wlurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1415-1425&author=D.+M.+Pattersonauthor=M.+Zweifelauthor=M.+R.+Middletonauthor=P.+M.+Priceauthor=L.+K.+Folkesauthor=M.+R.+L.+Stratfordauthor=P.+Rossauthor=S.+Halfordauthor=J.+Petersauthor=J.+Balkissoonauthor=D.+J.+Chaplinauthor=A.+R.+Padhaniauthor=G.+J.+S.+Rustin&title=Phase+I+clinical+and+pharmacokinetic+evaluation+of+the+vascular-disrupting+agent+OXi4503+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-11-2414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Patterson, Dan M.; Zweifel, Martin; Middleton, Mark R.; Price, Patricia M.; Folkes, Lisa K.; Stratford, Michael R. L.; Ross, Phil; Halford, Sarah; Peters, Jane; Balkissoon, Jai; Chaplin, Dai J.; Padhani, Anwar R.; Rustin, Gordon J. S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1415-1425</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Preclin. studies show that OXi4503 (combretastatin A1 diphosphate, CA1P) is more potent than other clin. evaluated vascular-disrupting agents.  Exptl. Design: Escalating doses of OXi4503 were given i.v. over 10 min on days 1, 8, and 15 every 28 days to patients with advanced solid tumors.  RESULTS: Doses were escalated in single-patient cohorts from 0.06 to 1.92 mg/m2, then expanded cohorts to 15.4 mg/m2 in 43 patients.  Common adverse drug reactions were hypertension, tumor pain, anemia, lymphopenia, and easily controllable nausea/vomiting and fatigue.  Five patients experienced different drug-related dose-limiting toxicities, atrial fibrillation, increased troponin, blurred vision, diplopia, and tumor lysis.  Prophylactic amlodipine failed to prevent adverse events.  Pharmacokinetics showed dose-dependent linear increases in peak plasma concns. and area under the curve value of OXi4503.  One partial response was seen in a heavily pretreated patient with ovarian cancer.  Dynamic contrast-enhanced MRI confirmed a dose effect and showed significant antivascular effects in 10 of 13 patients treated at doses of 11 mg/m2 or higher.  CONCLUSIONS: The max. tolerated dose was 8.5 mg/m2 but escalation to 14 mg/m2 was possible with only temporary reversible cerebrovascular toxicity by excluding hypertensive patients.  As a tumor response was seen at 14 mg/m2 and max. tumor perfusion redns. were seen at doses of 11 mg/m2 or higher, the recommended phase II dose is from 11 to 14 mg/m2.  Clin Cancer Res; 18(5); 1415-25.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgz59a0dQud7Vg90H21EOLACvtfcHk0lii05mfmTjnhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wlurc%253D&md5=9414d480dc5eef26ec066054dc96b124</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2414%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DD.%2BM.%26aulast%3DZweifel%26aufirst%3DM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DPrice%26aufirst%3DP.%2BM.%26aulast%3DFolkes%26aufirst%3DL.%2BK.%26aulast%3DStratford%26aufirst%3DM.%2BR.%2BL.%26aulast%3DRoss%26aufirst%3DP.%26aulast%3DHalford%26aufirst%3DS.%26aulast%3DPeters%26aufirst%3DJ.%26aulast%3DBalkissoon%26aufirst%3DJ.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DPadhani%26aufirst%3DA.%2BR.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26atitle%3DPhase%2520I%2520clinical%2520and%2520pharmacokinetic%2520evaluation%2520of%2520the%2520vascular-disrupting%2520agent%2520OXi4503%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1415%26epage%3D1425%26doi%3D10.1158%2F1078-0432.CCR-11-2414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohena, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">Structure-activity relationship and in vitro and in vivo evaluation of the potent cytotoxic anti-microtubule agent <i>N</i>-(4-methoxyphenyl)-<i>N</i>,2,6-trimethyl-6,7-dihydro-5<i>H</i>-cyclo-penta[<i>d</i>]pyrimidin-4-aminium chloride and its analogues as antitumor agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6829</span><span class="NLM_x">–</span> <span class="NLM_lpage">6844</span><span class="refDoi"> DOI: 10.1021/jm400639z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400639z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6829-6844&author=A.+Gangjeeauthor=Y.+Zhaoauthor=S.+Raghavanauthor=C.+C.+Rohenaauthor=S.+L.+Mooberryauthor=E.+Hamel&title=Structure-activity+relationship+and+in+vitro+and+in+vivo+evaluation+of+the+potent+cytotoxic+anti-microtubule+agent+N-%284-methoxyphenyl%29-N%2C2%2C6-trimethyl-6%2C7-dihydro-5H-cyclo-penta%5Bd%5Dpyrimidin-4-aminium+chloride+and+its+analogues+as+antitumor+agents&doi=10.1021%2Fjm400639z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm400639z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400639z%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DRohena%26aufirst%3DC.%2BC.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DStructure-activity%2520relationship%2520and%2520in%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%2520the%2520potent%2520cytotoxic%2520anti-microtubule%2520agent%2520N-%25284-methoxyphenyl%2529-N%252C2%252C6-trimethyl-6%252C7-dihydro-5H-cyclo-penta%255Bd%255Dpyrimidin-4-aminium%2520chloride%2520and%2520its%2520analogues%2520as%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6829%26epage%3D6844%26doi%3D10.1021%2Fjm400639z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Prota, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargsten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buey, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pohlmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinelt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span> </span><span class="NLM_article-title">The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">426</span><span class="NLM_x">, </span> <span class="NLM_fpage">1848</span><span class="NLM_x">–</span> <span class="NLM_lpage">1860</span><span class="refDoi"> DOI: 10.1016/j.jmb.2014.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1016%2Fj.jmb.2014.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=24530796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2014&pages=1848-1860&author=A.+E.+Protaauthor=F.+Danelauthor=F.+Bachmannauthor=K.+Bargstenauthor=R.+M.+Bueyauthor=J.+Pohlmannauthor=S.+Reineltauthor=H.+Laneauthor=M.+O.+Steinmetz&title=The+novel+microtubule-destabilizing+drug+BAL27862+binds+to+the+colchicine+site+of+tubulin+with+distinct+effects+on+microtubule+organization&doi=10.1016%2Fj.jmb.2014.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization</span></div><div class="casAuthors">Prota, Andrea E.; Danel, Franck; Bachmann, Felix; Bargsten, Katja; Buey, Ruben M.; Pohlmann, Jens; Reinelt, Stefan; Lane, Heidi; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1848-1860</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Microtubule-targeting agents are widely used for the treatment of cancer and as tool compds. to study the microtubule cytoskeleton.  BAL27862 is a novel microtubule-destabilizing drug that is currently undergoing phase I clin. evaluation as the prodrug BAL101553.  The drug is a potent inhibitor of tumor cell growth and shows a promising activity profile in a panel of human cancer models resistant to clin. relevant microtubule-targeting agents.  Here, we evaluated the mol. mechanism of the tubulin-BAL27862 interaction using a combination of cell biol., biochem. and structural biol. methods.  Tubulin-binding assays revealed that BAL27862 potently inhibited tubulin assembly at 37 °C with an IC50 of 1.4 μM and bound to unassembled tubulin with a stoichiometry of 1 mol/mol tubulin and a dissocn. const. of 244 ± 30 nM.  BAL27862 bound to tubulin independently of vinblastine, without the formation of tubulin oligomers.  The kinetics of BAL27862 binding to tubulin were distinct from those of colchicine, with evidence of competition between BAL27862 and colchicine for binding.  Detn. of the tubulin-BAL27862 structure by X-ray crystallog. demonstrated that BAL27862 binds to the same site as colchicine at the intradimer interface.  Comparison of crystal structures of tubulin-BAL27862 and tubulin-colchicine complexes shows that the binding mode of BAL27862 to tubulin is similar to that of colchicine.  However, comparative analyses of the effects of BAL27862 and colchicine on the microtubule mitotic spindle and in tubulin protease-protection expts. suggest different outcomes of tubulin binding.  Taken together, our data define BAL27862 as a potent, colchicine site-binding, microtubule-destabilizing agent with distinct effects on microtubule organization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIsVCA_6rcHLVg90H21EOLACvtfcHk0lii05mfmTjnhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlSrtrs%253D&md5=147ddbbfe5b90157cb8b2e04e1791668</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2014.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2014.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DDanel%26aufirst%3DF.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DBuey%26aufirst%3DR.%2BM.%26aulast%3DPohlmann%26aufirst%3DJ.%26aulast%3DReinelt%26aufirst%3DS.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DThe%2520novel%2520microtubule-destabilizing%2520drug%2520BAL27862%2520binds%2520to%2520the%2520colchicine%2520site%2520of%2520tubulin%2520with%2520distinct%2520effects%2520on%2520microtubule%2520organization%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D426%26spage%3D1848%26epage%3D1860%26doi%3D10.1016%2Fj.jmb.2014.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span> <span class="citation_source-book">Molecular Operating Environment</span> (MOE 2013.08); <span class="NLM_publisher-name">Chemical Computing Group, Inc.</span>: <span class="NLM_publisher-loc">Montreal, Quebec, Canada</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span><a href="http://www.chemcomp.com" class="extLink">www.chemcomp.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Molecular+Operating+Environment+%28MOE+2013.08%29%3B+Chemical+Computing+Group%2C+Inc.%3A+Montreal%2C+Quebec%2C+Canada%2C+2013%3B+www.chemcomp.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DMolecular%2520Operating%2520Environment%26pub%3DChemical%2520Computing%2520Group%252C%2520Inc%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Gewald, K.</span><span> </span><span class="NLM_article-title">Heterocycles from CH-acidic nitriles. IX. Reaction of α-hydroxy ketones with malononitrile</span> <span class="citation_source-journal">Chem. Ber.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1966</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">1002</span><span class="NLM_x">–</span> <span class="NLM_lpage">1007</span><span class="refDoi"> DOI: 10.1002/cber.19660990340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1002%2Fcber.19660990340" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1966&pages=1002-1007&author=K.+Gewald&title=Heterocycles+from+CH-acidic+nitriles.+IX.+Reaction+of+%CE%B1-hydroxy+ketones+with+malononitrile&doi=10.1002%2Fcber.19660990340"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcber.19660990340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcber.19660990340%26sid%3Dliteratum%253Aachs%26aulast%3DGewald%26aufirst%3DK.%26atitle%3DHeterocycles%2520from%2520CH-acidic%2520nitriles.%2520IX.%2520Reaction%2520of%2520%25CE%25B1-hydroxy%2520ketones%2520with%2520malononitrile%26jtitle%3DChem.%2520Ber.%26date%3D1966%26volume%3D99%26spage%3D1002%26epage%3D1007%26doi%3D10.1002%2Fcber.19660990340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Tinley, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leal, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randall-Hlubek, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cessac, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkens, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Novel 2-methoxyestradiol analogues with antitumor activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1538</span><span class="NLM_x">–</span> <span class="NLM_lpage">1549</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=1538-1549&author=T.+L.+Tinleyauthor=R.+M.+Lealauthor=D.+A.+Randall-Hlubekauthor=J.+W.+Cessacauthor=L.+R.+Wilkensauthor=P.+N.+Raoauthor=S.+L.+Mooberry&title=Novel+2-methoxyestradiol+analogues+with+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTinley%26aufirst%3DT.%2BL.%26aulast%3DLeal%26aufirst%3DR.%2BM.%26aulast%3DRandall-Hlubek%26aufirst%3DD.%2BA.%26aulast%3DCessac%26aufirst%3DJ.%2BW.%26aulast%3DWilkens%26aufirst%3DL.%2BR.%26aulast%3DRao%26aufirst%3DP.%2BN.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DNovel%25202-methoxyestradiol%2520analogues%2520with%2520antitumor%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D1538%26epage%3D1549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Perez, E. A.</span><span> </span><span class="NLM_article-title">Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2086</span><span class="NLM_x">–</span> <span class="NLM_lpage">2095</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1158%2F1535-7163.MCT-09-0366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=19671735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFCnurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2086-2095&author=E.+A.+Perez&title=Microtubule+inhibitors%3A+Differentiating+tubulin-inhibiting+agents+based+on+mechanisms+of+action%2C+clinical+activity%2C+and+resistance&doi=10.1158%2F1535-7163.MCT-09-0366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance</span></div><div class="casAuthors">Perez, Edith A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2086-2095</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Microtubules are important cellular targets for anticancer therapy because of their key role in mitosis.  Microtubule inhibitors (MTI) such as taxanes, vinca alkaloids, and epothilones stabilize or destabilize microtubules, thereby suppressing microtubule dynamics required for proper mitotic function, effectively blocking cell cycle progression and resulting in apoptosis.  In spite of their antitumor activity, innate or acquired drug resistance to MTIs such as the taxanes is common, limiting their overall clin. efficacy.  Further insight into the mechanisms of action of microtubule-targeting drugs has lead to the discovery of novel agents that may provide higher efficacy with limited toxicity and help overcome resistance to conventional MTIs.  This review will focus on the different mechanisms of action of MTIs, potential factors related to resistance and tolerability, and will discuss the recent approval as well as the development of new antineoplastic agents. [Mol Cancer Ther 2009;8(8):2086-95].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1HM8JP4QG8LVg90H21EOLACvtfcHk0ljJUsB5mMCiBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFCnurw%253D&md5=1d8dec9ed6c0f061032cec57c96c833e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0366%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DE.%2BA.%26atitle%3DMicrotubule%2520inhibitors%253A%2520Differentiating%2520tubulin-inhibiting%2520agents%2520based%2520on%2520mechanisms%2520of%2520action%252C%2520clinical%2520activity%252C%2520and%2520resistance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2086%26epage%3D2095%26doi%3D10.1158%2F1535-7163.MCT-09-0366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Chiou, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, A.</span><span> </span><span class="NLM_article-title">Comparing the relationship of taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer</span> <span class="citation_source-journal">Lung</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">181</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1007/s00408-003-1029-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1007%2Fs00408-003-1029-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2003&pages=267-273&author=J.+F.+Chiouauthor=J.+A.+Liangauthor=W.+H.+Hsuauthor=J.+J.+Wangauthor=S.+T.+Hoauthor=A.+Kao&title=Comparing+the+relationship+of+taxol-based+chemotherapy+response+with+P-glycoprotein+and+lung+resistance-related+protein+expression+in+non-small+cell+lung+cancer&doi=10.1007%2Fs00408-003-1029-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2Fs00408-003-1029-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00408-003-1029-7%26sid%3Dliteratum%253Aachs%26aulast%3DChiou%26aufirst%3DJ.%2BF.%26aulast%3DLiang%26aufirst%3DJ.%2BA.%26aulast%3DHsu%26aufirst%3DW.%2BH.%26aulast%3DWang%26aufirst%3DJ.%2BJ.%26aulast%3DHo%26aufirst%3DS.%2BT.%26aulast%3DKao%26aufirst%3DA.%26atitle%3DComparing%2520the%2520relationship%2520of%2520taxol-based%2520chemotherapy%2520response%2520with%2520P-glycoprotein%2520and%2520lung%2520resistance-related%2520protein%2520expression%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DLung%26date%3D2003%26volume%3D181%26spage%3D267%26epage%3D273%26doi%3D10.1007%2Fs00408-003-1029-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Trock, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonessa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, R.</span><span> </span><span class="NLM_article-title">Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">–</span> <span class="NLM_lpage">931</span><span class="refDoi"> DOI: 10.1093/jnci/89.13.917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1093%2Fjnci%2F89.13.917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=9214671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A280%3ADyaK2szlslensA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=917-931&author=B.+J.+Trockauthor=F.+Leonessaauthor=R.+Clarke&title=Multidrug+resistance+in+breast+cancer%3A+A+meta-analysis+of+MDR1%2Fgp170+expression+and+its+possible+functional+significance&doi=10.1093%2Fjnci%2F89.13.917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance</span></div><div class="casAuthors">Trock B J; Leonessa F; Clarke R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">917-31</span>
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">BACKGROUND:  P-glycoprotein (gp170; encoded by the MDR1 gene [also known as PGY1]) is a membrane protein capable of exporting a variety of anticancer drugs from cells.  MDR1/gp170 expression has been studied in breast cancer, but the prevalence of this expression and its role in breast tumor drug resistance are unclear.  PURPOSE:  We conducted a critical review and meta-analysis of studies examining MDR1/gp170 expression in breast cancer to estimate the likely prevalence and clinical relevance of this expression.  We also explored reasons for differences in the findings from individual studies.  METHODS:  Published papers on MDR1/gp170 expression in breast cancer were identified by searching several literature databases and reviewing the bibliographies of identified papers.  Variability across the studies in the proportion of tumors expressing MDR1/gp170 was assessed by use of chi-squared tests of homogeneity, weighted means, and weighted linear regression.  Pooled relative risks (RRs) for the association between the induction of MDR1/gp170 expression and prior chemotherapy and associations between MDR1/gp170 expression and several clinical outcomes were estimated by use of Mantel-Haenszel methods.  Heterogeneity among the pooled RRs was explored by use of chi-squared tests.  Reported P values are two-sided.  RESULTS:  Thirty-one studies were identified and evaluated.  The proportion of breast tumors expressing MDR1/gp170 in all of the studies was 41.2%, but there was substantial heterogeneity in the values across individual studies (P<.0001).  Regression analyses demonstrated that a considerable portion of the observed heterogeneity was a consequence of the change, over time, from RNA hybridization-based assays to immunohistochemistry-based assays of MDR1/gp170 expression.  Measuring MDR1/gp170 expression before versus after chemotherapy and use of cytotoxic drugs that are not substrates for gp170 also contributed to the heterogeneity.  Treatment with chemotherapeutic drugs or hormonal agents was associated with an increase in the proportion of tumors expressing MDR1/gp170 (RR = 1.77; 95% confidence interval [CI] = 1.46-2.15).  Patients with tumors expressing MDR1/gp170 were three times more likely to fail to respond to chemotherapy than patients whose tumors were MDR1/gp170 negative (RR = 3.21; 95% CI = 2.28-4.51); this RR increased to 4.19 (95% CI = 2.71-6.47) when considering only patients whose tumor expression of MDR1/gp170 was measured after chemotherapy.  MDR1/gp170 expression was not associated with lymph node metastases, estrogen receptor status, tumor size, tumor grade, or tumor histology.  CONCLUSIONS AND IMPLICATIONS:  MDR1/gp170 expression in breast tumors is associated with treatment and with a poor response to chemotherapy.  The data are consistent with a contributory role for MDR1/gp170 in the multidrug resistance in some breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQbw1eYY31XbVvAgqb2vdc5fW6udTcc2ebFMU_oJ5WVErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2szlslensA%253D%253D&md5=b575e441d936b05ec924ead0ef4ccd4a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F89.13.917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F89.13.917%26sid%3Dliteratum%253Aachs%26aulast%3DTrock%26aufirst%3DB.%2BJ.%26aulast%3DLeonessa%26aufirst%3DF.%26aulast%3DClarke%26aufirst%3DR.%26atitle%3DMultidrug%2520resistance%2520in%2520breast%2520cancer%253A%2520A%2520meta-analysis%2520of%2520MDR1%252Fgp170%2520expression%2520and%2520its%2520possible%2520functional%2520significance%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1997%26volume%3D89%26spage%3D917%26epage%3D931%26doi%3D10.1093%2Fjnci%2F89.13.917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Binkhathlan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavasanifar, A.</span><span> </span><span class="NLM_article-title">P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: Current status and future perspectives</span> <span class="citation_source-journal">Curr. Cancer Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">326</span><span class="NLM_x">–</span> <span class="NLM_lpage">346</span><span class="refDoi"> DOI: 10.2174/15680096113139990076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.2174%2F15680096113139990076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=23369096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVOjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=326-346&author=Z.+Binkhathlanauthor=A.+Lavasanifar&title=P-glycoprotein+inhibition+as+a+therapeutic+approach+for+overcoming+multidrug+resistance+in+cancer%3A+Current+status+and+future+perspectives&doi=10.2174%2F15680096113139990076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives</span></div><div class="casAuthors">Binkhathlan, Ziyad; Lavasanifar, Afsaneh</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">326-346</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  One of the major causes of failure in cancer chemotherapy is multidrug resistance (MDR), where cancer cells simultaneously become resistant to different anticancer drugs.  Over-expression of membrane efflux pumps like P-glycoprotein (P-gp) that recognizes different chemotherapeutic agents and transports them out of the cell, plays a major role in MDR.  The shortcoming of P-gp inhibitors in clinic was attributed to their non-specific action on P-gp and/or non-selective distribution to non-target organs that leads to intolerable side effects by the P-gp inhibitor at doses required for P-gp inhibition upon systemic administration.  Another major issue is the reduced elimination of P-gp substrates (e.g. anticancer drugs) and intolerable toxicities by anticancer drugs when co-administered with P-gp inhibitors.  To overcome these shortcomings, new generation of P-gp inhibitors with improved specificity for P-gp were developed.  More recently, attention was paid to the use of drug delivery systems primarily to restrict P-gp inhibition to tumor and reduce the non-selective inhibition of P-gp in non-target organs.  This review will provide an overview and update on the status of P-gp inhibition approaches and the role of drug delivery systems in overcoming P-gp mediated MDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6kCA4RDN2s7Vg90H21EOLACvtfcHk0liaCdmsO4KyMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVOjsbY%253D&md5=9fc1e50504313ae7735049fcaadcb9ff</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2174%2F15680096113139990076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15680096113139990076%26sid%3Dliteratum%253Aachs%26aulast%3DBinkhathlan%26aufirst%3DZ.%26aulast%3DLavasanifar%26aufirst%3DA.%26atitle%3DP-glycoprotein%2520inhibition%2520as%2520a%2520therapeutic%2520approach%2520for%2520overcoming%2520multidrug%2520resistance%2520in%2520cancer%253A%2520Current%2520status%2520and%2520future%2520perspectives%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2013%26volume%3D13%26spage%3D326%26epage%3D346%26doi%3D10.2174%2F15680096113139990076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Leonard, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fojo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, S. E.</span><span> </span><span class="NLM_article-title">The role of ABC transporters in clinical practice</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">411</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span><span class="refDoi"> DOI: 10.1634/theoncologist.8-5-411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1634%2Ftheoncologist.8-5-411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=14530494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslyls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=411-424&author=G.+D.+Leonardauthor=T.+Fojoauthor=S.+E.+Bates&title=The+role+of+ABC+transporters+in+clinical+practice&doi=10.1634%2Ftheoncologist.8-5-411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ABC transporters in clinical practice</span></div><div class="casAuthors">Leonard, Gregory D.; Fojo, Tito; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">411-424</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Drug resistance remains one of the primary causes of suboptimal outcomes in cancer therapy.  ATP-binding cassette (ABC) transporters are a family of transporter proteins that contribute to drug resistance via ATP-dependent drug efflux pumps.  P-glycoprotein (P-gp), encoded by the MDR1 gene, is an ABC transporter normally involved in the excretion of toxins from cells.  It also confers resistance to certain chemotherapeutic agents.  P-gp is overexpressed at baseline in chemotherapy-resistant tumors, such as colon and kidney cancers, and is upregulated after disease progression following chemotherapy in malignancies such as leukemia and breast cancer.  Other transporter proteins mediating drug resistance include those in the multidrug-resistance-assocd. protein (MRP) family, notably MRP1, and ABCG2.  These transporters are also involved in normal physiol. functions.  The expressions of MRP family members and ABCG2 were not well worked out in cancer.  Increased drug accumulation and drug resistance reversal with P-gp inhibitors were well documented in vitro, but only suggested in clin. trials.  Limitations in the design of early resistance reversal trials contributed to disappointing results.  Despite this, 3 randomized trials have shown statistically significant benefits with the use of a P-gp inhibitor in combination with chemotherapy.  Improved diagnostic techniques aimed at the selection of patients with tumors that express P-gp should result in more successful outcomes.  Further optimism is warranted with the advent of potent, nontoxic inhibitors and new treatment strategies, including the combination of new targeted therapies with therapies aimed at the prevention of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr317MZ9jawCbVg90H21EOLACvtfcHk0liaCdmsO4KyMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslyls74%253D&md5=b474f45fd5c45962acfff61840c04a6b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.8-5-411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.8-5-411%26sid%3Dliteratum%253Aachs%26aulast%3DLeonard%26aufirst%3DG.%2BD.%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DThe%2520role%2520of%2520ABC%2520transporters%2520in%2520clinical%2520practice%26jtitle%3DOncologist%26date%3D2003%26volume%3D8%26spage%3D411%26epage%3D424%26doi%3D10.1634%2Ftheoncologist.8-5-411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Fojo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menefee, M.</span><span> </span><span class="NLM_article-title">Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.1093/annonc/mdm172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1093%2Fannonc%2Fmdm172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=17656560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A280%3ADC%252BD2sngs1SitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&pages=3-8&author=T.+Fojoauthor=M.+Menefee&title=Mechanisms+of+multidrug+resistance%3A+The+potential+role+of+microtubule-stabilizing+agents&doi=10.1093%2Fannonc%2Fmdm172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents</span></div><div class="casAuthors">Fojo T; Menefee M</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">18 Suppl 5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">v3-8</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">Antimitotic agents that target the dynamic equilibrium between the microtubule polymer and tubulin heterodimers are key components of chemotherapeutic regimens for various solid tumors.  These agents can be divided into two major classes based on their effect on microtubule polymerization and the mass of microtubule polymers: those that inhibit polymerization, such as the vinca alkaloids and those that stabilize microtubules, such as the taxanes and epothilones.  The taxanes paclitaxel (Taxol) and docetaxel (Taxotere) were the first antimicrotubule agents approved for use in solid tumors, but their usefulness is often limited by development of drug resistance.  The epothilones are distinguished from the taxanes structurally and functionally and have been shown in vitro and in preclinical models to have superior potency to the taxanes.  The epothilones are not susceptible to P-glycoprotein-mediated efflux and have shown activity against taxane-resistant tumors.  Other natural-product microtubule-stabilizing agents also have promising pharmacologic profiles.  This article discusses mechanisms of drug resistance and summarizes scientific and clinical data supporting the potential of novel microtubule-stabilizing agents for achieving broad antitumor efficacy without the emergence of drug resistance.  The ability to reduce the development of resistance with the epothilones and other microtubule-stabilizing agents may provide additional treatment options at the time of presentation and in the setting of taxane resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTF5uhi21MM5z0O18WR3iAofW6udTcc2eYTDJFeKRjcAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sngs1SitA%253D%253D&md5=ddbd9ea289b1a1cb1f79d6be860f2bfa</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdm172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdm172%26sid%3Dliteratum%253Aachs%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DMenefee%26aufirst%3DM.%26atitle%3DMechanisms%2520of%2520multidrug%2520resistance%253A%2520The%2520potential%2520role%2520of%2520microtubule-stabilizing%2520agents%26jtitle%3DAnn.%2520Oncol.%26date%3D2007%26volume%3D18%26spage%3D3%26epage%3D8%26doi%3D10.1093%2Fannonc%2Fmdm172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scagliotti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danenberg, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, R. V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bepler, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novello, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooc, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boni, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marinis, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marangolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozzelino, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costanzo, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rinaldi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salonga, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, C.</span><span> </span><span class="NLM_article-title">Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3548</span><span class="NLM_x">–</span> <span class="NLM_lpage">3553</span><span class="refDoi"> DOI: 10.1038/sj.onc.1206419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1038%2Fsj.onc.1206419" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=3548-3553&author=R.+Rosellauthor=G.+Scagliottiauthor=K.+D.+Danenbergauthor=R.+V.+N.+Lordauthor=G.+Beplerauthor=S.+Novelloauthor=J.+Coocauthor=L.+Crinoauthor=J.+J.+Sanchezauthor=M.+Taronauthor=C.+Boniauthor=F.+D.+Marinisauthor=M.+Tonatoauthor=M.+Marangoloauthor=F.+Gozzelinoauthor=F.+D.+Costanzoauthor=M.+Rinaldiauthor=D.+Salongaauthor=C.+Stephens&title=Transcripts+in+pretreatment+biopsies+from+a+three-arm+randomized+trial+in+metastatic+non-small-cell+lung+cancer&doi=10.1038%2Fsj.onc.1206419"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1206419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1206419%26sid%3Dliteratum%253Aachs%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DScagliotti%26aufirst%3DG.%26aulast%3DDanenberg%26aufirst%3DK.%2BD.%26aulast%3DLord%26aufirst%3DR.%2BV.%2BN.%26aulast%3DBepler%26aufirst%3DG.%26aulast%3DNovello%26aufirst%3DS.%26aulast%3DCooc%26aufirst%3DJ.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DJ.%2BJ.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DBoni%26aufirst%3DC.%26aulast%3DMarinis%26aufirst%3DF.%2BD.%26aulast%3DTonato%26aufirst%3DM.%26aulast%3DMarangolo%26aufirst%3DM.%26aulast%3DGozzelino%26aufirst%3DF.%26aulast%3DCostanzo%26aufirst%3DF.%2BD.%26aulast%3DRinaldi%26aufirst%3DM.%26aulast%3DSalonga%26aufirst%3DD.%26aulast%3DStephens%26aufirst%3DC.%26atitle%3DTranscripts%2520in%2520pretreatment%2520biopsies%2520from%2520a%2520three-arm%2520randomized%2520trial%2520in%2520metastatic%2520non-small-cell%2520lung%2520cancer%26jtitle%3DOncogene%26date%3D2003%26volume%3D22%26spage%3D3548%26epage%3D3553%26doi%3D10.1038%2Fsj.onc.1206419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Dumontet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaac, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Souquet, P.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bejui-Thivolet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacheco, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peloux, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankfurter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luduena, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perol, M.</span><span> </span><span class="NLM_article-title">Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy</span> <span class="citation_source-journal">Bull. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=15749640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A280%3ADC%252BD2M7hslyntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2005&pages=25-30&author=C.+Dumontetauthor=S.+Isaacauthor=P.-J.+Souquetauthor=F.+Bejui-Thivoletauthor=Y.+Pachecoauthor=N.+Pelouxauthor=A.+Frankfurterauthor=R.+Luduenaauthor=M.+Perol&title=Expression+of+class+III+beta+tubulin+in+non-small+cell+lung+cancer+is+correlated+with+resistance+to+taxane+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy</span></div><div class="casAuthors">Dumontet Charles; Isaac Sylvie; Souquet Pierre-Jean; Bejui-Thivolet Francoise; Pacheco Yves; Peloux Nadine; Frankfurter Anthony; Luduena Richard; Perol Maurice</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin du cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">E25-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This study determined the prevalence and the prognostic value of the expression of microtubule components in tumors of 19 patients with non small cell lung cancer receiving taxane-based regimens.  Patient samples were stained with antibodies directed against total beta tubulin, classes I, II and III beta tubulin isotypes, delta2 alpha tubulin, tau protein, and the P-gp protein involved in the classical multidrug resistance phenotype.  All tumors were stained with pan-beta tubulin antibody and class I tubulin isotype.  A majority of the tumor samples expressed class II and class III, although the percentage of positive cells varied significantly between tumors. delta2 alpha tubulin, tau protein and Pgp protein were found in only one tumor sample each.  Progression-free survival was shorter (41 days) in patients whose tumors expressed high levels of class III tubulin isotype in comparison to patients with low levels (288 days, p = 0.02).  There were 2 responses to chemotherapy among 9 patients (22%) with high levels of class III tubulin vs. 6 among 10 patients (60%) with low levels of expression (Fisher exact test: p = 0.11).  These data suggest that high expression of class III tubulin by tumor cells is associated with poor prognosis in patients with NSCLC receiving a taxane-based regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQuPQNJ4K3goDMsgLhIoICsfW6udTcc2eamTG2xCyi7nbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7hslyntA%253D%253D&md5=db24a04afdf73ba06c4c152ecd7dc5f0</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DIsaac%26aufirst%3DS.%26aulast%3DSouquet%26aufirst%3DP.-J.%26aulast%3DBejui-Thivolet%26aufirst%3DF.%26aulast%3DPacheco%26aufirst%3DY.%26aulast%3DPeloux%26aufirst%3DN.%26aulast%3DFrankfurter%26aufirst%3DA.%26aulast%3DLuduena%26aufirst%3DR.%26aulast%3DPerol%26aufirst%3DM.%26atitle%3DExpression%2520of%2520class%2520III%2520beta%2520tubulin%2520in%2520non-small%2520cell%2520lung%2520cancer%2520is%2520correlated%2520with%2520resistance%2520to%2520taxane%2520chemotherapy%26jtitle%3DBull.%2520Cancer%26date%3D2005%26volume%3D92%26spage%3D25%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Sève, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaac, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trédan, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Souquet, P.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachéco, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérol, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafanéchère, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penet, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peiller, E.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumontet, C.</span><span> </span><span class="NLM_article-title">Expression of class III β-tubulin is predictive of patient outcome in patients with non–small cell lung cancer receiving vinorelbine-based chemotherapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5481</span><span class="NLM_x">–</span> <span class="NLM_lpage">5486</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1158%2F1078-0432.CCR-05-0285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=16061864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvFSmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=5481-5486&author=P.+S%C3%A8veauthor=S.+Isaacauthor=O.+Tr%C3%A9danauthor=P.-J.+Souquetauthor=Y.+Pach%C3%A9coauthor=M.+P%C3%A9rolauthor=L.+Lafan%C3%A9ch%C3%A8reauthor=A.+Penetauthor=E.-L.+Peillerauthor=C.+Dumontet&title=Expression+of+class+III+%CE%B2-tubulin+is+predictive+of+patient+outcome+in+patients+with+non%E2%80%93small+cell+lung+cancer+receiving+vinorelbine-based+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non-Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy</span></div><div class="casAuthors">Seve, Pascal; Isaac, Sylvie; Tredan, Olivier; Souquet, Pierre-Jean; Pacheco, Yves; Perol, Maurice; Lafanechere, Laurence; Penet, Aurelie; Peiller, Eva-Laure; Dumontet, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5481-5486</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: To det. the prevalence and the prognostic value of microtubule component expression in tumors of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).  Exptl. Design: Expression of microtubular components was immunohistochem. examd. in 93 tumor samples from untreated patients with stage III and IV NSCLC.  All patients received vinorelbine-based chemotherapy.  Response to chemotherapy, progression-free survival, and overall survival were correlated with the expression of microtubule proteins.  RESULTS: The response rate was 27.3% (21 partial responses among 77 valuable patients).  Although expression of microtubule components was not assocd. with the response rate, high class III {szligbeta}-tubulin expression was correlated with resistance to vinorelbine, defined as disease progression under treatment.  Patients whose tumors expressed high levels of class III β-tubulin isotype had shorter progression-free survival and overall survival (P = 0.002 and 0.001, resp.).  High Δ2 α-tubulin expression was assocd. with a shorter overall survival (P = 0.018).  Tubulin II levels were not found to be correlated with patient outcome.  A multivariate anal., taking into account sex, age, histol., stage, wt. loss, and class II β-tubulin, class III β-tubulin, and Δ2 α-tubulin levels, confirmed that class III {szligbeta}-tubulin expression was independently correlated with progression-free survival (P = 0.04) and overall survival (P = 0.012).  CONCLUSIONS: These findings suggest that a high level of expression of class III {szligbeta}-tubulin in tumor cells is assocd. with resistance to vinorelbine and a poor prognosis in patients with NSCLC receiving vinorelbine-based chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQLbZO_aEZCLVg90H21EOLACvtfcHk0liPyUCOV7qJOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvFSmtbc%253D&md5=144a54ce9966814240d86f5b92dbc2e6</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0285%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A8ve%26aufirst%3DP.%26aulast%3DIsaac%26aufirst%3DS.%26aulast%3DTr%25C3%25A9dan%26aufirst%3DO.%26aulast%3DSouquet%26aufirst%3DP.-J.%26aulast%3DPach%25C3%25A9co%26aufirst%3DY.%26aulast%3DP%25C3%25A9rol%26aufirst%3DM.%26aulast%3DLafan%25C3%25A9ch%25C3%25A8re%26aufirst%3DL.%26aulast%3DPenet%26aufirst%3DA.%26aulast%3DPeiller%26aufirst%3DE.-L.%26aulast%3DDumontet%26aufirst%3DC.%26atitle%3DExpression%2520of%2520class%2520III%2520%25CE%25B2-tubulin%2520is%2520predictive%2520of%2520patient%2520outcome%2520in%2520patients%2520with%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%2520receiving%2520vinorelbine-based%2520chemotherapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D5481%26epage%3D5486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Tommasi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacalamita, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellizzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedele, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiriatti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomssen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendzierski, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latorre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorusso, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schittulli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zito, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavallaris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paradiso, A.</span><span> </span><span class="NLM_article-title">Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β-tubulins</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">2078</span><span class="NLM_x">–</span> <span class="NLM_lpage">2085</span><span class="refDoi"> DOI: 10.1002/ijc.22557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1002%2Fijc.22557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=17285590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkt1Oitbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2007&pages=2078-2085&author=S.+Tommasiauthor=A.+Mangiaauthor=R.+Lacalamitaauthor=A.+Bellizziauthor=V.+Fedeleauthor=A.+Chiriattiauthor=C.+Thomssenauthor=N.+Kendzierskiauthor=A.+Latorreauthor=V.+Lorussoauthor=F.+Schittulliauthor=F.+Zitoauthor=M.+Kavallarisauthor=A.+Paradiso&title=Cytoskeleton+and+paclitaxel+sensitivity+in+breast+cancer%3A+The+role+of+%CE%B2-tubulins&doi=10.1002%2Fijc.22557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of β-tubulins</span></div><div class="casAuthors">Tommasi, Stefania; Mangia, Anita; Lacalamita, Rosanna; Bellizzi, Antonia; Fedele, Vita; Chiriatti, Annalisa; Thomssen, Christopher; Kendzierski, Nancy; Latorre, Agnese; Lorusso, Vito; Schittulli, Francesco; Zito, Francesco; Kavallaris, Maria; Paradiso, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2078-2085</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The antineoplastic effect of paclitaxel is mainly related to its ability to bind the β subunit of tubulin, thus preventing tubulin chain depolarization and inducing apoptosis.  The relevance of the Class 1 β-tubulin characteristics have also been confirmed in the clin. setting where mutations of paclitaxel-binding site of β-tubulin Class I have been related to paclitaxel resistance in non small cell lung and ovarian cancers.  In the present study, we verified the hypothesis of a relationship between mol. alterations of β-tubulin Class I and paclitaxel sensitivity in a panel of breast cell lines with different drug IC50.  The Class I β-tubulin gene cDNA has been sequenced detecting heterozygous missense mutations (exon 1 and 4) only in MCF-7 and SK-BR-3 lines.  Furthermore, the expression (at both mRNA and protein level) of the different isotypes have been analyzed demonstrating an assocn. between low cell sensitivity to paclitaxel and Class III β-tubulin expression increasing.  Antisense oligonucleotide (ODN) expts. confirmed that the inhibition of Class III β-tubulin could at least partially increase paclitaxel-chemosensitivity.  The hypothesis of a relationship between β-tubulin tumor expression and paclitaxel clin. response has been finally verified in a series of 92 advanced breast cancer patients treated with a first line paclitaxel-based chemotherapy.  Thirty-five percent (95% CI: 45-31) of patients with high Class III β-tubulin expression showed a disease progression vs. only 7% of patients with low expression (35% vs. 7%, p < 0.002).  Our study suggests that Class III β-tubulin tumor expression could be considered a predictive biomarker of paclitaxel-clin. resistance for breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBTFhVq0oPHrVg90H21EOLACvtfcHk0liPyUCOV7qJOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkt1Oitbo%253D&md5=efd1c3424ce6be7595069049392d016c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fijc.22557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.22557%26sid%3Dliteratum%253Aachs%26aulast%3DTommasi%26aufirst%3DS.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DLacalamita%26aufirst%3DR.%26aulast%3DBellizzi%26aufirst%3DA.%26aulast%3DFedele%26aufirst%3DV.%26aulast%3DChiriatti%26aufirst%3DA.%26aulast%3DThomssen%26aufirst%3DC.%26aulast%3DKendzierski%26aufirst%3DN.%26aulast%3DLatorre%26aufirst%3DA.%26aulast%3DLorusso%26aufirst%3DV.%26aulast%3DSchittulli%26aufirst%3DF.%26aulast%3DZito%26aufirst%3DF.%26aulast%3DKavallaris%26aufirst%3DM.%26aulast%3DParadiso%26aufirst%3DA.%26atitle%3DCytoskeleton%2520and%2520paclitaxel%2520sensitivity%2520in%2520breast%2520cancer%253A%2520The%2520role%2520of%2520%25CE%25B2-tubulins%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2007%26volume%3D120%26spage%3D2078%26epage%3D2085%26doi%3D10.1002%2Fijc.22557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Ferrandina, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zannoni, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paglia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallotta, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mozzetti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scambia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferlini, C.</span><span> </span><span class="NLM_article-title">Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2774</span><span class="NLM_x">–</span> <span class="NLM_lpage">2779</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-2715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1158%2F1078-0432.CCR-05-2715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=16675570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD28Xltlamsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=2774-2779&author=G.+Ferrandinaauthor=G.+F.+Zannoniauthor=E.+Martinelliauthor=A.+Pagliaauthor=V.+Gallottaauthor=S.+Mozzettiauthor=G.+Scambiaauthor=C.+Ferlini&title=Class+III+%CE%B2-tubulin+overexpression+is+a+marker+of+poor+clinical+outcome+in+advanced+ovarian+cancer+patients&doi=10.1158%2F1078-0432.CCR-05-2715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients</span></div><div class="casAuthors">Ferrandina, Gabriella; Zannoni, Gian Franco; Martinelli, Enrica; Paglia, Amelia; Gallotta, Valerio; Mozzetti, Simona; Scambia, Giovanni; Ferlini, Cristiano</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2774-2779</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Overexpression of β III tubulin has been involved in paclitaxel resistance in several exptl. models.  We investigated the role of β III tubulin as predictor of clin. outcome in ovarian cancer patients given platinum/paclitaxel treatment.  We also investigated whether β III tubulin expression could be modified after the selective pressure represented by chemotherapy in vivo.  Exptl. Design: The study was designed to include a series of consecutive ovarian cancer patients with unresectable disease at time of first surgery, who underwent interval debulking surgery with pathol. assessment of response to treatment with platinum/paclitaxel chemotherapy.  Immunostaining was done on formalin-fixed, paraffin-embedded tissue sections from pretreatment and posttreatment tissue biopsies by using the polyclonal rabbit anti-class III β-tubulin antibody.  Results: β III Tubulin immunoreaction was obsd. in 51 of 62 (82.2%) cases.  β III Tubulin positivity was neither assocd. with clinicopathol. variables nor with pathol. response to chemotherapy.  Significantly lower percentages of β III tubulin positivity were obsd. in posttreatment (range, 5-80%; median, 20%) vs. pretreatment (range 10-100%; median, 40%) tissue biopsies (P = 0.0011).  Cases with high β III tubulin expression showed a worse overall survival with respect to cases with low β III tubulin expression (median overall survival, 25 vs. 46 mo; P = 0.002).  Multivariate anal. showed that high content of β III tubulin remains independently assocd. with a worse prognosis.  Conclusions: Assessment of β III tubulin could be useful to identify poor prognosis ovarian cancer patients candidates to more aggressive and/or targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkRULoF4-0uLVg90H21EOLACvtfcHk0ljJDcNha5twlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xltlamsb0%253D&md5=569d52a398426b7b06eddeb7b0e98751</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-2715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-2715%26sid%3Dliteratum%253Aachs%26aulast%3DFerrandina%26aufirst%3DG.%26aulast%3DZannoni%26aufirst%3DG.%2BF.%26aulast%3DMartinelli%26aufirst%3DE.%26aulast%3DPaglia%26aufirst%3DA.%26aulast%3DGallotta%26aufirst%3DV.%26aulast%3DMozzetti%26aufirst%3DS.%26aulast%3DScambia%26aufirst%3DG.%26aulast%3DFerlini%26aufirst%3DC.%26atitle%3DClass%2520III%2520%25CE%25B2-tubulin%2520overexpression%2520is%2520a%2520marker%2520of%2520poor%2520clinical%2520outcome%2520in%2520advanced%2520ovarian%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D2774%26epage%3D2779%26doi%3D10.1158%2F1078-0432.CCR-05-2715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Mozzetti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferlini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Concolino, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raspaglio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prislei, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranelletti, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrandina, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scambia, G.</span><span> </span><span class="NLM_article-title">Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">305</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=15671559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVegtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=298-305&author=S.+Mozzettiauthor=C.+Ferliniauthor=P.+Concolinoauthor=F.+Filippettiauthor=G.+Raspaglioauthor=S.+Prisleiauthor=D.+Galloauthor=E.+Martinelliauthor=F.+O.+Ranellettiauthor=G.+Ferrandinaauthor=G.+Scambia&title=Class+III+%CE%B2-tubulin+overexpression+is+a+prominent+mechanism+of+paclitaxel+resistance+in+ovarian+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients</span></div><div class="casAuthors">Mozzetti, Simona; Ferlini, Cristiano; Concolino, Paola; Filippetti, Flavia; Raspaglio, Giuseppina; Prislei, Silvia; Gallo, Daniela; Martinelli, Enrica; Ranelletti, Franco Oreste; Ferrandina, Gabriella; Scambia, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">298-305</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The vast majority of women with advanced ovarian cancer will ultimately relapse and develop a drug-resistant disease with an overall 5-yr survival of <50%.  Unfortunately, the mechanisms of drug resistance actually operating in patients are still unknown.  To address this issue, in 41 patients affected by advanced ovarian cancer the three main mechanisms of paclitaxel resistance were investigated: overexpression of MDR-1 gene, point mutations at prominently expressed α-tubulin and β-tubulin genes and selective alterations in the expression of β-tubulin isotypes.  MDR-1 and the β-tubulin isotypes expression were evaluated by semiquant. and real-time PCR.  On the same specimens, quant. immunohistochem. was also done in the tumor area.  No statistically significant changes of MDR-1 expression were noticed between the sensitive and resistant patients either at the mRNA or protein level.  The tubulin mutations for the ubiquitous α-tubulin and β-tubulin genes were evaluated by automated DNA sequencing, and in all patients, no mutations were detected in both resistant and sensitive cases.  With regard to the expression of tubulin isoforms, a statistically significant up-regulation of class III β-tubulin was found in the resistant subset.  It is worth noting that this statistically significant increase of the expression of class III β-tubulin was detectable at the mRNA and protein level.  By a direct comparison of the three main known mechanisms of paclitaxel resistance, this study indicates that overexpression of class III β-tubulin is the most prominent mechanism of paclitaxel resistance in ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_j0ZXNlGPW7Vg90H21EOLACvtfcHk0ljJDcNha5twlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVegtrg%253D&md5=861e1e01da277ff2f4d76b458ebe5e48</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMozzetti%26aufirst%3DS.%26aulast%3DFerlini%26aufirst%3DC.%26aulast%3DConcolino%26aufirst%3DP.%26aulast%3DFilippetti%26aufirst%3DF.%26aulast%3DRaspaglio%26aufirst%3DG.%26aulast%3DPrislei%26aufirst%3DS.%26aulast%3DGallo%26aufirst%3DD.%26aulast%3DMartinelli%26aufirst%3DE.%26aulast%3DRanelletti%26aufirst%3DF.%2BO.%26aulast%3DFerrandina%26aufirst%3DG.%26aulast%3DScambia%26aufirst%3DG.%26atitle%3DClass%2520III%2520%25CE%25B2-tubulin%2520overexpression%2520is%2520a%2520prominent%2520mechanism%2520of%2520paclitaxel%2520resistance%2520in%2520ovarian%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D298%26epage%3D305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Hwang, J.-E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, W.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shim, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bae, W.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, E.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, I.-J.</span><span> </span><span class="NLM_article-title">Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1186/1471-2407-13-431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1186%2F1471-2407-13-431" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=431-431&author=J.-E.+Hwangauthor=J.-Y.+Hongauthor=K.+Kimauthor=S.-H.+Kimauthor=W.-Y.+Choiauthor=M.-J.+Kimauthor=S.-H.+Jungauthor=H.-J.+Shimauthor=W.-K.+Baeauthor=E.-C.+Hwangauthor=K.-H.+Leeauthor=J.-H.+Leeauthor=S.-H.+Choauthor=I.-J.+Chung&title=Class+III+%CE%B2-tubulin+is+a+predictive+marker+for+taxane-based+chemotherapy+in+recurrent+and+metastatic+gastric+cancer&doi=10.1186%2F1471-2407-13-431"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-13-431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-13-431%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DJ.-E.%26aulast%3DHong%26aufirst%3DJ.-Y.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DChoi%26aufirst%3DW.-Y.%26aulast%3DKim%26aufirst%3DM.-J.%26aulast%3DJung%26aufirst%3DS.-H.%26aulast%3DShim%26aufirst%3DH.-J.%26aulast%3DBae%26aufirst%3DW.-K.%26aulast%3DHwang%26aufirst%3DE.-C.%26aulast%3DLee%26aufirst%3DK.-H.%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DCho%26aufirst%3DS.-H.%26aulast%3DChung%26aufirst%3DI.-J.%26atitle%3DClass%2520III%2520%25CE%25B2-tubulin%2520is%2520a%2520predictive%2520marker%2520for%2520taxane-based%2520chemotherapy%2520in%2520recurrent%2520and%2520metastatic%2520gastric%2520cancer%26jtitle%3DBMC%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D431%26epage%3D431%26doi%3D10.1186%2F1471-2407-13-431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Stengel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leese, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, B. V. L</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purohit, A.</span><span> </span><span class="NLM_article-title">Class III β-tubulin expression and in vitro resistance to microtubule targeting agents</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">102</span><span class="NLM_x">) </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span><span class="refDoi"> DOI: 10.1038/sj.bjc.6605489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1038%2Fsj.bjc.6605489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=20029418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlKisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2010&pages=316-324&issue=102&author=C.+Stengelauthor=S.+P.+Newmanauthor=M.+P.+Leeseauthor=B.+V.+L+Potterauthor=M.+J.+Reedauthor=A.+Purohit&title=Class+III+%CE%B2-tubulin+expression+and+in+vitro+resistance+to+microtubule+targeting+agents&doi=10.1038%2Fsj.bjc.6605489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Class III β-tubulin expression and in vitro resistance to microtubule targeting agents</span></div><div class="casAuthors">Stengel, C.; Newman, S. P.; Leese, M. P.; Potter, B. V. L.; Reed, M. J.; Purohit, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">316-324</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Class III β-tubulin overexpression is a marker of resistance to microtubule disruptors in vitro, in vivo and in the clinic for many cancers, including breast cancer.  The aims of this study were to develop a new model of class III β-tubulin expression, avoiding the toxicity assocd. with chronic overexpression of class III β-tubulin, and study the efficacy of a panel of clin. and pre-clin. drugs in this model.  Methods: MCF-7 (ER+ve) and MDA-MB-231 (ER-ve) were either transfected with pALTER-TUBB3 or siRNA-tubb3 and 24 h later exposed to test compds. for a further 96 h for proliferation studies.  RT-PCR and immunoblotting were used to monitor the changes in class III β-tubulin mRNA and protein expression.  Results: The model allowed for subtle changes in class III β-tubulin expression to be achieved, which had no direct effect on the viability of the cells.  Class III β-tubulin overexpression conferred resistance to paclitaxel and vinorelbine, whereas downregulation of class III β-tubulin rendered cells more sensitive to these two drugs.  The efficacy of the colchicine-site binding agents, 2-MeOE2, colchicine, STX140, ENMD1198 and STX243 was unaffected by the changes in class III β-tubulin expression.  Conclusion: These data indicate that the effect of class III β-tubulin overexpression may depend on where the drug's binding site is located on the tubulin.  Therefore, this study highlights for the first time the potential key role of targeting the colchicine-binding site, to develop new treatment modalities for taxane-refractory breast cancer.  British Journal of Cancer (2010) 102, 316-324; doi:10.1038/sj.bjc.6605489 www.bjcancer.com Published online 22 Dec. 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hulEpiTJA7Vg90H21EOLACvtfcHk0ljJDcNha5twlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlKisQ%253D%253D&md5=02d84566d0f23c1781ba74a1add4fed2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605489%26sid%3Dliteratum%253Aachs%26aulast%3DStengel%26aufirst%3DC.%26aulast%3DNewman%26aufirst%3DS.%2BP.%26aulast%3DLeese%26aufirst%3DM.%2BP.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPurohit%26aufirst%3DA.%26atitle%3DClass%2520III%2520%25CE%25B2-tubulin%2520expression%2520and%2520in%2520vitro%2520resistance%2520to%2520microtubule%2520targeting%2520agents%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2010%26volume%3D102%26issue%3D102%26spage%3D316%26epage%3D324%26doi%3D10.1038%2Fsj.bjc.6605489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorpe, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disch, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey-Downs, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dybdal-Hargreaves, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohena, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangjee, A.</span><span> </span><span class="NLM_article-title">The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-<i>d</i>]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3753</span><span class="NLM_x">–</span> <span class="NLM_lpage">3772</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.04.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1016%2Fj.bmc.2014.04.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=24890652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslCns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=3753-3772&author=X.+Zhangauthor=S.+Raghavanauthor=M.+Ihnatauthor=J.+E.+Thorpeauthor=B.+C.+Dischauthor=A.+Bastianauthor=L.+C.+Bailey-Downsauthor=N.+F.+Dybdal-Hargreavesauthor=C.+C.+Rohenaauthor=E.+Hamelauthor=S.+L.+Mooberryauthor=A.+Gangjee&title=The+design+and+discovery+of+water+soluble+4-substituted-2%2C6-dimethylfuro%5B2%2C3-d%5Dpyrimidines+as+multitargeted+receptor+tyrosine+kinase+inhibitors+and+microtubule+targeting+antitumor+agents&doi=10.1016%2Fj.bmc.2014.04.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents</span></div><div class="casAuthors">Zhang, Xin; Raghavan, Sudhir; Ihnat, Michael; Thorpe, Jessica E.; Disch, Bryan C.; Bastian, Anja; Bailey-Downs, Lora C.; Dybdal-Hargreaves, Nicholas F.; Rohena, Cristina C.; Hamel, Ernest; Mooberry, Susan L.; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3753-3772</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The design, synthesis and biol. evaluations of fourteen 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidines are reported.  Four compds. inhibit vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor β (PDGFR-β), and target tubulin leading to cytotoxicity.  Compd. I has nanomolar potency, comparable to sunitinib and semaxinib, against tumor cell lines overexpressing VEGFR-2 and PDGFR-β.  Further, I binds at the colchicine site on tubulin, depolymerizes cellular microtubules and inhibits purified tubulin assembly and overcomes both βIII-tubulin and P-glycoprotein-mediated drug resistance, and initiates mitotic arrest leading to apoptosis.  In vivo, its HCl salt, I·HCl, reduced tumor size and vascularity in xenograft and allograft murine models and was superior to docetaxel and sunitinib, without overt toxicity.  Thus I·HCl affords potential combination chemotherapy in a single agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz0a4q7mfRm7Vg90H21EOLACvtfcHk0ljc-N0SbNcdTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslCns78%253D&md5=b35cd4ed7f053ea14d7ef5ee33828b38</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.04.049%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DDisch%26aufirst%3DB.%2BC.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DBailey-Downs%26aufirst%3DL.%2BC.%26aulast%3DDybdal-Hargreaves%26aufirst%3DN.%2BF.%26aulast%3DRohena%26aufirst%3DC.%2BC.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DThe%2520design%2520and%2520discovery%2520of%2520water%2520soluble%25204-substituted-2%252C6-dimethylfuro%255B2%252C3-d%255Dpyrimidines%2520as%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520and%2520microtubule%2520targeting%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D3753%26epage%3D3772%26doi%3D10.1016%2Fj.bmc.2014.04.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Risinger, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helms, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeBoeuf, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopper-Borge, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luduena, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruh, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">The taccalonolides: Microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">8881</span><span class="NLM_x">–</span> <span class="NLM_lpage">8888</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-2037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1158%2F0008-5472.CAN-08-2037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=18974132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSkur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=8881-8888&author=A.+L.+Risingerauthor=E.+M.+Jacksonauthor=L.+A.+Polinauthor=G.+L.+Helmsauthor=D.+A.+LeBoeufauthor=P.+A.+Joeauthor=E.+Hopper-Borgeauthor=R.+F.+Luduenaauthor=G.+D.+Kruhauthor=S.+L.+Mooberry&title=The+taccalonolides%3A+Microtubule+stabilizers+that+circumvent+clinically+relevant+taxane+resistance+mechanisms&doi=10.1158%2F0008-5472.CAN-08-2037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The Taccalonolides: Microtubule Stabilizers That Circumvent Clinically Relevant Taxane Resistance Mechanisms</span></div><div class="casAuthors">Risinger, April L.; Jackson, Evelyn M.; Polin, Lisa A.; Helms, Gregory L.; LeBoeuf, Desiree A.; Joe, Patrick A.; Hopper-Borge, Elizabeth; Luduena, Richard F.; Kruh, Gary D.; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8881-8888</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The taccalonolides are a class of structurally and mechanistically distinct microtubule-stabilizing agents isolated from Tacca chantrieri.  A crucial feature of the taxane family of microtubule stabilizers is their susceptibility to cellular resistance mechanisms including overexpression of P-glycoprotein (Pgp), multidrug resistance protein 7 (MRP7), and the βIII isotype of tubulin.  The ability of four taccalonolides, A, E, B, and N, to circumvent these multidrug resistance mechanisms was studied.  Taccalonolides A, E, B, and N were effective in vitro against cell lines that overexpress Pgp and MRP7.  In addn., taccalonolides A and E were highly active in vivo against a doxorubicin- and paclitaxel-resistant Pgp-expressing tumor, Mam17/ADR.  An isogenic HeLa-derived cell line that expresses the βIII isotype of tubulin was generated to evaluate the effect of βIII-tubulin on drug sensitivity.  When compared with parental HeLa cells, the βIII-tubulin-overexpressing cell line was less sensitive to paclitaxel, docetaxel, epothilone B, and vinblastine.  In striking contrast, the βIII-tubulin-overexpressing cell line showed greater sensitivity to all four taccalonolides.  These data cumulatively suggest that the taccalonolides have advantages over the taxanes in their ability to circumvent multiple drug resistance mechanisms.  The ability of the taccalonolides to overcome clin. relevant mechanisms of drug resistance in vitro and in vivo confirms that the taccalonolides represent a valuable addn. to the family of microtubule-stabilizing compds. with clin. potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAZHYmJfQNPLVg90H21EOLACvtfcHk0ljc-N0SbNcdTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSkur%252FI&md5=1f53ab12cdbebd7627482a6821f910b3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-2037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-2037%26sid%3Dliteratum%253Aachs%26aulast%3DRisinger%26aufirst%3DA.%2BL.%26aulast%3DJackson%26aufirst%3DE.%2BM.%26aulast%3DPolin%26aufirst%3DL.%2BA.%26aulast%3DHelms%26aufirst%3DG.%2BL.%26aulast%3DLeBoeuf%26aufirst%3DD.%2BA.%26aulast%3DJoe%26aufirst%3DP.%2BA.%26aulast%3DHopper-Borge%26aufirst%3DE.%26aulast%3DLuduena%26aufirst%3DR.%2BF.%26aulast%3DKruh%26aufirst%3DG.%2BD.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DThe%2520taccalonolides%253A%2520Microtubule%2520stabilizers%2520that%2520circumvent%2520clinically%2520relevant%2520taxane%2520resistance%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D8881%26epage%3D8888%26doi%3D10.1158%2F0008-5472.CAN-08-2037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="note"><p class="first last">We thank the NCI for providing the tumor cell growth inhibitory activity in the NCI 60-cell line panel for compound <b>3</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Synthesis and biological activities of (<i>R</i>)- and (<i>S</i>)-<i>N</i>-(4-methoxyphenyl)-<i>N</i>,2,6-trimethyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6151</span><span class="NLM_x">–</span> <span class="NLM_lpage">6155</span><span class="refDoi"> DOI: 10.1021/jm2007722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6151-6155&author=A.+Gangjeeauthor=Y.+Zhaoauthor=E.+Hamelauthor=C.+Westbrookauthor=S.+L.+Mooberry&title=Synthesis+and+biological+activities+of+%28R%29-+and+%28S%29-N-%284-methoxyphenyl%29-N%2C2%2C6-trimethyl-6%2C7-dihydro-5H-cyclopenta%5Bd%5Dpyrimidin-4-aminium+chloride+as+potent+cytotoxic+antitubulin+agents&doi=10.1021%2Fjm2007722"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm2007722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007722%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DWestbrook%26aufirst%3DC.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DSynthesis%2520and%2520biological%2520activities%2520of%2520%2528R%2529-%2520and%2520%2528S%2529-N-%25284-methoxyphenyl%2529-N%252C2%252C6-trimethyl-6%252C7-dihydro-5H-cyclopenta%255Bd%255Dpyrimidin-4-aminium%2520chloride%2520as%2520potent%2520cytotoxic%2520antitubulin%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6151%26epage%3D6155%26doi%3D10.1021%2Fjm2007722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. M.</span><span> </span><span class="NLM_article-title">Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4173</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1021/bi00313a026</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00313a026" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1984&pages=4173-84&author=E.+Hamelauthor=C.+M.+Lin&title=Separation+of+active+tubulin+and+microtubule-associated+proteins+by+ultracentrifugation+and+isolation+of+a+component+causing+the+formation+of+microtubule+bundles&doi=10.1021%2Fbi00313a026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fbi00313a026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00313a026%26sid%3Dliteratum%253Aachs%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DC.%2BM.%26atitle%3DSeparation%2520of%2520active%2520tubulin%2520and%2520microtubule-associated%2520proteins%2520by%2520ultracentrifugation%2520and%2520isolation%2520of%2520a%2520component%2520causing%2520the%2520formation%2520of%2520microtubule%2520bundles%26jtitle%3DBiochemistry%26date%3D1984%26volume%3D23%26spage%3D4173%26epage%3D84%26doi%3D10.1021%2Fbi00313a026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin</span> <span class="citation_source-journal">Cell Biochem. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1385/CBB:38:1:1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1385%2FCBB%3A38%3A1%3A1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=12663938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtVaisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=1-21&author=E.+Hamel&title=Evaluation+of+antimitotic+agents+by+quantitative+comparisons+of+their+effects+on+the+polymerization+of+purified+tubulin&doi=10.1385%2FCBB%3A38%3A1%3A1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin</span></div><div class="casAuthors">Hamel, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">CBBIFV</span>;
        ISSN:<span class="NLM_cas:issn">1085-9195</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Most antimitotic compds. have highly specific interactions with tubulin, the major protein component of microtubules.  It is, therefore, often desirable to characterize interactions of these agents with tubulin.  In particular, quant. comparisons between new and old ("std.") agents, between different classes of agent, and between structural analogs (e.g., for a structure-activity relationship study) are important.  Because antimitotic drugs have a variety of effects on tubulin and bind at multiple distinct sites on the protein, the tubulin assembly reaction is probably the only universally applicable reaction that can be analyzed.  In my lab., we use the assembly of purified tubulin induced by higher concns. of monosodium glutamate as our basic assay system.  This report presents a detailed description of our current routine assay, including the effects of a variety of reaction components on the reaction.  In addn., the variety of effects that reaction components can have on the quant. results obtained with drugs, using the colchicine site drug combretastatin A-4 as a model compd., is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLvDICXLUiYbVg90H21EOLACvtfcHk0lh1hqcH8LSwOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtVaisLY%253D&md5=c37c365cc707e237f43feffca64d706b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1385%2FCBB%3A38%3A1%3A1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FCBB%253A38%253A1%253A1%26sid%3Dliteratum%253Aachs%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DEvaluation%2520of%2520antimitotic%2520agents%2520by%2520quantitative%2520comparisons%2520of%2520their%2520effects%2520on%2520the%2520polymerization%2520of%2520purified%2520tubulin%26jtitle%3DCell%2520Biochem.%2520Biophys.%26date%3D2003%26volume%3D38%26spage%3D1%26epage%3D21%26doi%3D10.1385%2FCBB%3A38%3A1%3A1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Verdier-Pinard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, H.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagle, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falck, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerwick, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1998&pages=62-76&author=P.+Verdier-Pinardauthor=J.-Y.+Laiauthor=H.-D.+Yooauthor=J.+Yuauthor=B.+Marquezauthor=D.+G.+Nagleauthor=M.+Nambuauthor=J.+D.+Whiteauthor=J.+R.+Falckauthor=W.+H.+Gerwickauthor=B.+W.+Dayauthor=E.+Hamel&title=Structure-activity+analysis+of+the+interaction+of+curacin+A%2C+the+potent+colchicine+site+antimitotic+agent%2C+with+tubulin+and+effects+of+analogs+on+the+growth+of+MCF-7+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerdier-Pinard%26aufirst%3DP.%26aulast%3DLai%26aufirst%3DJ.-Y.%26aulast%3DYoo%26aufirst%3DH.-D.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DMarquez%26aufirst%3DB.%26aulast%3DNagle%26aufirst%3DD.%2BG.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DWhite%26aufirst%3DJ.%2BD.%26aulast%3DFalck%26aufirst%3DJ.%2BR.%26aulast%3DGerwick%26aufirst%3DW.%2BH.%26aulast%3DDay%26aufirst%3DB.%2BW.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DStructure-activity%2520analysis%2520of%2520the%2520interaction%2520of%2520curacin%2520A%252C%2520the%2520potent%2520colchicine%2520site%2520antimitotic%2520agent%252C%2520with%2520tubulin%2520and%2520effects%2520of%2520analogs%2520on%2520the%2520growth%2520of%2520MCF-7%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Pharmacol.%26date%3D1998%26volume%3D53%26spage%3D62%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Krishan, A.</span><span> </span><span class="NLM_article-title">Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">–</span> <span class="NLM_lpage">193</span><span class="refDoi"> DOI: 10.1083/jcb.66.1.188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1083%2Fjcb.66.1.188" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1975&pages=188-193&author=A.+Krishan&title=Rapid+flow+cytofluorometric+analysis+of+mammalian+cell+cycle+by+propidium+iodide&doi=10.1083%2Fjcb.66.1.188"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1083%2Fjcb.66.1.188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.66.1.188%26sid%3Dliteratum%253Aachs%26aulast%3DKrishan%26aufirst%3DA.%26atitle%3DRapid%2520flow%2520cytofluorometric%2520analysis%2520of%2520mammalian%2520cell%2520cycle%2520by%2520propidium%2520iodide%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1975%26volume%3D66%26spage%3D188%26epage%3D193%26doi%3D10.1083%2Fjcb.66.1.188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Rohena, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telang, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risinger, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sikorski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellogg, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupton, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Biological characterization of an improved pyrrole-based colchicine site agent identified through structure-based design</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">296</span><span class="refDoi"> DOI: 10.1124/mol.115.101592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;key=10.1124%2Fmol.115.101592" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=287-296&author=C.+C.+Rohenaauthor=N.+S.+Telangauthor=C.+Daauthor=A.+L.+Risingerauthor=J.+A.+Sikorskiauthor=G.+E.+Kelloggauthor=J.+T.+Guptonauthor=S.+L.+Mooberry&title=Biological+characterization+of+an+improved+pyrrole-based+colchicine+site+agent+identified+through+structure-based+design&doi=10.1124%2Fmol.115.101592"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.101592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.101592%26sid%3Dliteratum%253Aachs%26aulast%3DRohena%26aufirst%3DC.%2BC.%26aulast%3DTelang%26aufirst%3DN.%2BS.%26aulast%3DDa%26aufirst%3DC.%26aulast%3DRisinger%26aufirst%3DA.%2BL.%26aulast%3DSikorski%26aufirst%3DJ.%2BA.%26aulast%3DKellogg%26aufirst%3DG.%2BE.%26aulast%3DGupton%26aufirst%3DJ.%2BT.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DBiological%2520characterization%2520of%2520an%2520improved%2520pyrrole-based%2520colchicine%2520site%2520agent%2520identified%2520through%2520structure-based%2520design%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D89%26spage%3D287%26epage%3D296%26doi%3D10.1124%2Fmol.115.101592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B','PDB','4O2B'); return false;">PDB: 4O2B</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i48"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00237">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_31383"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00237">10.1021/acs.jmedchem.6b00237</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Elemental analysis, high-resolution mass spectra (HRMS) (EI), and docked poses of target compounds <b>4</b>–<b>9</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_002.csv">CSV</a>)</p></li><li><p class="inline">Figure 3 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Figure 11b (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Figure S1 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_005.pdb">PDB</a>)</p></li><li><p class="inline">Figure S2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_006.pdb">PDB</a>)</p></li><li><p class="inline">Figure S3 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_007.pdb">PDB</a>)</p></li><li><p class="inline">Figure S4 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_008.pdb">PDB</a>)</p></li><li><p class="inline">Figure S5 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_009.pdb">PDB</a>)</p></li><li><p class="inline">Figure S6 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_010.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_001.pdf">jm6b00237_si_001.pdf (682.93 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_002.csv">jm6b00237_si_002.csv (0.47 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_003.pdb">jm6b00237_si_003.pdb (556.12 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_004.pdb">jm6b00237_si_004.pdb (3.75 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_005.pdb">jm6b00237_si_005.pdb (553.16 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_006.pdb">jm6b00237_si_006.pdb (1.06 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_007.pdb">jm6b00237_si_007.pdb (1.06 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_008.pdb">jm6b00237_si_008.pdb (553.36 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_009.pdb">jm6b00237_si_009.pdb (553.05 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00237/suppl_file/jm6b00237_si_010.pdb">jm6b00237_si_010.pdb (553.05 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00237&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00237%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-12%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00237" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995845ec5a23c8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
